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nSummary
A problem in modern, agile aircraft is the possibility of the pilot 
losing consciousness during manoeuvres which can impose forces (G) many 
times that of gravitational acceleration.
There is a possibility that the next generation of agile aircraft will 
exceed the level of anti-G protection presently available and the 
possibility of pharmacological intervention had been considered as an 
additional means of raising G-tolerance.
Arginine vasopressin plays an active role in maintaining blood 
pressure, particularly in hypovolaemic situations, by its powerful 
vasoconstrictive action and control of heart output. As a potential G 
protection agent AVP has the appeal of not appearing to produce 
hypertension.
The human centrifuge has normally been used to investigate problems of 
acceleration protection, but because of the hostile environment and space 
restraints, it has been difficult to carry out systematic biochemical 
investigations and lower body negative pressure has been used to simulate 
the cardio-vascular stress of G.
The level of plasma catecholamines and arginine vasopressin has been 
measured during different exposure levels to lower body negative pressure 
and following b blockade with Propranolol combined with lower body 
negative pressure. No correlation could be established between peripheral 
circulating plasma levels of catecholamines and arginine vasopressin for
11
any of the experimental conditions. However, dramatic oscillations in 
plasma noradrenaline levels were seen and a distinct pattern of arginine 
vasopressin secretion was observed at presyncope.
The role of arginine vasopressin during syncope was investigated and 
small increases in plasma levels of this vasoactive hormone appeared to 
play a protective role in some subjects. In subsequent experiments, a 
bolus of arginine vasopressin was injected prior to exposure to lower body 
negative pressure, but this did not appear to have any effect on tolerance 
to lower body negative pressure and in some subjects it was positively 
detrimental.
Ill
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CHAPTER ONE
Introduction
Man's advance into the environment of flight has exposed him to 
accelerations far greater than the gravity which he normally experiences. 
The adverse physiological effects of these accelerations are important in 
the Royal Air Force, as the performance of modern fast jets is now 
becoming limited by the pilots’ ability to withstand these forces. It is 
even possible that some form of pharmacological intervention may become 
necessary to increase a pilot's tolerance to levels of acceleration likely 
to be imposed by the newer generations of combat aircraft. The appli­
cation of negative pressure to the lower body produces a cardiovascular 
stress, similar to the acceleration vector most commonly experienced by 
pilots, +Gg.
The forces of acceleration are usually expressed in multiples of G, 
the ratio between the applied acceleration measured in metres/sec2 and 
gravitational acceleration (9.81m/s2). The vector direction of the 
applied forces is expressed by a + or - and a suffix letter such that +G^ 
is the force vector normally experienced by aircrew when, for example, 
pulling out from a dive, or looping. The complete three co-ordinate 
system for designating G forces (Gell, 1961) is illustrated in Figure 1.1.
The accelerations to be considered in this thesis are long duration 
radial accelerations, acting in the long, or 2, axis of the body, and 
which are produced by a change of direction of motion of an aircraft. The 
more agile aircraft in service can currently sustain accelerations of up 
to 8G while manoeuvring in combat, and levels of lOG or more will become 
possible in the future. If the head of the pilot is directed towards the
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Figure 1.1 The definition of inertial force vectors acting 
on the body. Note that the accelerative force 
acts in the opposite direction to the inertial 
force.
centre of rotation, then the inertial force is centrifugal (+Gz), so that 
he is forced down into his seat. There is a hydrostatic drop in pressure 
from heart to head level and a considerable reduction in blood flow to the 
head with visual symptoms (greyout and blackout) and eventual loss of 
consciousness. The cardiovascular stress of attempted compensation is 
exacerbated by pooling of blood in the lower body. Previous research at 
this Institute, using the human centrifuge, investigated the effects of 
sustained +Gg on some aspects of endocrine function. This research 
indicated that arginine vasopressin (AVP) may play an active role in 
maintaining blood pressure. From the literature, although there are some 
contradictions, the catecholamine, dopamine, may be one of the compounds 
actively involved in the control of plasma AVP levels.
This thesis describes experiments to investigate the effect of Lower 
Body Negative Pressure (LBNP) on the secretion of AVP and the catechol­
amines: adrenaline, noradrenaline and dopamine. LBNP can produce severe 
cardiovascular stress comparable to that of + G ^  acceleration, by making 
the subject effectively hypovolaemic although there is no actual fluid 
loss, but without such problems as the coriolis effect and associated 
nausea. A more controlled blood sampling regime is also possible with 
LBNP. Sampling is difficult or impossible while spinning and the normal 
experimental duration of a centrifuge run is too short, usually only a few 
seconds, to allow the biochemical events to be accurately followed. The 
"stress" development is usually somewhat slower for LBNP, making possible 
a more systematic study of the biochemical changes that occur with time. 
Like centrifugation, LBNP can be graded, its duration accurately defined 
and the stress instantly reversible in the event of syncope.
Although reasonable results had been obtained for the analysis of the 
catecholamines, adrenaline and noradrenaline, using the single radio- 
enzymatic derivative assay of Peuler and Johnson (1977), the method was 
not entirely satisfactory because of occasional poor reproducibility. A 
modified method using High Pressure Liquid Chromatography (HPLC) with 
ultra violet detection has been developed, as has a method for the 
analysis of dopamine using an acétylation procedure.
As LBNP is being used .tjQ- create a stress comparable to that of 
aircraft accelerations, it is necessary to discuss these accelerations in 
some detail, as well as methods currently used to mitigate their effects.
Acceleration is defined as the rate of change of velocity with time 
and occurs when there is a change in the speed or direction of motion of a 
body. Newton’s first law states that a body will remain in a state of 
rest or uniform motion in a straight line, unless acted upon by a force. 
Flight acceleration is classified as either a short or long duration.
Short duration which is encountered in situations such as a crash, may 
result in a pathological condition, whereas it is a change in physiology 
that occurs with long duration acceleration.
In an unprotected, relaxed subject, unconsciousness usually occurs 
between +5 and +6Gg, depending on the individual and the rate of onset 
of G. Unconsciousness is due to impairment of cerebral blood flow. At an 
onset rate of less than 2Gs-l, however, retinal blood flow is affected 
before obvious cerebral effects. Peripheral vision is progressively lost 
at 3-4Gg, ’’grey-out", until vision is completely lost, "blackout", at 4- 
5Gg. Hearing and mental orientations are still sufficient for intelligent 
conversation, and unconsciousness occurs at approximately l.OG^ higher.
The determining factor for these effects upon vision and consciousness is 
cardiovascular.
In upright man the blood in the vessels from the heart to the brain 
constitutes a column of fluid which, at IG^, exerts a hydrostatic pressure 
of some 25 mmHg. A mean arterial pressure of 100 mmHg at heart level would 
thus be decreased to 75 mmHg at the level of the brain. It might be 
expected, therefore, that the mean arterial pressure at brain level would 
be zero at +40^, since the hydrostatic pressure opposing flow would be 
increased fourfold to 100 mmHg, and cerebral blood flow would cease. This 
is not the case, however, as both cerebrospinal fluid and venous blood 
are subject to the same hydrostatic laws as the arterial circulation and 
reflex systems are also triggered. Thus, a venous syphon effect plus, 
given time, reflex compensatory mechanisms, afford 1-2G of protection.
As a consequence of raised hydrostatic pressures in the vessels below 
the heart, blood pools in the lower limbs and abdomen, thereby decreasing 
the effective circulating blood volume, reducing venous return and 
impairing cardiac output. The physiological changes are similar to those 
seen in haemorrhage and both situations generate similar reflex 
sympathetic responses, notably tachycardia and selective vasocon­
striction. In man, the carotid sinus reflex is almost certainly 
responsible for the former, but its role in inducing vasoconstriction is 
probably slight (Roddie and Shepherd, 1957).
Methods of protection against +G_ acceleration
There are three groups of methods for protecting the pilot against 
+Gg: mechanical, physiological and pharmaceutical. Mechanical methods
include the anti-G suit, a garment containing air bladders over the lower
limbs and abdomen. Inflation of these bladders to a pressure proportional 
to the applied acceleration increases peripheral resistance, raises 
intra-abdominal pressure reduces blood pooling, and in the case of the 
suit worn by RAF aircrew, gives an increase in G tolerance of 1-1.5G 
(Nicholson,1965). Reclining the seat backwards reduces the hydrostatic 
height between the head and heart, but this starts to have a significant 
effect on G tolerance only at an inclination of 45° or more (Stewart, 
1940, Crossley and Glaister, 1971, Burns, 1975).
Physiologically, tensing of the leg muscles decreases the venous 
capacitance of the limbs and so reduces peripheral pooling of blood.
Pilots can also be trained to use respiratory manoeuvres designed to raise 
intra-thoracic pressure. The Valsalva manoeuvre, a forced expiration 
against a closed glottis, gives an improvement in tolerance of +1.5Gg or 
more (Shulbrooks and Leverett, 1973), but must be used with caution as the 
initial rise in arterial pressure is reversed after a few seconds because 
of a secondary impairment of venous return. This can lead to 
unconsciousness (Wood and Lambert, 1952). However, a prolonged elevation 
in blood pressure can be achieved by making the manoeuvre intermittent.
The M-1 is a forced expiration against a partially closed glottis with an 
inspiratory gasp repeated every 3-4s, while in the L-1 the subject strains 
against a closed glottis, and then takes a quick breath, again every 3- 
4s. These manoeuvres, together with muscle tensing, can give an increase 
in G tolerance of up to +4G%.
The respiratory manoeuvres described above are physically tiring to 
carry out, and may be assisted by positive pressure breathing (PPB) in 
which air is supplied to the pilot’s mask at a pressure of up to 50 mmHg, 
Used in combination with an anti-G suit, PPB offers similar protection to
the other respiratory manoeuvres (Shulbrooks, 1973; Glaister & Lisher, 
1976), and appears to be considerably less fatiguing (Leverett, Burton et 
al, 1973), effectively raising the overall tolerance of the pilot to the 
sustained accelerations likely to be encountered in combat.
The above methods used in combination, i.e. anti-G suit, PPB and 
muscle tensing, give a trained pilot protection up to approximately +80^, 
the sustained capability of existing aircraft. The next generation of 
aircraft are expected to exceed this level and to achieve the necessary 
increase in tolerance, aircrew may have to fly in a reclined position. 
Thus, seats should have the capability of rotating backwards during 
combat. This is a very difficult and costly engineering development with 
the many constraints applied to the cockpit of modern fast jets. The 
advantage of a supine or semisupine seating position is that it converts 
the direction of G from +G^ to +Gx, Fig. 1.1, for which man has a 
considerably higher tolerance. An alternative to supination could be an 
appropriate pharmacological intervention for which several compounds have 
been tried in the past, but with limited success. Reviewed by Howard, 
1965, ephedrine increased the time of action of adrenaline which is 
normally very transient. Atropine, Nikethamide, pilocarpine and 
amphetamine sulphate appeared to have no effect on black-out threshold, 
i.e. loss of vision, without loss of consciousness, although some drugs 
have reduced the fatigue of repeated exposures acceleration. Adrenal 
cortical extracts and posterior pituitary extracts have been tried with 
varying success and desoxycorticosterone, if given for days prior to 
exposure to +G^ acceleration, reduced the recovery time for brain 
potentials to be re-established, if the accelerations had been 
sufficiently high to cause their extinction. The inhalation of carbon 
dioxide significantly raises the blackout threshold although there are.
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constraints on the concentration and length of time of administration. To 
date no specific compound has been developed for use in aircrew.
Lower Body Negative Pressure
The laboratory method commonly used for investigating G stress is the 
man carrying centrifuge. There are limitations, however, when trying to 
carry out investigations where blood samples are taken. Thus, it is 
difficult to remove samples during actual acceleration exposures as there 
is no space for an investigator in the centrifuge gondola, and he too, 
would be exposed to a similar level of stress. Hence, blood sampling is 
normally restricted to pre-run and post-run periods. The G usually 
experienced in an aircraft is +Gg, Fig 1.1, in which body fluids are 
forced away from the head to the feet. To investigate this situation more 
thoroughly, lower body negative pressure has been used. LBNP produces a 
similar cardiovascular stress to that of +G^ without the associated nausea 
and tumbling effects often experience by people after riding on the 
centrifuge.
The LBNP device. Fig. 1.2, is a rectangular aluminium box reinforced 
with angle iron and with airtight joints. The box can be split into two 
parts which are held together by overcentre latches. The abdominal seal 
consists of a split baffle plate constructed of Paxolin, to which is 
attached a three section iris diaphragm. Body weight on the lower rim 
of the baffle is spread by means of a fibre-glass moulding which extends 
80mm into the box and is covered by soft rubber. The baffle plate is a 
loose fit in the headend of the box where it lies against adjustable 
spacers and is held in place firmly during suction by atmospheric 
pressure. The baffle plate is adjusted, to lie comfortably just below the 
lower ribs laterally, so that the major part of the anterior abdominal
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wall may be subjected to negative pressure. Sealing is achieved by a 
latex rubber skirt which extends from mid-chest to the front rim of the 
box. During abdominal suction the skirt is drawn against the skin and 
transmits atmospheric pressure to parts of the body external to the baffle 
plate. For the current series of experiments, the adjustable foot rest 
shown in Fig. 1.2 was removed. With a foot rest, the downwards motion of 
the body caused by suction would tend to be resisted by calf muscle 
tension, and as a wholly relaxed state was required to monitor calf blood 
vessel volume, alternative support was provided by foam padding placed on 
the crutch support.
A maximum depression of -110 mmHg (-14,7 kPa) could be obtained 
using a BVC Engineering air/vacuum pump. (Though not the official SI 
unit, mmHg will be used throughout this thesis where a mercury manometer 
graduated in mm has been used for measurement. For conversion to SI 
units, the factor 1 mmHg = 133.3 Pa may be used). The chamber was 
controlled to the selected pressure using a combination of an air bleed 
and choke valve. The level was set using a mercury filled manometer and 
the level constantly monitored and recorded on a Gould recorder via an 
Ether Ltd pressure transducer (Type UP) and transducer bridge amplifier.
Cardiovascular effects of LBNP
The application of LBNP causes an elevation in lower body vascular 
transmural pressure, the magnitude of which is directly related to the 
level of reduced pressure applied. The elevation in vascular transmural 
pressure leads to sequestering of blood in the lower capacitance vessels, 
predominantly veins, (Wolthuis et al 1974), this event taking place 
within a few seconds of LBNP being applied. Subsequently, but to a
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lesser extent, there is translocation of plasma filtrate into extra- 
vascular spaces according to Starling's law. This translocation appears 
to proceed at a steady rate over the time that suction is applied, 
although there are limits imposed by the muscle sheaths and connective 
tissue of the leg.
Several different methods have been used to estimate the volume of 
fluid lost to the lower body during LBNP. Brown et al (1966) measured 
the longitudinal shift in body centre of gravity at a negative pressure 
of “70 mmHg, and estimated that 0.75 litre of blood had pooled in the 
lower body. Musgrave et al (1969) measured leg volume changes using 
water-plethysmography and showed increases of 0.5-0.6 litre at a 
negative pressure of -40 mmHg, applied for 5 minutes, and of 0.45 litre 
at -20 mmHg for 20 minutes. Murray et al (1965) used venisection 
techniques at various levels of negative pressure, and concluded that at 
least 0.5 litre must be lost from the central circulation if presyncopal 
episodes are to occur. Chemical techniques were used by Balakhovshii et 
al (1970) who measured circulating blood volume by analysing carboxy- 
haemoglobin levels before and after LBNP at -80 mmHg and estimated a loss 
of 1.5 litres from the circulation after 10 minutes of suction.
The loss of blood to the lower body during LBNP leads to direct and 
adaptive alterations in the central circulation (Wolthius et al, 1974). 
Central venous pressure falls by 3-7 mmHg and negative (subatmospheric) 
central venous pressures are often recorded at LBNP levels of-40 mmHg or 
below. This finding can be interpreted as resulting from a reduced venous 
return and diminished right heart filling and output. Changes in central 
venous and right atrial pressures are directly related to the level of 
LBNP applied (Wolthius et al, 1974). The response to these effects is a 
significant reduction in cardiac output, via a reduced stroke volume, and
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a decreased arterial blood pressure which, through neurocirculatory 
reflexes leads to an increase in total peripheral resistance and 
tachycardia.
There are several local changes in the peripheral circulation and in 
the organ systems served by the circulation. There is a decreased forearm 
blood flow and volume, and splanchnic blood flow is also reduced (Rowell 
et al, 1972) due to an increase in local vascular resistance. There is a 
decrease in cerebral blood volume which presumably affects cerebral 
perfusion and cerebral function (Wolthius et al, 1974). The constriction 
of the arteriolar and possible alteration in limb venous tone (Samueloff 
et al, 1966) could constitute a significant blood reserve that may 
contribute to the central blood pool.
Arginine Vasopressin (Anti-diuretic Hormone)
Arginine Vasopressin (AVP) is secreted along with oxytocin by the 
posterior pituitary gland. These two peptides are also found in neurons 
that project from the paraventricular nuclei to the hindbrain and spinal 
cord. Arginine vasopressin is synthesised in the cell bodies of neurons 
in the supraoptic and paraventricular nuclei and transported down the 
axons of these neurons to the posterior lobe. Arginine vasopressin is 
synthesised as part of a larger precursor molecule, prepropressophysin 
which contains a leader sequence of 19 amino acid residues followed by the 
arginine vasopressin moiety, vasopressin neurophysin and a glycopeptide. 
The precursor molecules are synthesised in the ribosomes of the cell 
bodies of the neurons. The leader sequences are removed in the 
endoplasmic reticulum, packaged into secretory granules in the Golgi 
apparatus, and transported down the axons by axoplasmic flow to endings in
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the posterior pituitary. Cleavage of the precusor molecule occurs during 
transport (Ganong, 1985).
For so small a compound, an octopeptide, AVP has many and varied 
functions. As well as its vasopressor and antidiuretic effect, discussed 
below, it also has a potent effect on the liver, which may involve calcium 
in a second messenger system, in contrast to the action in the kidney 
which is mediated through a second messenger using cyclic AMP, Knowles 
(1981) has shown that changes in phosphatidylinositol metabolism are 
involved in the coupling between vasopressin binding in hepatocytes, and 
calcium movements in the liver of the rat. Hue et al (1981) showed that, 
when incubated with glucose, AVP stimulates glycolysis in hepatocytes 
prepared from fed or starved rats. They demonstrated the stimulation of 
phosphofructokinase activity and the accumulation of a stimulator of 
phosphofructokinase which they considered to be fructose 2.6-biphosphate, 
Arginine vasopressin is a non-selective gastro-intestinal and pancreatic 
vasoconstrictor (Schwurkes and Charbon, 1978), and causes platelet 
aggregation (Grant and Scrutton, 1980), and Berrettini et al (1981) have 
demonstrated human platelet AVP receptors. Arginine vasopressin has been 
shown to have behavioural effects (Koob and Bloom, 1982). In 
particular, animal experiments have suggested a role for AVP in the 
enhancement of both consolidation and retrieval of memory (Bloom, 1981). 
Weingarten et al (1981) investigated the effects of administering 1- 
desamino-8-D-AVP (DDAVP) on human memory functions. The results, when 
compared to those obtained with placebo, suggested significant improve­
ments in healthy subjects treated with DDAVP, and similar changes in 3 out 
of 4 patients suffering from endogenous mood disturbance with cognitive 
impairment.
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Fig 1:3 Amino Acid Sequences
1 2 3 4 5  6 7 8 9
Cys Tyr Phe Gin Asn Cys Pro Arg Gly (NH2)
Arginine Vasopressin (Mammals)
Cys Tyr Phe Gin Asn Cys Pro Lys Gly (NH2)
Lysine Vasopressin (Pigs)
Cys Tyr lie Gin Asn Cys Pro Leu Gly (NH2) 
Oxytocin (Mammals)
Cys Tyr lie Gin Asn Cys Pro lie Gly (NH2) 
Mesotocin (birds, reptiles, amphibia)
Cys Tyr lie Ser Asn Cys Pro lie Gly (NH2)
Isotocin (bony fishes)
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One explanation for this varied role of AVP may be evolutionary in 
origin. Arginine vasopressin belongs to a 'family' of hormones of similar 
size and amino acid sequence. Arginine vasopressin along with oxytocin is 
produced within the mammalian pituitary gland. Oxytocin has a unique 
action on uterine muscle and milk secretion, but despite this the two 
hormones differ only by two amino acid substitutions at positions 3 and 8 
within the molecule, Fig 1:3. Variations of both hormones formed by 
different amino acid substitutes at positions 3, 4 and 8 are found within 
other vertebrate groups. Fig 1:3. This molecular polymorphism may 
indicate that oxytocin and AVP have a common evolutionary origin and 
retain some of their original functions. Sawyer and Pang (1980) injected 
arginine vasotocin (AVT) into fishes: the systemic vasocontrictor response 
observed suggests that the primitive function of AVT may be related to 
cardiovascular regulation. During early amphibean evolution AVT may have 
been adapted to serve new osmoregulatory functions. The primative 
glomerular anti-diuretic response to AVT is a localised rather than a 
generalised vasoconstrictor response. Responses by renal tubules, skin 
and urinary bladders may have been a subsequent adaption of AVT and its 
analogue AVP, in mammals, thereby increasing their usefulness as 
osmoregulatory hormones. Several other groups of structurally similar 
hormones also exist and again within these groups each particular hormone 
exhibits slight variations in structure when isolated from different 
species of animals.
Effects of LBNP and Posture on AVP Release
LBNP and postural changes, i.e. head up tilt, have been used 
extensively to study cardiovascular dynamics, orthostasis, hypertension 
and syncope.
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Os et al (1984) investigated the effect of posture on the 
arteriovenous difference of plasma AVP, in a group of 50 year old normal 
males. They showed that in the supine position arterial plasma AVP was 
significantly increased over venous AVP. However, after 30 minutes, 
upright venous AVP had increased by 45% and although arterial AVP also 
increased the arteriovenous difference was no longer significant. This 
was interpreted as a substantial amount of AVP being removed by receptors 
in the peripheral vascular beds, i.e. forearm, as well as the liver and 
kidneys. Segar and Moore (1968) tested the hypothesis that alterations in 
the intravascular distribution of blood affect AVP secretion in man, using 
thermal and positional changes to test the theory. The data indicated 
that changes in activity of intrathoracic stretch receptors, in response 
to redistribution of blood, alter AVP secretion independently of changes 
in serum osmolality. The rapidity of change of plasma AVP indicated a 
great sensitivity and a prime functional role for the volume receptors in 
the regulation of AVP secretion. Share et al (1972), however, found no 
change in AVP plasma levels in salt depleted and ambulatory subjects, when 
investigating posture and sodium depletion, but found x9 fold increases in 
plasma renin levels and concluded that either there are different volume 
receptors for renin and AVP or the AVP control mechanism may be less 
sensitive to slow, small changes in blood volume. Davies et al (1976) 
used 85'’ head-up tilt to study the relationship between AVP concentration, 
plasma renin activity and the change of plasma volume. A biphasic rise in 
AVP was observed, a small initial rise at 3 minutes was followed by a 
rapid and striking rise at 30-40 minutes, when the fall in plasma volume, 
some 17% drop, had reached its peak. A large rise in AVP in subjects who 
experienced syncope was also noted.
Goldsmith et al (1982) used LBNP to examine the contribution of 
cardiopulmonary and sinoaortic baroreceptors to the nonosmotic release of
18
AVP in normal man and on the response of the sympathetic nervous system 
activity, using plasma noradrenaline as an index. The results showed no 
increase in AVP level, when there was a fall in central venous pressure 
(CVP) that resulted in sympathetic activation presumably via cardio­
pulmonary receptors, A further fall in CVP that led to a modest 
unloading of the sinoaortic baroreceptors, which in turn led to further 
increased sympathetic activity, also failed to stimulate AVP,
Hypotension, however, was shown to cause a rapid and significant rise in 
AVP, Rogg and Moore (1968) had previously demonstrated increases in AVP 
using LBNP at negative pressures of -30 mmHg or greater, for a period of 
30 minutes, but not at -20 mmHg and suggested that the AVP rise is due to 
a shift of blood from the thorax to the lower extremities with a 
subsequent release of intrathoracic baroreceptor inhibition of AVP 
secretion, the -20 mmHg level not pooling sufficient a volume to stimulate 
a rise in AVP.
Although the pressor action of AVP has been known for some time 
(Oliver & Schafer, 1895), its precise role in changes of blood volume and 
pressure is uncertain. Arginine vasopressin injected into normal subjects 
does not appear to raise blood pressure unless in large quantities over 
500pg/ml circulating blood volume (Padfield et al, 1987, Johnston et al, 
1981), It is possible, however, that small increases of AVP over a long 
period may elevate blood pressure. The findings of low concentrations of 
AVP in benign essential hypertension argues against a causal role for AVP 
(Padfield et al, 1976). It was considered a possibility that AVP is a 
causative agent in malignant hypertension, although a direct link could 
not be established, the raised levels of AVP were thought more likely due 
to a contracted plasma volume following salt and water loss. This work is 
supported by Davies et al (1983), three groups were examined normo-
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tensive, mildy hypertensive and more severely hypertensive patients, both 
under basal conditions and using 85° head up tilt to stimulate AVP 
release. The data demonstrated that AVP does not have a role in causing 
or perpetuating non-accelerated essential hypertension in man.
The role of AVP and cardiovascular regulation has been reviewed by 
Johnston et al (1981) and Cowley (1982). There is a species difference in 
response to AVP with humans being the least pressor sensitive when 
compared with dogs and rats. Despite this apparent lack of AVP pressor 
sensitivity, there is evidence that systemic vascular resistance is 
significantly altered by considerably smaller concentrations of plasma 
AVP than those normally required to raise arterial pressure. Animal 
studies in the rat have shown mesenteric vessels are more sensitive to AVP 
than angiotensin II and smaller arterioles are more sensitive than larger 
vessels. The femoral and carotid arteries in the dog also exhibit 
significant alterations in diameter and elasticity within physiological 
concentrations of AVP.
Arginine vasopressin at normal concentrations can significantly 
decrease heart rate and cardiac output, whereas arterial pressure remained 
unchanged, thus indicating that total peripheral resistance had increased. 
AVP infused into the dog caused a decrease in heart rate without a change 
in stroke volume, the peripheral resistance doubling. The decrease in 
cardiac output is in part a direct result of the bradycardia per se 
rather than depressed cardiac performance or other possible alterations 
in systemic vascular resistance.
Baroreceptor denervation or CNS ablation studies suggest that AVP acts 
under normal conditions to enhance the ability of baroreceptor reflexes to 
offset changes in arterial pressure and only when the strongly opposing
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autonomie response is removed does arterial pressure rise in response to 
the systemic vasoconstrictor action of AVP.
At the present time although the major sites of AVP action and the 
specific mechanism of these responses remain unclear, data suggest that 
AVP is capable of significantly modifying important reflex mechanisms 
involved in the control of the cardiovascular system and that these 
alterations can occur at plasma concentrations of AVP that are well within 
the observed physiological range.
The anti-diuretic action by AVP on the kidney, acts by altering the 
permiability of the collecting ducts which are located in the loops of 
Henle. The kidney functioning by a counter current multiplication system, 
(Moffat 1971). The large volume of glomerular filtrate is reduced by ca 
80%, by the active re-absorption of sodium accompaning an osmotically 
equivalent amount of water. A relatively small volume of isomotic fluid 
enters the loop of Henle, from which it leaves as a hypo-osmotic 
solution. During its passage through the loop it has established an. 
osmotic gradient in the medulla by a counter-current multiplier system 
involving the active transport of sodium and chloride ions from the 
ascending limb, to the descending limb. More sodium is reabsorbed from ' 
the distal tube and the fluid then traverses the hyperosmotic medulla in 
the collecting duct. If AVP is present, water accompanies sodium out of 
the distal tubule and also is osmatically withdrawn from the collecting 
duct as it passes through the hyperosmotic medulla; thus producing a 
concentrated urine. In the absence of AVP, water remains in the distal 
tubule and in the collecting duct since the walls are impermeable to 
water. The urine is then dilute.
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The anti-diuretic effect of AVP has been shown to be mediated through 
a second messenger system, which uses cyclic adenosine 3 ’, 5' mono­
phosphate as the second intracellular messenger. Bockaert et al (1973) 
used pig [^H] Lysine-vasopressin binding to receptors in pig kidney plasma 
membranes, precautions were taken to eliminate vasopressin deteriorating 
systems which are normally present. Their results show a non-linear 
coupling, with a Hill coefficient of 0.43 +/- 0.13 for the dose-cyclase 
activation relationship at equilibrium. This suggests a negative co- 
operativity effect as described by Kosland et al (1966). This theory is 
supported by Hechter et al (1978) who also showed in pig membrane 
preparations that the relationship between hormone concentration and 
enzyme activation was negatively co-operative.
A variety of studies have been carried out into the effect of 
different levels of hydration on AVP secretion. Drew et al (1984) 
investigated the effects of chronic infusion of AVP in salt restricted 
water deprived man, a sustained natriuresis occurred accompanied by falls 
in plasma renin activity, aldosterone and noradrenaline, which they felt 
contradicted the view that sodium excretion induced by AVP, is solely a 
function of water retention. A marked fall in packed cell volume (PCV) 
was also observed during the infusion of AVP, in spite of the contraction 
of total body water. An increase in plasma volume due to AVP would be a 
useful physiological mechanism for an animal facing depletion, where the 
secretion of a hormone capable of preserving plasma volume at the expense 
of other body fluid compartments, would be a useful addition to other 
homeostatic mechanisms.
Woods and Johnston (1983) compared the rise of AVP in dehydrated 
normal Long-Evans rats, with Brattleboro diabetes insipidus rats who are 
genetically deficient in AVP. The administration of AVP and a synthetic
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AVP analogue (1, desamino-8-D-arglnine vasopressin) a potent antidiuretic, 
but with minimal pressor activity, demonstrated that both the antidiuretic 
and vasoconstrictor properties of AVP are important, in the cardiovascular 
response to dehydration. Kimura et al (1976) examined various states of 
hydration in water loading, infusion of hypertonic saline, acute 
fluorosemide induced hydration combined with postural changes, the results 
did not show any correlation between AVP and Plasma Renin Activity (PRA). 
They concluded that plasma osmolality is the dominant variable in 
regulating plasma AVP unless the degree of hypovolemia is sufficient to 
overcome the osmotic dominance. Conversely, PRA activity was influenced 
more by changes in effective blood voliwne than those of plasma 
osmolality, Harrison et al (1986) considered that as rehydration does not
abolish the increases in AVP and PRA there is an intrathoracic
baroreceptor involvement in the regulation of AVP and renin release.
Arginine vasopressin probably plays a role in the chronic hypotensive
response seen during acclimatisation to exercise training. Large 
decreases in plasma volume with conversely large increases in AVP and PRA 
have been observed (Greenleaf et al, 1981). Levels of exercise intensity 
greater than 40% V02 max are required to cause immediate changes in 
plasma osmolality and stimulate AVP release (Convertino et al, 1981).
Hypoxia, which is of considerable importance to aircrew, did not 
increase plasma AVP release in people who adjusted well to high altitude 
(Forsling and Milledge, 1977), although it had been demonstrated in the 
anaesthetized dog (Forsling and Ullman, 1974). As acute mountain sickness 
is associated with fluid retention and in severe cases pulmonary of 
cerebral oedema, there was a possible role for AVP as a causative agent. 
Harber et al (1981) could not establish any correlation between AVP and
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altitude in eight mountaineers including, tragically, one who died from 
cerebral oedema. Mills (1984) concluded that hypoxia does not stimulate 
AVP even at high +G^ levels.
Catecholamines
Three catecholamines are synthesized in the human body: dopamine, 
noradrenaline and adrenaline. Each compound has in common a catechol 
(dihydroxybenzene) nucleus and an amine-containing side chain. Blaschko 
(1973) described the basic synthetic pathway from L-tyrosine to 
adrenaline. Fig. 1.4, although individual cells do not carry out all the 
reactions shown. Chromaffin cells, which produce adrenaline, are located 
in mammals mainly in the adrenal medulla, or in clusters or singly 
outside the adrenal gland. Plasma adrenaline may be used therefore as an 
index of adrenal medullary activity. The adrenergic neurones, noradren­
ergic or dopaminergic in mammals, occurring mainly in the postganglionic 
sympathetic fibres and in the CNS. Noradrenaline plasma levels may be 
regarded as a relatively specific index of adrenergic nerve activity. It 
is, however, only a semi-quantitative estimate of the amount of 
noradrenaline released by neural activity because most of the 
noradrenaline is taken back into the adrenergic neurone by an active 
uptake process (uptake 1) or taken up into extraneous tissue (uptake 2) 
(Iverson, 1973). In the chromaffin cells, the amines serve as hormones, 
they are released into the blood stream and act as chemical messengers to 
their specific cellular receptor. In the neurones the message only 
reaches those excitable units that are innervated by them.
Dopamine which was for many years thought to be merely a precursor in 
the synthesis of noradrenaline and adrenaline, is predominantly a 
neurotransmitter within the CNS and has been particularly implicated in
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the control of the secretion of growth hormone, prolactin and possibly 
AVP. Highly selective receptors for dopamine have also been identified in 
the peripheral and mesenteric arterioles, the sympatheic ganglion and the 
renal circulation (Kruk and Pycock, 1983). Dopamine has been shown to be 
produced in the kidneys where it has been implicated as a natriuretic 
hormone because it inhibits the tubular transport of sodium (Lee, 1982).
It is the former two catecholamines which are most often associated with 
stress response.
The physiological effects of noradrenaline and adrenaline are 
determined by the receptors to which they bind. These receptors have 
been divided into two main groups, alpha and beta (discussed below). 
Noradrenaline is almost exclusively an a-adrenergic agonist, whereas 
adrenaline stimulates both a and b receptors. The more important function 
of these receptors with regards stress are those with cardio-vascular and 
metabolic effects.
The cardiac effects of the catecholamines include the induction of a 
tachycardia and increases in cardiac contractility, ventricular 
excitability and coronary blood flow (b effects). At the same time, 
there is an a-adrenergic induction of cutaneous and splanchnic vasocon­
striction which increase peripheral resistance, but an increase in blood 
flow to skeletal muscle due to selective vasodilation also occurs as a 
result of b stimulation. Alpha stimulation of skeletal muscle produces an 
increased release of acetylcholine, while b stimulation increases 
glycogenolysis.
Adrenaline and noradrenaline induce hyperglycaemia by activating 
glycogenolysis and, most importantly, by inhibiting insulin secretion (a
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action) (Porte, 1967). These actions are probably more dependent upon 
noradrenaline release at nerve terminals in the liver and pancreatic cells 
rather than the release of adrenaline in the circulation. A comparison 
between stimulation of the hepatic or splanchnic innervation in the dog 
suggested that, when compared with the hepatic innervation, the adrenal 
medullae "had little part in the control of hepatic glycogenolysis under 
normal conditions" (Edwards and Silver, 1972). Overall, the role of the 
sympathetic nervous system in glucose homeostasis is difficult to assess, 
but it is likely that the hyperglycaemia action of growth hormone and 
glucagon are more important than that of other catecholamines under normal 
conditions (Marks, 1981).
The total amount of glucose available for fuel is very limited and it 
is generally agreed that fatty acids and ketones are important sources of 
energy. Ketones, by virtue of their water solubility, are more accessible 
to transport in the CNS where they are an important source of energy.
They are produced exclusively in the liver and their rate of production is 
determined by the concentration of non-esterified fatty acids in the 
circulation. The catecholamines play a fundamental role in the 
mobilization of fatty acids by the stimulation of adenyl cyclase, thereby 
increasing the cyclic AMP content of fat cells. The increased cyclic AMP 
is then thought to stimulate triglyceride lipase which releases non- 
esterified fatty acids into the circulation (Newsholme and Start, 1976).
The question of a direct action of the catecholamines upon the CNS 
remains controversial, but adrenaline has been shown to cross the blood 
brain barrier in the region of the hypothalamus (Weil-Malherbe et al, 
1959). Within the CNS, however, the three catecholamines serve as 
neurotransmitters. Neurons that form dopamine are lacking in the last two 
enzymes of the metabolic chain namely dopamine b-hydroxylase and
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noradrenaline N-methyltransferase. Those neurons that form noradrenaline 
contain no noradrenaline N-methyltransferase.
Action of catecholamine in_the CNS
A link between brain catecholamines and two particular types of mental 
illness has long been suspected (Fuller, 1983). Depression is postulated 
to involve a deficiency of noradrenaline and possibly of other brain 
amines. Schizophrenia may be a disease of abnormal dopaminergic function. 
Low levels of adrenaline, noradrenaline and serotonin have been found in 
the brains of some depressed patients at post mortem. Anti-schizophrenic 
drugs are potent dopamine receptor blockers and antagonism of dopamine 
function is believed to account for their suppression of psychotic 
behaviour. A cause of psychosis may be excessive dopaminergic input to 
some brain regions.
All three types of catecholamine neurons have been implicated in the 
central regulation of blood pressure (Scriabine et al, 1982). Drugs that 
act on each of the three types of catecholamine neurons can lower blood 
pressure. Direct acting dopamine agonists can lower blood pressure by 
stimulation of peripheral dopamine receptors in renal vasculature, but 
activation of central dopamine receptors may also lower blood pressure. 
Several antihypertensive drugs act on central noradrenaline and adrenaline 
neurons, mono-amine oxidase (MAO) inhibitors, which lower blood pressure, 
increase adrenaline, noradrenaline and dopamine concentrations in the 
brain.
Catecholamines have been shown to be active in regulating pituitary 
hormone secretion, perhaps the best example being the effect of dopamine 
on prolactin secretion (Gudelsky, 1981). Dopamine released into the
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portal circulation suppresses secretion of prolactin on reaching the 
anterior pituitary gland. Dopamine antagonists elevate serum prolactin 
concentration by blocking the endogenous control mechanisms and dopamine 
agonists reduce plasma prolactin concentrations. Catecholamines have 
been implicated in the control of many other hormones in the anterior 
pituitary including adrenocorticotrophic hormone, growth hormone, 
thyrotrophin and gonadotrophin by influencing releasing factors and 
release-inhibiting factors.
Besides the functions discussed above, catecholamine neurons have many 
other roles. Food intake can be controlled by catecholamines. 
Catecholamines also participate in the regulation of body temperature. 
Dopamine deficiency is the primary defect in Parkinson's disease, and 
restoration of dopaminergic function by administration of the dopamine 
precursor L-Dopa or direct dopamine agonists, is now a useful means of 
treating Parkinson's disease.
General actions of catecholamines
The original description of adrenaline as a stress hormone was that of 
Cannon (1914) from his experiments of cats exposed to barking dogs. He 
formulated the "emergency-function" theory of adrenal medullary activity, 
the fight or flight reaction. This theory was based on the proposal that 
many of the physiological effects of adrenaline serve the goal of 
preparing the organism to meet threatening situations involving fear, rage 
or pain. These effects have been demonstrated by many investigators and 
can be broadly divided into psychological and physical stimuli.
Psychological stimuli can be caused by anticipation, unpredictability 
or novelty of a situation which produces a rise in adrenaline output
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which correlates with the degree of arousal evoked by the stressor 
(Frankenhauser, 1975). Repeated exposure to the stimuli in which the
subject learns to control the situation usually leads to a fall in 
adrenaline excretion. Frankenhauser and Rissler (1970) showed that if 
humans who were exposed to unpredictable electric shocks, were given tasks 
which enabled them to avoid the electric shocks, adrenaline excretion was 
reduced. Noradrenaline excretion remained elevated, however, as long as 
the subject was in an attention demanding activity situation. The 
increases in noradrenaline were only about 50% above basal control values, 
whereas the adrenaline had increased by some threefold above normal.
Repeated exposure does not necessarily reduce adrenaline excretion. 
Adrenaline remains, elevated even with experienced subjects, in situations 
such as parachuting where adrenaline levels are high with both experienced 
and novice parachutists (Bloom et al, 1963). This is also the case for 
noradrenaline and has led to speculation as to whether catecholamine 
excretion may be used in predicting personality traits. The results have 
been conflicting, but adrenaline does appear to be increased in certain 
emotional states, including fear and anger (Frankenhauser, 1975). Large 
increases have been observed in urinary adrenaline in this laboratory 
(unpublished data) in a pilot who was known to be angry due to ground 
delays, and apparently extrovert characters appear to have overall higher 
levels of both urinary adrenaline and noradrenaline than more introvert 
persons. Lundberg (1976) showed that crowding on commuter trains caused 
elevation in adrenaline when compared with quiet, uncrowded train 
journeys.
The advantages of catecholamine production in response to psycho­
logical stress are not entirely clear. Experiments on infusion of
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catecholamines into human subjects have suggested that performance of 
certain tasks may be improved, particularly by adrenaline (Frankenhauser 
and Jarne, 1963). Among normal healthy individuals, those who have 
relatively high catecholamine excretion levels tend to perform better in 
terms of speed, accuracy and endurance than those with lower levels. The 
relationship appears to be particularly marked for adrenaline, but also 
appears true for noradrenaline (Frankenhauser, 1975).
Various forms of exercise have been used to demonstrate the effect of 
physical stimuli on the excretion of catecholamines, an effect which is 
largely dependent on the duration and intensity of the activity. Galbo et 
al (1975) measured plasma catecholamines during and post graded and 
prolonged treadmill running. At 44% Vo2(max), no significant changes were 
observed, but at higher work loads, 77 and 100% maximal oxygen uptake, 
sixfold increases in both adrenaline and noradrenaline were seen.
Prolonged work also caused significant increases in both catecholamines 
with a further rise at exhaustion. This work agrees with those of many 
authors, although Haggendal et al (1970) who measured arterial catechola­
mines during graded ergometer exercise, only found an increase in 
noradrenaline and suggested that exercise does not stimulate the adrenal 
medullae. They also concluded that trained subjects had lower 
noradrenaline than unconditioned subjects. There is the possibility that 
the fluorimetric method used by Haggendal may not have been sensitive 
enough to measure adrenaline.
Fitness does appear to have some effect on catecholamine secretion. 
Bloom et al (1976) compared the hormonal response to graded ergometer 
exercise between 6 well trained cyclists and 6 untrained subjects.
Although the catecholamines increased, they were less in the trained group 
than the untrained, particularly with regards to adrenaline. Similar
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results were obtained by Davies et al (1977) who investigated the effects 
of a training program on the urinary excretion of catecholamines. 
Noradrenaline excretion was reduced in the trained group under both 
exercise and resting conditions. An interesting observation was made by 
Elmadjian et al (1957) who measured urinary catecholamine excretion in 
hockey players, some of whom took part in active competition, while others 
observed the game. The results showed large increases in noradrenaline 
and smaller increases in adrenaline in active participants, whereas only 
adrenaline increased in the audience. It therefore seems likely that 
clear distinction between noradrenaline and adrenaline secretion may not 
always exist in response to physical stressors. Some caution in 
interpretation of much data has to be used as sensitive methods for the 
analysis of catecholamines has only recently become available.
Receptors
The concept of a receptor for a substance arises from the ability of 
tissue to recognise and respond to minute quantities of a substance in a 
very precise way. Different criteria may be used defining a receptor, 
the most useful being to identify the endogenous physiological agent 
which normally interacts with the receptor. Alternative classification of 
receptors use behavioural, physiological, anatomical biochemical and 
pharmacological criteria.
Considerable biochemical and pharmacological evidence exists which 
indicate that multiple classes of dopamine receptors are present in 
vertebrate and invertebrate nervous and endocrine systems (Goldberg et 
al, 1978, Kebabian and Caine, 1979, Leff and Creese, 1983). Kebabian and 
Caine (1979) divided dopamine receptors into two main groups, D-1 and D-2
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receptors. D-1 dopamine receptors mediate the stimulation of adenylate 
cyclase activity, while D-2 dopamine receptors are either unassociated 
with this enzyme or inhibit its action. D-2 receptors are also 
characterised by being especially sensitive to the actions of butyro- 
phenones i.e. haloperidol and spiroperidol. Other types of dopamine 
receptors have been described, depending on their affinity for various 
agonists and antagonists. A site, in the striatum, because of its binding 
characteristics has been classified as a D-3 receptor. Leff and Creese 
(1983) consider, however, that this receptor is in fact a D-1 type 
receptor, which when labelled by (^H) thioscanthenes exhibit a high 
affinity state for agonists, formed as tertiary complex of agonist 
receptor and OTP binding protein, their research continues in this field. 
Dopaminergic transmission has been shown to occur only in the CNS. Three 
sites have been identified the nigro-neostriatal pathway, the midbrain 
mesolimbic forbrain system and the tutero-infundibular system. Dopamine 
receptors have been identified at five sites within the nigro-striatal 
axis (Kebabian and Caine, 1979), three being D-2 designated receptors and 
two D-1 type. In the striatum there are D-2 presynaptic receptors which 
control tyrosine hydroxylase and postsynaptic receptors which respond to 
ergot agonists in vivo. There are also postsynaptic receptors which are 
closely associated to adenylate cyclase. In the substancia nigra there 
are D-1 presynaptic dopamine receptors and D-1 autoreceptors. The 
function of many of these receptors is unclear.
Many peripheral tissues respond to exogenously applied dopamine, but 
do not appear to have dopaminergic innervation. Dopamine receptors are 
believed to be located in some sympathetic ganglia, exocrine glands and 
the gastro-intestinal tract and on mesenteric and renal arteries 
(Goldberg et al, 1978). In the sympathetic ganglia of the autonomic 
nervous system, dopamine receptors, linked to adenylate cyclase, appear
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to cause changes in the permeability of the postganglionic neuronal 
membrane. Dopamine causes a dose-dependent vasodilator response in the 
renal and mesenteric arteries, this effect can be attenuated by pre­
treatment with dopamine receptor blockers, a or b-adrenoceptor blockers do 
not affect the dopamine response. Increased secretion of enzymes, using 
dopamine agonists, from the salivary gland, and pancreas has been 
observed, as has the relaxation of the gastro-intestinal tract in isolated 
preparations. Dopamine is also found in the glomus cell of the carotid 
body, where it appears to have a role in control of respiratory reflexes. 
Hypoxia decreases dopamine release in the carotid body; this removes the 
hyperpolarisation of sensory neurones and reflexly stimulates 
respiration.
The release of prolactin from the anterior pituitary appears to be ' 
regulated by an inhibitory D-2 dopamine receptor. The action could be 
blocked by a combination of phentolamine and propranolol, adrenaline and 
noradrenaline have also been found to be active in inhibition of 
prolactin (Goldberg et al, 1978). Dopamine also inhibits, in the anterior 
pituitary, a vasoactive intestinal peptide stimulated adenylate cyclase, 
whilst in the intermediate lobe dopamine inhibits the badrenergic agonist 
stimulated synthesis of cAMP leading to a reduction in a-melanocyte 
stimulation hormone release (Leff and Creese, 1983).
Stimulation of D-1 receptors increases renal blood flow, whereas drugs 
which modify the activity of D-2 receptors have been used to treat 
endocrinological and psychiatric disorders.
Adrenergic receptors were first observed, although not defined, by Sir 
Henry Dale, 1906, who found that some types of adrenaline response could
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be inhibited by ergot alkaloids, whereas others were unaffected. Ahlquist 
(1948) extended these observations on the basis of a detailed pharma­
cological study. He compared the relative efficacy of adrenaline, 
noradrenaline and other methyl derivatives i.e. isoprenalin and concluded 
that there were two types of response mediated by two different classes of 
receptor, which he termed a-receptors and breceptors. Beta receptors have 
since been subdivided into two further groups 1 and 2 (Lands et al, 1967) 
and there is evidence that a similar classification should be applied to 
the a receptors (Berthelsen and Pettinger, 1977). In general terms the b 
receptor is characterised by an agonist relative potency series: 
isoprenalin> adrenaline> noradrenaline> phenylephrine; isoprenalin being 
the most potent. In contrast, the receptor is characterised by a 
relative potency series: noradrenaline> adrenaline> phenylephrine> 
isoprenalin.
The properties of adrenergic receptors have been reviewed by Jenkinson 
(1973) and Motulsky and Insel (1982). Some of the typical actions of 
adrenaline and noreadrenaline, (discussed above) indicate that a and b 
receptors often behave in an antagonistic fashion. Adrenaline is capable 
of stimulating two different responses, sometimes in the same type of 
cell. This implies that not only are there two types of receptor system, 
but there must also be at least two different 'second-messenger' systems 
involved. The response mediated by b receptors has been shown to be the 
activation of the enzyme adenylatecyclase which is responsible for the 
synthesis of cyclic 3'-5'-adenosine monophosphate. The a-receptor is able 
to regulate the influence of calcium into cells and stimulates the 
production of another nucleotide cyclic 3'-5'-guanosine monophosphate 
(cyclic GMP),
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Control of AVP secretion
Several factors are involved in the stimulation or inhibition of AVP, 
making for potentially complex interactions. There is some dispute in the 
literature as to whether dopamine acts as an inhibitor or stimulator of 
AVP release. Animal preparations have produced a variety of responses, 
but the human responses appear to contradict the idea that dopamine 
stimulates AVP release. Phenothiazines, which block the action of 
dopamine, have been shown to increase AVP secretion (Shah et al, 1973: De 
Rivera, 1975), whilst haloperidol, a CNS dopamine blocker, has been shown 
to have little effect on plasma AVP level (Kendler et al, 1978). Lightman 
and Forsling (1980) found that L-Dopa, a precursor of dopamine which can 
cross the blood brain barrier, decreased resting levels of AVP and 
inhibited the rise of AVP following a 65“ head up tilt. The use of a 
carbidopa an aromatic L-amino acid decarboxylase inhibitor blocked the 
effect of L-Dopa on AVP release. As carbidopa cannot cross the blood 
brain barrier and does not inhibit the accumulation of dopamine in the 
brain after administration, they postulated that its action on the L-Dopa 
induced inhibition of AVP is at a site outside the blood brain barrier. 
Within the hypothalamo-hypophysial system only the pituitary gland and 
the median eminence of the hypothalamus are outside the blood brain 
barrier. Lightman et al (1983) consider that as the pituitary contains 
high concentrations of dopamine, can convert L-Dopa to dopamine and nerve 
endings in the median eminence have been shown to contain dopamine, AVP 
and neurophysin, that either or both of these areas is the site of an 
inhibitary effect of dopamine on AVP secretion.
Dopamine is formed in the kidney from circulating L-Dopa (Lee, 1982) 
the likely site being the renal tubular cells, although the renal 
dopaminergic nerves may be involved. The dopamine formed within the
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kidney probably acts on specific receptors, which in turn results in 
vasodilation of renal blood vessels, by action on vascular receptors and 
natriuresis, and an effect on tubular sodium transport mechanism.
Dopamine blockade, using domperidone, blocked the naturetic response to 
lower body positive pressure (Bennet et al, 1982), but as urine flow was 
unaffected there did not appear to be any interference with AVP 
suppression, suggesting that it is a very localised effect within the 
kidney and not part of a general mechanism and is probably acting through 
a D-1 receptor.
Changes in blood osmolality influence the secretion of AVP. Bromo- 
criptin, a dopamine agonist, stimulated a rise in plasma AVP (Robinson et 
al, 1982) indicating that the osmotically induced release of AVP is under 
dopaminergic control in man.
Both cardiovascular receptors and baroreceptors have been shown to 
have an influence on AVP secretion. A reduction in blood volume is an 
effective stimulus for the release of AVP. Two groups of receptors have 
been shown to function in volume regulation of AVP release. They are the 
left atrial stretch, or b receptors, and the atrial baroreceptors (Share, 
1976). A decreased activity of the carotid sinus baroreceptors results in 
an increased plasma AVP concentration. Whereas an increase in left atrial 
pressure, achieved in some cases by inflating a balloon in the left 
atrium, inhibits the release of AVP, presumably as a result of an 
increased afferent impulse activity from the atrial b receptors, although 
this view is disputed by some workers. Goldsmith et al (1984) did not 
show an increase in AVP following increased intracardiac and arterial 
pressure in humans. Their subjects were mildly water restricted and the 
left atrial response only appears to occur with small volume changes.
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Leimbach et al (1984) argued that some of the controversy may be due to an 
interaction between osmoreceptors and baroreceptors regulation of AVP in 
man, such that the modulating effect of baroreceptors may be masked unless 
serum osmolality is elevated. An increase in renal excretion of sodium 
and water in both anaethetised and conscious animals has been observed 
with left atrial volume expansion (Cowley, 1982). AVP seems to play a 
significant role in preventing cardiovascular volume overloads by
initiating renal excretion of water. Occlusion of the carotid arteries
has been shown to elevate plasma AVP levels significantly (Cowley, 1982), 
in the dog the changes were prevented by denervation of the carotid sinus. 
Berl et al (1974a) investigating the b adrenergic stimulation of AVP 
showed that isoproterenol stimulated AVP release by altering baroreceptor 
tone rather than by direct central or depressor effect of the
catecholamine. The same baroreceptor pathways have been shown to be
involved in the suppression of ÀVP release with noradrenaline (Berl et al, 
1974b) and may well be the common pathway whereby nonosmotic stimuli 
control AVP release.
Constriction of the carotid arteries above and below the carotid sinus 
(Berl et al, 1974a) showed that the constriction above did not affect 
urinary osmolality or water clearance, whereas constriction below the 
carotid sinus was associated with an antidiuresis. Interruption of para­
sympathetic pathways by bilateral cervical vagotomy, in the dog, also 
produces an antidiuresis (Schrier et al, 1972, Share and Levy, 1962).
This would indicate two groups of receptors are concerned with the 
regulation of plasma AVP within the vascular system. One group located in 
the carotid sinuses and a second group with afferent nerve fibres in the 
vagi.
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Although left atrial and other cardiopulmonary pressures respond to 
small changes in volume, it seems likely that arterial baroreceptors 
play a significant role in initiating AVP release during more extreme 
conditions of hypovolemia. Cowley et al (1984) concluded that in the dog 
AVP enhances the ability of the carotid reflexes to normalise decreases of 
arterial pressure, but buffers a rise in pressure from its own vasoactive 
properties by initiating a fall of cardiac output.
Angiotensin II may have an effect on AVP secretion, although again 
there appears to be controversy between different groups of workers 
(Cowley, 1982); because the renin-angiotensin-aldosterone axis is of 
fundamental importance for the conservation of body sodium and AVP for 
water conservation. It has been suggested that angiotensin II acts on 
the CNS to increase BP, stimulate drinking and increase the secretion of 
AVP and ACTH. In man only large doses of angiotensin II through I.V. or 
intracarotid administration stimulates AVP secretion (Reid et al, 1983), 
the most likely site of the action being the circumventricular organs and 
the supraoptic nucleus of the hypothalamus. With present knowledge it 
seems likely that the cardiopulmonary and arterial baroreceptors, but 
not circulatory angiotensin II, constitute the major afferent part of an 
arterial pressure feedback control system, whereby changes of blood volume 
and/or arterial pressure can initiate alteration of AVP secretion, which 
in turn influence systemic vascular resistance and acutely compensates for 
the fall of arterial pressure.
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CHAPTER TWO
Introduction
Previous experiments, using the man carrying centrifuge, and 
investigating the biochemical and physiological effects of (1) variable 
seat back angle and (2) positive pressure breathing, generally showed an 
increase in AVP with + G ^  acceleration (Mills, 1983). In a series of 
experiments using baboons (unpublished data), administration of an AVP 
antagonist d(CH2)$-Tyr(Me)AVP, produced a reduction in blood pressure 
particularly at higher +0^ levels compared to control runs. These results 
were considered to support those of other workers who have shown that AVP 
is actively involved in the control of blood pressure, and markedly so in 
stress situations similar to +0^ in which a decrease in extracellular 
fluid volume results in an increase in plasma AVP. The receptors 
mediating this response are located within the vascular system, and 
evidence from the literature suggests that intrathoracic baroreceptors 
(Rogg and Moore, 1968; Segar and Moore, 1968; Harrison, 1986), left atrial 
receptors (Schrier et al, 1979) and carotid baroreceptors (Share and Levy, 
1962; Schrier and Berl, 1972) may all be involved in the control of the 
pressor action of AVP. The catecholamine dopamine has been implicated in 
the control of plasma AVP levels by suppressing the secretion of AVP. The 
methodology for the analysis of plasma catecholamines has recently been 
improved, making a detailed study of the relationship between dopamine, 
the other catecholamines and AVP a practical proposition.
There was little information in the literature of the precise response 
and sequence of secretion of catecholamines to cardiovascular stress in 
normal subjects, most blood sampling being over several minutes, or on a
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before-and-after basis. A series of experiments has been carried out 
using LBNP to produce cardiovascular stress. Initially, a systematic 
examination of the changes in peripheral plasma levels of the three 
catecholamines - noradrenaline, adrenaline and dopamine - in response to 
different levels of LBNP was undertaken, and the possible influence of 
these catecholamines on AVP secretion was investigated.
Subjects and Experimental procedure
Seven normal male volunteers, 19-49 years of age, were each subjected 
to four levels of LBNP, these being -30 mmHg, -60 mmHg and -90 mmHg, with 
0 mmHg as a control. Inexperienced subjects were given several runs at 
various levels of negative pressure to familiarise them to the sensations 
and effects, before entering them into the trial. The order of runs was 
determined by a randomly selected 4x4 Latin square which was inverted for 
subjects 5, 6 and 7. Only two runs were carried out on any one day, at 
approximately 09.30 and 10.30 hours, to avoid any possible circadian 
variations in response. Subjects were asked to eat their normal breakfast 
and to avoid alcohol the preceding evening. Those who had not drunk any 
fluid from getting up in the morning prior to the experimental period were 
given a cup of water to drink (circa 250 ml), 15 minutes before entering 
the LBNP chamber.
The subject entered the LBNP chamber and a green code venflon catheter 
(internal diameter 1.0mm) was inserted into an antecubital vein. He was 
then left undisturbed for 30 minutes. Mercury strain gauges were fitted 
round each calf at a standard circumference of 13.5 inches, and the calf 
circumference was continuously recorded on a pen recorder and the 
percentage increases calculated. Interpretation of the results from the 
mercury strain gauges were confined to those obtained from the right leg
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as the other gauge was subsequently found to be unreliable. Two minutes 
prior to the application of suction, the vacuum pump was turned on and a 
10 ml sample of venous blood taken.
Subjects were asked to try and relax as much as possible as tensing of 
the calf muscles is known to be a potent mechanism for venous emptying 
(Folkow and Neil, 1971) and could, therefore, modify the circulatory 
response to LBNP. At zero time (0 minutes) the selected level of suction 
was applied and maintained for 5 minutes, or until the subject showed 
signs of pre-syncope as manifested by facial pallor, the subject feeling 
lightheaded and sweaty, and a precipitous fall in blood pressure and 
bradycardia, in which case the run was stopped immediately. The subject 
remained undisturbed in the LBNP chamber for 10 minutes after the box 
pressure had returned to normal. Presyncopal subjects remained in the 
LBNP box to complete 5 minutes plus the 10 minute post-suction period.
For the control 0 mmHg runs, suction was applied momentarily to suck in 
the rubber skirt in an attempt to keep the anticipation effect constant: 
this also provided an event mark on the recorder.
One ml blood samples were collected at 30 second intervals from 
0 minutes to +4.5 minutes and 10 ml samples collected at -2, +5 and +15 
minutes. If a subject did show evidence of presyncope, a 10 ml blood 
sample was taken immediately the suction was released and the time noted: 
one ml blood samples were then collected at 30 second intervals until the 
+5 minutes point and a 10 ml sample was collected at +15 minutes. Blood 
samples were collected into chilled heparinised tubes and the plasma 
separated as quickly as possible in a refrigerated Mistral 4L centrifuge. 
All plasma samples were stored at -70° until assayed. For catecholamine 
analysis, 20 ul of a solution containing 95 mg ethyleneglycolbis
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(aminoethyl ether) tetra acetic acid and 60 mg reduced glutathione per ml 
of solution at a pH of 6-7 (pH adjusted with 6M NaOH), was added for each 
ml of whole blood, to give a final concentration of 6.5 mmol/1 and 3.9 
mmol/1 respectively. The 10 ml blood samples were assayed for both AVP and 
catecholamines; the 1 ml samples for catecholamines only.
Micro-haematocrit analysis was carried out on all blood samples.
Blood pressure was measured at 30 second intervals from -2 minutes to 
+7 minutes, and finally at +15 minutes by clinical sphygmoraanometry; 
heart rate was monitored continuously using EGG electrodes connected to an 
oscilloscope and pen recorder. Heart rate measurements were made at 30 
second intervals from the recorder trace with an averaged 10 second sample 
period, ie 5 seconds either side of the chosen point.
At least one week was allowed for each subject between runs, to permit 
recovery of blood volume.
All subjects were fully briefed on the procedures and gave their 
written informed consent to the procedure.
Statistical Methods
Not all the subjects were able to tolerate -90 mmHg for the full 5 
minutes: consequently there was considerable variability in the data. In 
an attempt to overcome this problem the results were analysed in three 
different ways.
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First, evidence for an effect of the four different negative pressure 
levels on blood pressure, heart rate and the plasma concentrations of the 
three catecholamines was sought by examining the data for the experi­
mental periods at the three lowest pressure levels which could be 
tolerated by all the subjects.
Second, the four results obtained immediately before termination of 
each run were investigated at all four pressure levels, including runs in 
which had subjects exhibited pre-syncopal symptoms and the run had had to 
be terminated prematurely.
Finally, the relationship between plasma catecholamine levels and 
blood pressure measurements was investigated for each of the three condi­
tions (0, -30 and -60 mmHg suction), where all subjects completed the full 
5 minutes of LBNP.
For the first two investigations, analysis of variance was employed, 
while for the third, analysis of covariance was used. Three factors were
identified; subject, negative pressure level and time (ie minute) of
exposure. Subjects were treated as a random effect while negative 
pressure and time were treated as fixed effects.
Before analysis of variance (ANOVA) was employed, it was important to
check that the assumptions of ANOVA held reasonably well. Thus, if they 
do not hold adequately, a transformation of the raw scores should be made 
to a scale in which they do hold. The assumption of ANOVA for all 
variables were investigated using a combination of the maximum likelihood 
method of Box and Cox (1964) and the methods of Anscombe (1961), applied 
to the complete data from the lower pressure levels (First analysis). As
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a result of this investigation it was concluded that the following trans­
formations should be applied:-
Adrenaline x 0.25
Noradrenaline x 0.33
Dopamine x 0.25
Blood pressure (l)log(x)
(systolic)
Blood pressure (2)log(x)
(diastolic)
Heart Rate log(x)
Right leg X 0.5
Results
All subjects were able to tolerate LBNP at 0, -30 mmHg and -60 mmHg for 
five minutes. In four of the seven subjects, the -90 mmHg run was 
terminated early either because of pre-syncope, or gross discomfort.
Analysis of the plasma catecholamine assays produced a complex 
picture. It revealed rapid oscillations in plasma catecholamine levels 
which were more pronounced for individuals than for the group. An example 
is illustrated in Fig. 2.1. The magnitude of the oscillations tended to 
increase with the level of LBNP.
Mean plasma AVP levels were significantly higher at termination of the 
-60 mmHg and -90 mmHg runs (p< 0.01), than after the zero or -30 mmHg 
runs. Only one subject showed any increase of plasma AVP at -30 mmHg.
Plasma AVP levels were, however, elevated in four of the seven subjects 
during their -60 mmHg run; and four again at -90 mmHg, although these were 
not all the same subjects (table 2:1). One of the three subjects who
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Table 2,1. Plasma AVP levels (pmol/1) at the two higher
levels of negative pressure (mmHg).
Subject Pressure Pre- Post- Post-termination
1 .
2 .
3.
4.
5.
6.
7.
termination +10 minmmHg
61.5
41.5
-60-90
-60
-90
34.6
181.0
—60
-90
0.9
11.0108.6-60
—60
46.3
43.1
100.5
10.3
4.9
-60
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Fig. 2.1. Plasma noradrenaline concentrations in one 
subject with a typical response to negative 
pressure at control O-*"-'O~30 mmHg A— *—Aand 
-60 mmHg A* *A levels of suction.
49
_J
o
Ec
HIz
_J<zLUOCO<OCoz
— o
I Negative Pressure!
Times (Minutes)
Fig. 2.2. Mean plasma noradrenaline concentrations (n=7) at 
control O- *-0-30 mmHg A » t A - 60 mmHg A — A -90 mmHg 
#  #.  The point shown at +5 minutes is the
mean of the termination points at -90 mmHg which 
include presyncopal subjects. Mean values ± SEM.
P values (* P< 0.05 ** P< 0.01) refer to comparisons 
to control levels.
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failed to show a rise in plasma AVP during his -90 mmHg run, developed 
pre-syncope, and in him the 10 minute post-run sample showed a very 
markedly elevated level of plasma AVP (49.2 pmols/1), some 33 times his 
basal level.
The mean responses of plasma catecholamines to the four levels of LBNP 
are shown in Figs. 2.2, 2.3 and 2.4. The data have been presented on a 
minute by minute basis for clarity. As not all subjects could endure a 
full five minutes at -90 mmHg, only the mean values at -2, 0 minutes and 
the termination point, together with those at the termination point +10 
minutes are shown for runs performed at the -90 mmHg level.
The level of negative pressure to which the subjects were exposed had 
a significant effect upon plasma noradrenaline concentrations, which were 
directly related to the level of suction applied; -30 mmHg (p< 0.05); - 
60 mmHg (p< 0.01); and -90 mmHg (p< 0.001).
Plasma noradrenaline levels tended to rise rapidly in response to the 
application of negative pressure and were directly related to the fall in 
systolic blood pressure. Although in individuals there were oscillation 
in plasma noradrenaline levels during the course of a single run, the 
levels remained elevated and at the two higher levels of suction the 
overall trend was upwards.
Plasma adrenaline levels showed a marked rise relative to the control 
values in response to -60 mmHg and -90 mmHg (p< 0.01). Some subjects 
also had high plasma adrenaline levels in the -2 minute, pre-suction, 
sample.
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Fig. 2.3. Mean plasma adrenaline concentrations (n=7)
control 0->—0 “30 mmHg ^ — •A“60 mmHg A — A-90 mmHg 
#  #. Mean values ± SEM, P values (*P< 0.05)
refer to comparison with control levels.
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Fig. 2,4. Mean plasma dopamine concentrations (n=7) at
control G  0-30 mmHg A  A ”60 mmHg A  Aand
-90 mmHg #  #. There were no significant
differences between levels of LBNP.
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T + 10
Fig. 2.5. Mean levels of systolic blood pressure (N=7) 
for control O*'*O“30 mmHg A- *tA-60 mmHg Jr-HlLand
“90 mmHg (N=4) #. The fall in systolic
blood pressure with times at -60 and -90 mmHg 
was significant (P< 0.01) when compared to 
control values.
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IDopamine did not show any consistent or significant changes in plasma j
concentration in response to different levels of suction, and there were 
large differences in individual responses. Subjects who experienced 
presyncopy at -90 mmHg showed a downward trend in plasma dopamine 
(p< 0.05) and adrenaline (p< 0.05) levels over the period encompassed by
the last four samples taken during suction and prior to the onset of
presyncope.
The blood pressure response to the application of suction at -60 mmHg 
and -90 mmHg (p< 0.01) was an immediate fall in systolic pressure which 
was usually maintained until the end of the run (Fig, 2.5). Diastolic 
pressure showed no significant change at any level of suction. When pre­
syncopy occurred during the -90 mmHg, run there was a sudden and 
precipitous fall in blood pressure which responded dramatically to the 
release of the negative pressure stimulus.
A temporal relationship was established between blood pressure and 
plasma noradrenaline levels which increased significantly (p< 0.01), 
approximately 30 seconds after the fall in systolic blood pressure. There
was, however, no corresponding increase in systolic blood pressure as
plasma noradrenaline levels rose.
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Fig. 2.6. Mean heart rate in count per minute (N=7) for control 
0 -—O ”30 mmHg A --A -60 mmHg A — Aand -90 mmHg (N=4) 
Subjects who terminated early at -90 mmHg are not 
included in the mean values, although their initial 
response to LBNP was similar to those demonstrated. 
There was a significant increase (P< 0.001) in heart 
rate at both -60 and -90 mmHg when compared to control 
and -30 mmHg levels of LBNP. There was no significant 
difference between -60 and -90 mmHg.
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Fig. 2,7. Average increase in right leg calf circumference measured
with a mercury in silastic strain gauge, at a measured calf 
circumference of 13% inches (N=7) at control 0-*"0“30 mmHg
A  A-60 mmHg àf— ^and -90 mmHg # --- #(N=4) . There was a
significantly greater increase (P< 0.05) between -90 mmHg 
and -30 and -60 mmHg which were not significantly different 
from each other, but were significantly higher than control 
(P< 0.05).
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Heart rate (Fig. 2.6) increased steadily during suction at -60 mmHg 
and -90 mmHg (p< 0.001). In contrast, subjects with presyncopy during the 
-90 mmHg run developed bradycardia shortly before the sudden fall in blood 
pressure which characterised the condition. This bradycardia was 
sustained, following release of the suction, usually until the end of the 
10 minute measurement period. The blood pressure, on the other hand, 
recovered rapidly towards normal following release of the negative 
pressure, normal values being achieved within 0.5 to 1 minute.
There were no significant changes in haematocrit in any of the 
experimental periods.
The results from the mercury strain gauges fitted to the right leg 
(Fig. 2.7) showed a rapid initial expansion in calf circumference in 
response to the application of negative pressure. This was followed by a 
further steady linear increase at all three levels of exposure, although 
the increase was greater during the -90 mmHg (p< 0.05), than during the - 
30 mmHg and -60 mmHg runs. Findings at the -30 mmHg and -60 mmHg levels 
were not significantly different from each other, but calf volumes were 
significantly higher than for the controls (p< 0.05).
Examination of urine samples taken before and after the experiments 
showed a significant increase in excretion rates for both dopamine and 
sodium post-experiment at all levels including the control (p< 0.01), 
Tables 2:2 and 2:3 A residual scatter plot showed an inverse 
relationship between dopamine and sodium. Although both compounds 
increased in the post-run sample, the increase in sodium was less if the 
respective dopamine was higher and vice versa.
58
Table 2:2 Mean Dopamine excretion, nmol/min
Level of LBNP Pre- Post­
suction suction
0 mmHg 1.23 5.68
-30 mmHg 1.88 5.33
-60 mmHg 3.00 7.24
-90 mmHg 1.90 11.83
Table 2:3 Mean Sodium excretion, mmol/min
0 mmHg 105 159
-30 mmHg 74 159
-60 mmHg 71 123
-90 mmHg 133 159
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Discussion
The data derived from these experiments have produced a complex 
picture and indicate marked differences between individuals in response to 
comparable stimuli. The rapid oscillation in the plasma concentration of 
all three catecholamines indicates that the secretions in response to the 
particular stress applied are pulsatile. This pulsatile response was 
particularly noticeable with noradrenaline where the changes in plasma 
levels were highly significant, and increased in terms of both peak levels 
and frequency of pulse with increasing levels of LBNP, a dose related 
response. The rate of disappearance of noradrenaline from the plasma was 
also very rapid.
At first sight, the magnitude and rapidity of oscillation in plasma 
noradrenaline concentration would not appear to be an efficient method of 
responding to a sustained stress. However, complex feedback systems may 
be involved, mediated possibly through second messenger systems and the 
active uptake of noradrenaline, and these would have a considerable range 
in response times.
Increases of noradrenaline in the synaptic gap are associated with 
increased nerve stimulation, and many workers have demonstrated a pre- 
synaptic negative feedback mechanisms of control, triggered by the 
increase and mediated bya-adrenoceptors (Langer, 1977). This negative 
feed back mechanism is maintained until the concentration of released 
noradrenaline in the synaptic cleft falls below a certain level. 
Coincidentally, there is also a positive feedback mechanism for noradren­
aline release controlled by B-adrenoceptors which occurs at low 
frequencies of nerve stimulation and is mediated through an increase of 
cyclic AMP levels in noradrenergic nerve endings. These mechanisms of
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feedback control do suggest that rapid fluctuation in plasma noradrenaline 
levels might be expected, but whether they offer an explanation for the 
large changes in plasma noradrenaline observed in these experiments is 
open to speculation.
Other methods of feed-back control are likely to be in operation, one 
of which has been demonstrated in this research by the relationship 
between blood pressure and noradrenaline, this relationship indicated that 
although the sympathetic system was stimulated by a fall in systolic blood 
pressure in response to LBNP, it was ineffective in returning systolic 
blood pressure to normal in spite of large increases in plasma 
noradrenaline. Systolic blood pressure was maintained, however, at a 
lower level than normal for many individuals.
Large amounts of noradrenaline may also be required to elicit a 
sustained response to a continuous stress because noradrenaline is very 
labile, being rapidly 0-methylated in the general circulation and in 
noradrenergic nerve endings by monoamine oxidase to produce physio­
logically inactive deaminated derivatives.
Furthermore, continuous secretion of noradrenaline with sustained 
plasma levels could produce a refractory state in some of the receptor 
and effector organs, whilst pulsatile secretion would avoid this and tend 
to reinforce the response.
A significant outcome of noradrenaline being secreted in distinct 
pulses, is that the sampling regime for measurement of plasma 
noradrenaline and other catecholamines may be critical in similar 
experimental situations. As can be seen from Fig. 2:1, at the -30 mmHg
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level of LBNP, samples taken at the end of the run would give no 
indication that a modest sympathetic response had taken place.
On the assumption that the leg is cylindrical, the measured increase 
in calf circumference suggests a pooling of between 500 ml and 700 ml of 
fluid per leg, depending on LBNP level and the subject. This loss from 
the circulation, mainly of blood, together with the 350 ml estimated to 
pool in the abdomen during LBNP (Glaister and Crossley, 1974), produces an 
effective reduction in blood volume of between 1350 ml and 1750 ml.
Similar values have been reported using water plethysmography (Musgrave et 
al, 1969) and chemical methods (Balakhovskii et al, 1970) to estimate the 
amount of blood sequestered during LBNP, These conclusions are consistent 
with blood loss experiments carried out by Wallace and Sharpey Schafer 
(1941) which indicate that some 1500 ml of blood must be withdrawn from an 
average recumbent subject in order to produce syncope.
There is evidence for and against dopamine having a role in the 
control of AVP secretion, the conflict being due in part to the use of 
different animal species and preparations. An inhibitory role for 
dopamine has been demonstrated by Wolney et al (1974) who injected 
dopamine into the third ventricle of rats and observed a diuresis which 
could be blocked by treatment with pimozide, a blocker of dopamine 
receptors. In man, L-dopa infusions inhibit AVP release in response to 
headup tilt (Lightman and Forsling, 1980). Conversely, when dopamine was 
injected into the third ventricle or the nucleus accumbens of rats (Milton 
and Paterson, 1974), plasma AVP levels rose. 6-hydroxydopamine, which 
depletes central dopaminergic stores, blocked the ability of hyperosmotic 
sodium chloride and hypovolaemia to raise plasma AVP in rats (Miller et 
al, 1974) and cats (Milton and Paterson, 1973).
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The situation in man is no clearer, although there is strong evidence 
for dopamine having a suppressant effect on AVP secretion. Lightman and 
Forsling (1980) have shown, by infusing L-Dopa - a precursor of dopamine 
which can cross the blood brain barrier - a decrease in resting levels of 
AVP and an inhibition in the rise of AVP normally associated with a 65° 
head up tilt from the supine position, Carbidopa , an aromatic L-amino 
acid decarboxylase inhibitor, blocked this action of L-Dopa; implying that 
it was dopamine production which was controlling AVP secretion. However, 
the oral administration of bromocriptine, a central and peripheral 
dopamine agonist, produces an enhanced plasma AVP response to osmotic 
stimulation (Robinson et al, 1982) and to LBNP stress (Mohanty et al, 
1985).
Administration of the butyrophenone, haloperidol, a dopamine D2 
blocker (Kendler et al, 1978) was reported not to increase plasma AVP 
levels in normal subjects, possibly due to inadequate dosage. Thus, the 
butyrophenones are known to have a wide range of binding affinities for D2 
receptors (Leff and Creese, 1983). From the basis of the published 
evidence, Robinson et al (1982) concluded that whilst dopamine is 
stimulatory in the osmotic and emetic pathways, it is inhibitory in 
controlling volume-mediated AVP release. Although there are limited data 
in man on the control of AVP secretion by dopamine, Lightman and 
Forsling's work, which supports the theory of suppressant role in the 
pituitary by dopamine on AVP secretion, is difficult to refute; whereas 
there are feasible explanations for the failure of bromocriptine and 
haloperidol to produce the anticipated results. However, our own 
experiments, which, unlike previous work on this subject, rely upon direct 
measurement of circulating AVP and dopamine concentration in response to 
blood volume depletion, are also inconclusive in showing a controlling
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influence of dopamine on AVP secretion. Although a fall in blood dopamine 
levels occurred in subjects who experienced presyncope at -90 mmHg, the 
increase in plasma AVP that was observed in these subjects did not 
correlate with plasma dopamine in respect to either time or magnitude.
This lack of correlation may have been due to the timing of sampling 
following the onset of syncope. The extremely short half life of AVP in 
the circulation, approximately 5-7 minutes, and the rapidity with which 
its concentration in blood may change was not appreciated when these 
experiments were begun. Preliminary results of tests undertaken with more 
frequent sampling indicate that there is a distinct pattern of secretion 
of AVP at syncope, and that increases in plasma AVP may be missed under 
the experimental conditions employed in this and previous studies.
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CHAPTER THREE
EFFECT OF BETA ADRENORECEPTOR BLOCKADE ON 
PLASMA CATECHOLAMINES AND AVP
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Experiment 2 Beta Adrenoceptor Blockade 
Introduction
There has been considerable debate over the role of catecholamines in 
the control of AVP release. It might be expected that the catecholamines 
would have some influence on AVP secretion as the neurosecretory cells 
which are known to produce AVP are found in the supraoptic nucleus of the 
hypothalamus, an area which has been shown to have a high density of 
catecholamine nerve terminals. The previous experiment (Chapter 2) had 
been inconclusive in demonstrating a relationship between plasma 
catecholamine levels and AVP secretion, although plasma dopamine did fall 
significantly in presyncopal subjects. In an attempt to clarify the 
situation, b-adrenergic blockade, using propranolol, has been carried out 
during LBNP at 0 and -90 mmHg. Although it would also have been desirable 
to use specific dopamine blockers this was not practical, as no known 
dopamine antagonists were available which were cleared for use with LBNP.
Beta-adrenergic Blockade
Beta-adrenoceptor blocking agents are drugs which produce specific 
reversible antagonism of the effect of stimulation of b-adrenoceptors. 
Beta-adrenoceptors are characterised by being most sensitive to the 
actions of isoprenaline, a b-adrenoceptor agonist, and least sensitive to 
the action of noradrenaline. A further sub classification has been made 
into and bg receptors, both being located mostly on postsynaptic 
membrane sites. Beta^-receptors occur in cardiac muscle and their 
activation increases heart rate and contractility. Beta2~receptors are 
typically those associated with relaxation of smooth muscle e.g. in 
skeletal muscular blood vessels, intestine and bronchioles.
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There may be further sub-divisions in various tissues, as not all b -  
receptors can be categorised as or b2» (Knuck & Pyecock, 1983). A 
large number of b-adrenoceptors blockers are not selective for b^ or b2~ 
adrenoceptors and these have action on both types of b-adrenoceptor, 
although they vary in terms of potency and duration of action and in their 
reaction to the presence of agonists (Clark, 1977). In addition to being 
competitive b-adrenoceptor blockers, many agents in this class have 
membrane-stabilising activity (local anaesthetic action).
Membrane stabilisation is a term which describes the effect of a drug 
on cell membranes of heart and nerves and which results from an inhibition 
of the transfer of sodium across the membrane. Beta-adrenoceptors that 
stabilise membranes, prevent the conduction of propagated action 
potentials, measured by voltage clamp, without noticeably affecting the 
level of the resting membrane potential and repolarisation time. Activity 
of pacemaker centres is depressed whilst the threshold for stimulation and 
the effective refractory period, which is normally about 220 m-seconds 
(Bowman & Rand, 1980) is increased, although the precise duration was not 
stated in this study (Clark, 1977).
Beta-adrenoceptor antagonists prevent and suppress cardiac 
dysrhythmias. They are capable of exerting anti-arrhythmic activity in two 
different ways, either by specifically inhibiting the development of 
arrhythmia resulting from sympathetic hyperactivity, or by influencing the 
basic electrophysiological characteristics of the myocardial cell 
membrane. They also decrease the rate at which the myocardium utilises 
oxygen, although there is a difference between various b-adrenoceptor 
blockers as to the precise response. Beta-blockers have also been used 
for the control of skeletal-muscle tremor, and extremely commonly as anti­
hypertensive drugs (Clark, 1977).
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There is no complete explanation as to why b-adrenoceptor blockers 
lower blood pressure. There are several possible mechanisms (Clark, 1977) 
which may, in specific circumstances, or in combination with one another, 
provide the correct answer.
Beta-adrenoceptor blockers reduce the response of the heart to 
sympathetic stimulation, and this results in a decrease in heart rate and 
force of contraction with a consequent reduction in cardiac output. As 
blood pressure is related to the product of cardiac output and peripheral 
resistance, lowered cardiac output might be expected to decrease blood 
pressure. This does not ordinarily occur because peripheral resistance 
increases reflexly in response to decreased cardiac output. This 
response, on its own, is unlikely to account for the anti-hypertensive 
response observed following b-adrenergic blockade.
The release of the enzyme renin from the kidney is stimulated by the 
action of noradrenaline on the b-adrenoceptor in the sympathetic nerves 
of the kidney juxtoglomerular cells (Ganong, 1987). Renin converts 
angiotensinogen into angiotensin I which, in turn, is broken down by 
peptidyl peptidose into angiotensin II, Angiotensin II is a potent 
vasoconstrictor and it facilitates noradrenaline release from sympathetic 
nerve endings: it also stimulates aldosterone secretion by the adrenal 
cortex. Aldosterone facilitates sodium retention in the kidney tubules 
and thus, passively, the retention of water. This can lead to an increase 
in blood pressure, as in primary hyperaldosteronism (Conn's syndrome). 
Beta-adrenoceptor blockers can cause a decrease in renin release and this 
in turn reduces angiotensin production (Buhler et al, 1972; Michelakis et 
al, 1972).
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Presynaptic b-receptors appear to be involved in the control of 
noradrenaline release. At low frequencies of stimulation (1-5 Hz with 
supramaxsimal voltage, Langer, 1977), the release of noradrenaline is 
maintained by the action of noradrenaline on presynaptic b-receptors. 
There is the possibility, therefore, that some types of hypertension are 
caused by overactive presynaptic b-receptors, which in turn maintain high 
levels of noradrenaline in the synaptic cleft. In one form of essential 
hypertension there is an increase in sympathetic nerve activity. In 
others there is either an increase in transmitter noradrenaline per nerve 
impulse or a decrease in noradrenaline inactivation by uptake or 
metabolism (Bowman & Rand, 1980). Beta-receptor blockers acting at the 
presynaptic site would tend to reduce noradrenaline release from the 
neurogenic nerve endings.
There is also some evidence that stimulation of b-adrenoceptors in
the brain stem can lead to a rise in blood pressure by increasing
peripheral sympathetic tone. Competitive blockade of central b-adreno­
ceptors decreases peripheral sympathetic tone and tends to lower the 
blood pressure (Knuck & Pyecock, 1983).
Propranolol
Propranolol (Inderal) is a b-adrenergic blocking agent and has, as 
with all b-adrenergic blockers, a structural resemblance to the b- 
adrenergic agonist isoprenaline, particularly in the side chain. The b- 
adreno-ceptor blocking potency of propranolol is created by substitution 
on the aromatic ring of the hydroxyl groups in the 3- and -4 positions by 
a fused aromatic ring. The potency of propranolol is futher increased by 
the insertion of a methyleneoxy bridge (O-CH^) between the aromatic ring
and the assymetric carbon atom (Clark, 1977).
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Propranolol is a powerful local anaesthetic, and therefore membrane 
stabiliser, and shows considerably greater specificity for cardiac than 
nerve membranes. The optical enantiomers of propranolol possess the same 
local anaesthetic properties i.e. in their effect on the cardiac 
potential, whereas there is considerable difference between the two 
enantiomers in their b-adrenoceptor blocking activity, the laevo isomer 
being more active than the dextro isomer (Buckner & Patil, 1971; Howe & 
Shanks, 1966).
Propranolol has a depressant effect on heart rate, contractile force 
and cardiac output, by inhibiting the stimulant effect of noradrenaline 
released from cardiac sympathetic nerve endings. Unlike many b-adrenergic 
blocking agents, propranolol does not have an agonistic action (Fitzgerald 
& O'Donnell, 1972), Propranolol also decreases the rate at which the 
myocardium utilises oxygen, regardless of whether the b-adrenoceptor 
blockade is accompanied by a reduction in myocardial blood flow or not. 
There is a tendency for propranolol to decrease the ability of the left 
ventricle to perform useful mechanical work, but the efficiency with which 
work is performed is increased (Clark, 1977).
Acute administration of propranolol increases total peripheral 
resistance, possibly a reflex response to the reduction in cardiac output 
(Nies et al, 1973). Propranolol has also been shown to constrict vessels 
in the coronary, hepatic, pulmonary, splanchnic and renal vascular beds , 
(Clark, 1977). Administration of propranolol to guinea-pigs results in an 
increase in airways resistance. Although this has not been confirmed in 
man, propranolol has been shown to potentiate bronchospasm induced by 
histamine (Clark, 1977).
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There is some controversy as to how propranolol exerts its anti­
hypertensive effects. Lewis (1975) claims that it is primarily through 
the central nervous system (CNS), although the results on which he bases 
this claim are derived largely from animal experiments. The hypothesis is 
based on the observation that the antihypertensive effect is mediated by 
the 1-isomer, but not by the d-isomer of propranolol, indicating b-adreno­
ceptor blockade. Lewis observed, following intravenous injection of 
propranolol into rabbits, that the hypotensive effect was diminished in 
animals in whom central adrenergic neurones had been destroyed and whose 
preganglionic sympathetic nerve activity was thereby diminished. He 
extrapolated these results to man, in which species similar brain-plasma 
concentration ratio have been found as in the rabbits, following chronic 
oral dosing with propranolol (Lewis, 1975).
Buhler et al (1972) considers the antihypertensive effect of 
propranolol to be through a peripheral effect because of the suppression 
of renin release from the kidney (as discussed above). Offerhaus & van 
Zwieten (1974) found that the hypotensive effect of propranolol infused 
into the vertebral artery of cats was similar to that produced by infusing 
the drug peripherally, Lader & Tyrer (1972) could find no evidence for a 
CNS effect of propranolol using doses of up to 120mg in a study on its 
anxiolytic action.
Although propranolol is lipophilic and easily crosses the blood brain 
barrier, there does not appear to be conclusive evidence as to whether the 
antihypertensive effect is controlled through the CNS or peripherally, 
although its manner of action may depend on the actual levels of dosage 
used and the length of time for which the dose is given.
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Experimental Procedure
Six subjects were asked to undertake four LBNP runs: two controls at 
normal atmospheric pressure (0 mmHg), and two at -90 mmHg, once with 
placebo and once with 160mg of propranolol. The order of runs was 
randomised using a Latin square. A preliminary examination of the data 
from the previous experiment (Chapter 2) suggested that there was a 
possible effect, due to apprehension by the subject, as to the level of 
negative pressure he was about to receive. This effect was not confirmed 
when the full statistical analysis was carried out. However, as the 
experiment had already started, the later subjects were still told the 
pressure level they were going to receive, but not whether they were 
receiving placebo or propranolol.
In order to produce, as far as possible, a standard physiological 
response, subjects were taken to a presyncopal state. This could 
normally be achieved in a relaxed subject at -90 mmHg in six minutes or 
less. No restriction was placed on diet before the experimental period. 
Subjects were requested to partake of their normal breakfast and fluid 
intake. At approximately 08.30 hours the subject took two pills of either 
placebo or propranolol 80 mg. The experiment was started one hour later.
The same procedure was adopted as for the previous experiment (Chapter 
2), except in two respects. Blood pressure and heart rate were measured 
using a Dinomap Vital Signs Monitor sampling at approximately one minute 
intervals. ECO results were also displayed on a VIOOO Gould Monitor and 
ESIOOO recorder, as were the mercury strain gauge outputs. This procedure 
enabled better monitoring of the subject's condition than previously and 
reduced the number of medical staff required for each experiment from two 
to one. The second difference from the earlier series of experiments
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related to the air pump for the chamber which was now switched on by the 
subject using an enabling switch. This was manufactured from an electric 
drill switch with an extension handle fitted. The device could be held 
comfortably in the palm of the hand in the fully on position with very 
little pressure, but even the slightest relaxation opened the circuit and 
cut the motor. The power supply was, for safety, via a 6V DC stabilised 
powerpack switching device, which also had an override hit button for 
emergency use. Subjects appeared more relaxed when they were in control 
of the LBNP cabinet themselves and were more likely to take themselves to 
presyncope.
For the 0 mmHg control runs, the air pump was turned on at -2 minutes 
and turned off at +6 minutes. Ten ml blood samples were collected at 0, 
+2, +4, +6 and +16 minutes* For the -90 mmHg runs, the pump was again 
switched on at -2 minutes, negative pressure was applied at 0 minutes.
10 ml blood samples were collected at time zero (0 minutes) and then at 2 
minute intervals until the subject released the control switch, when 
another blood sample was immediately taken. A further 10 ml blood sample 
was taken 10 minutes after termination of negative pressure. The blood 
samples were treated as previously and all plasma samples were analysed 
for adrenaline, noradrenaline, dopamine and AVP. Where there was 
sufficient plasma remaining, cortisol was also measured.
It had also been intended to collect urine for analysis, but problems 
were encountered with many of the subjects being unable to produce samples 
in a reasonable time after conclusion of the experiment. This part of the 
investigation was therefore abandoned.
74
Statistical analysis
As in the previous experiment, it was decided that the best analytical 
approach to an experiment of this design was analysis of variance. As not 
all the subjects were able to withstand a full 6 minutes at -90 mmHg, only 
zero time, 2 minutes, termination (ie either 6 minutes or the early 
termination sample) and termination +10 minutes results were subjected to 
statistical analysis.
Four factors could be identified in the experiment;-
S (Subject)
C (0 and -12.0 kPa)
B (placebo/b-adrenoceptor blocker)
T (Time of sample)
T, C, B were treated as fully crossed fixed effects factors crossed 
with the random effect S. Lost data were estimated by standard least 
squares methods. Before analysis, the assumptions of analysis of variance 
were briefly investigated using the maximum likelihood method of Box and 
Cox (1964), checking the results by examination of the residual/fitted 
scatter plot following Anscombe (1961). It was concluded that the 
following transformations should be applied to the raw scores
AVP - Log (X)
Dopamine - (X)^/^
Heart rate - 1/X
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Results
There was no statistical difference in heart rate between placebo and 
beta blockade at 0 mmHg, although on cursory examination of the data it 
appeared to be present (Fig 3:1). Thus, four subjects had a marked 
reduction in heart rate after taking propranolol compared to placebo, but 
two had little or no difference in heart rate. At -90 mmHg, there was a 
significant increase in heart rate (p< 0.001) during suction in the 
placebo runs and marked differences were observed between b-blocker and 
placebo (p< 0.01); the heart rate increasing only slightly as suction was 
applied during b-adrenoceptor blockade (Fig 3:1). There was also a 
significant decrease in heart rate post suction in the placebo group 
(p< 0.05), when compared to the pre-suction level.
Systolic blood pressure was lower both before and after suction when 
propranolol was given, but followed the same pattern as after placebo 
(Fig. 3:2) when suction was applied. Post-suction systolic blood pressure 
was also reduced compared to pre-suction, but there was no significant 
effect with respect to the diastolic pressure.
Problems were encountered with the analysis of plasma samples for 
catecholamines and these are discussed more fully in Chapter 6. 
Differential analysis could be reproduced, but there was considerable 
variation from batch to batch in the absolute levels which also tended to 
be abnormally high, due in part to poor sensitivity. To reduce the error, 
all the samples from a particular individual were analysed in the same 
batch.
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Fig, 3:1. Mean Heart Rate (N=6) in beats per minute (BPM) for placebo
at 0 mmHg A — A  and -90 mmHg a  and for propranolol at
0 mmHg# - -#and 90 mmHgO— -O' There was a significant 
increase at -90 mmHg (p< 0.001) in subjects who had taken 
placebo. Marked differences were also found between 
placebo and propranolol (p< 0.01) at -90 mmHg. The fall in 
heart rate at the end of -90 mmHg for the placebo group was 
significantly less (p< 0.05) when compared to the pre­suction level.
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Fig. 3:2. Mean blood pressure at -90 mmHg (N=6). Mean systolic BP after
placebo A'— A. Mean systolic BP after propranolol A  A.
Although the mean systolic BP following taking propranolol was 
lower, the difference was not significant. Mean diastolic BP 
after placebo O — O  Mean diastolic BP after propranolol#- 
There was no significant difference.
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Fig. 3:3. Mean plasma noradrenaline values (N=6). All subjects 
completed 4 minutes, the 6 minute point includes the 
termination values of those who stopped between 5 and 
6 minutes.
Plasma noradrenaline levels were high, both at 0 #  i
(* p< 0,05) and -90 mmHg A  A i *  p< 0.05) in subjects
after they had taken propranolol compared to placebo
at 0 O  Oand -90 mmHg -A A. Plasma noradrenaline
was also increased (# p< 0.05) on the application of 
suction when compared to the starting value at 0 
minutes.
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Although the results varied between subjects, plasma noradrenaline 
levels were high, both at 0 and -90 mmHg, in the subjects after they had 
taken propranolol (p< 0.05; Fig. 3:3) compared to placebo. Plasma 
noradrenaline also increased during the -90 mmHg runs when compared to 
control values (p< 0.05). Because of the wider sampling times compared to 
the previous experiment, fluctuations between samples were somewhat 
reduced. The actual responses of individuals to negative pressure was 
however extremely variable, some subjects showing increasing levels of 
plasma noradrenaline with time, while others showed a decrease - usually 
after an initial rise. Plasma adrenaline (Fig. 3:4) also showed an 
increase in subjects who had taken propranolol (p< 0.05) irrespective of 
LBNP pressure level. There was also an increase of plasma adrenaline in 
the -90 mmHg runs over 0 mmHg runs (p< 0.05). There were no significant 
changes in plasma adrenaline with respect to time during any of the runs.
Plasma dopamine levels tended to fall with time from the starting 
level (p< 0.05), but this was the same for both the 0 and -90 mmHg runs. 
There was no significant difference between b-adrenoceptor blockade and 
placebo (Fig. 3:5).
Propranolol had no affect on plasma cortisol. There was however a 
significant increase in plasma cortisol (p< 0.001) in the 10 minutes post 
suction samples of the -90 mmHg runs when compared with control values, 
for both placebo and b-blockade.
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Fig, 3:4. Mean plasma adrenaline level (N=6). There was an
increase in plasma adrenaline (* p< 0.05) at 0 —#
and -90 mmHg ^  -Ain subjects after they had taken pro­
pranolol. Placebo 0 mmHgO— O “90 mmHg A*— A. Plasma 
adrenaline was also significantly increased at -90 mmHg for 
placebo (# p< 0.05). There was no effect of time for either 
placebo or propranolol.
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Fig. 3:5. Mean plasma dopamine (N=6)
-90 mmHg propranolol ▲ ------- mmHg# #propranolol,
-90 mmHg placebo A  A, 0 mmHg O — Oplacebo. The 6 minute
point includes the termination value of subjects who did
not complete 6 minutes. There was a significant fall
(p< 0.05) for all conditions except the -90 mmHg placebo run,
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Fig. 3:6. Mean plasma AVP (N - 6) The 6 minute point includes 
subjects whose runs terminated early.
-90 mmHg propranolol A  A~9Q mmHg placebo A  A
0 mmHg propranolol#- - #0 mmHg placebo O O
There was a significant rise in plasma AVP at 6 the minutes 
termination point (*** p< 0.001) at -90 mmHg for both placebo 
and propranolol. There was no significant difference between 
placebo and propranolol.
83
Plasma AVP levels were not affected by b-adrenoceptor blockade. 
Although not all subjects responded, there was nevertheless a significant 
increase in plasma AVP (p< 0.001) in the sample taken at the termination 
of the -90 mmHg runs and in the 10 minute post run sample (Fig. 3:6) for 
both placebo and propranolol. No changes were found in the control runs. 
The increase in AVP was rapid and dramatic as presyncope developed, and 
indeed some subjects had exhibited only small increases of plasma AVP in 
the blood sample collected immediately preceding presyncope. One subject 
did not produce any increases in plasma AVP secretion during his control 
or -90 mmHg runs; two subjects did not produce a rise in plasma AVP during 
their -90 mmHg b-blockade run but did when they had received placebo. It 
was felt that in these particular circumstances the subjects terminated 
the tests earlier during the b-blockade than during the control runs, 
either through discomfort or inexperience rather than because they felt 
faint. One other subject did, however, lose consciousness even though 
the enabling switch worked perfectly satisfactorily. The onset of syncope 
was so rapid that, in this particular case, the release of negative 
pressure was not sufficiently rapid to prevent syncope occuring. A 4 
second period of asystole resulted with no untoward effect. The plasma 
AVP level was 122 pmol/1 in a blood sample taken immediatley after the 
subject had recovered.
Discussion
The overall responses of plasma noradrenaline and adrenaline were 
similar to those in the previous experiment, although the oscillations 
were far less. This effect was probably due to a wider sampling interval 
of 2 minutes instead of 30 seconds; also 10 ml blood samples take 
proportionately longer to extract and this would help dampen sudden 
changes in circulating blood levels.
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It might be expected that following b-adrenergic blockade plasma 
catecholamine levels would be reduced, since b-adrenergic blockade should 
interfere with the stimulatory positive feedback mechanism, and excess 
noradrenaline in the synaptic cleft would also stimulate negative feedback 
control of noradrenaline secretion via a-adrenoceptors. This, however, 
was not the case, adrenaline and noradrenaline levels being higher both at 
normal pressure and during LBNP when the subject had taken propranolol.
Other workers have also found increased plasma catecholamines after 
subjects took propranolol. Propranolol taken before exercise produces 
greater increases in subjects' plasma catecholamines than with exercise 
alone (Irvin et al, 1974; Galbo et al, 1976). However, Irvine cited 
Halmagyi et al (1971) who demonstrated, following combined# and b 
adrenergic blockade in animals subjected to haemorrhagic shock, that those 
animals had lower plasma catecholamines than animals who were not 
blockaded, but were subjected to haemorrhagic shock (LBNP produces a 
similar loss of blood to the central circulation as haemorrhage). It is 
unfortunate that AVP measurements were not carried out by Halmgyi as we 
have occasionally found high levels of AVP at presyncope with low levels 
of the catecholamines. This might suggest that AVP is involved in a 
negative feedback mechanism on catecholamine production. There is some 
confirmatory evidence for this view. Infusion of AVP decreased plasma 
noradrenaline (Ebert et al, 1986) and sympathetic nerve activity in 
rabbits (Schmid et al, 1984).
Higher plasma levels of adrenaline and noradrenaline during b-adreno­
ceptor blockade are possibly due to their inability to bind to their 
respective receptors and, therefore by inference, more would remain in 
circulation; alternatively, more noradrenaline and adrenaline might be
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produced to counter the circulatory stress being imposed because their 
normal action had been blocked. Propranolol has been shown to cause hypo- 
glycaemia in a few patients who were already prone to hypoglycaemia 
(Kother et al, 1966), or in conditions where hypoglycaemia may occur 
(Abramson et al 1966). Galbo et al (1976) who found significant increases 
in adrenaline and noradrenaline during severe exercise with and without 
propranolol considered the increase in adrenaline might be due to 
decreased glucose availability because of prolonged exercise.
Hypoglycaemia had it occurred in this experiment, although unlikely, could 
also have produced an elevation in plasma adrenaline levels. The 
usefulness of blood glucose determinations were only considered following 
analysis of the results to establish if any incidents of hypoglycaemia had 
occured, unfortunately there was insufficient plasma remaining.
Plasma cortisol determinations were included as an additional 
evaluation of the subjects' stress response and as an indirect measure of 
ACTH secretion. AVP appears to stimulate ACTH secretion in the pituitary 
for some stress situations by modulating corticotropin release factor 
(Gibbs, 1986), The only significant effect of plasma cortisol observed 
were increases in the 10 minute post LBNP sample, which would suggest that 
if AVP has an effect on ACTH and hence plasma cortisol levels it is very 
delayed.
Except in one subject, there appeared to be no effect of propranolol 
on plasma AVP levels during LBNP. Berl et al (1974a) demonstrated an 
increased AVP secretion during b-adrenergic stimulation with isoproterenol 
(a b-adrenoceptor agonist) and a reduction in AVP secretion during a- 
adrenergic stimulation with noradrenaline (Berl et al, 1974b). Their 
conclusion was that AVP release is controlled by altering baroreceptor 
pathways rather than by direct central or depressor effects of
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catecholamines. From the results of Berl et al's two experiments it could 
be argued that b-adrenergic blockade should have had the reverse effect to 
that of b-adrenergic stimulation - ie AVP secretion should have been 
suppressed - as it should have been with high levels of plasma 
noradrenaline (a-adrenoceptor stimulation). However, in spite of b- 
ladrenergic. blockade and high levels of plasma noradrenaline which were 
found in both placebo and propranolol during -90 mmHg runs, there was an 
elevation in AVP, particularly towards the end of the run or at pre­
syncope. It is possible, however, that plasma AVP levels had been 
suppressed until the conditions at presyncope overrode this mechanism.
In the original hypothesis it was argued that if dopamine were one of 
the main contollers of AVP secretion, by suppressing AVP secretion in the 
pituitary, a fall in plasma dopamine should be accompanied by a rise in 
plasma AVP levels. In this series of experiments, although dopamine fell 
significantly, the fall was irrespective of condition or ingestion of 
propranolol. These findings suggest that the plasma dopamine results 
observed were purely a time effect, or that the anticipation of the test 
had caused an initial rise in plasma dopamine - possibly acting in a 
precursor role. However, there is no evidence from measurements of the 
other catcholamines to support this assumption.
In the previous experiments (Chapter 2), a significant fall in plasma 
dopamine was observed at pre-syncope, however, no correlation could be 
established in that experiment or the present one as to whether there is 
any relationship between plasma AVP and plasma dopamine. If it is 
accepted that dopamine is a causative agent in the suppression of AVP 
secretion (Lightman & Forsling, 1980), then there appear to be two 
possibilities. (1). The dopamine suppressing AVP secretion is secreted
87
only via dopaminergic neurones inside the blood brain barrier, such as 
those in the intra-hypothalamic system which have their cell bodies in the 
arcuate nucleus and project into the intermediate and posterior lobes of 
the pituitary. Lightman & Forsling's work with 1-Dopa would support the 
view that the dopamine which controls AVP secretion is contained within 
the blood brain barrier. There is, however, likely to be an interchange 
of dopamine between the pituitary and the general circulation, as the 
posterior pituitary is outside the blood brain barrier. The changes in 
dopamine level taking place within the pituitary might, however, be 
swamped by the levels of plasma dopamine present in the general 
circulation, the sensitivity of the plasma assay being insufficient to 
detect any small changes. (2). If circulating plasma dopamine were the 
controlling agent, the likelihood of missing the precise response is high 
because of an inadequate sampling regime, as has already been shown by the 
rapid oscillations in plasma catecholamine levels. Even if the dopamine 
which controls AVP secretion does originate in the CNS, circulating 
plasma dopamine may still have an influence on dopamine receptors in the 
posterior pituitary in much the same way as circulating noradrenaline can 
be removed from the circulation by active uptake (Langer, 1977).
88
CHAPTER 4
THE RELATIONSHIP BETWEEN PLASMA AVP AND LBNP TOLERANCE
89
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Experiment three - plasma AVP levels in fainting
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Introduction
Davies et al (1976) and Baylis and Heath (1977) demonstrated increased 
plasma AVP secretion at syncope, and its level of production has been used 
to differentiate between fainters and non-fainters (Shvartz et al, 1981). 
Our previous studies have produced anomalous results, with one group of 
subjects producing large quantities of plasma AVP at presyncope, whilst 
the other subjects had only a slight increase in plasma AVP, or none at 
all. An initial study was, therefore, undertaken to establish the 
proportion of subjects who fail to show an increase in plasma AVP at 
presyncope. In reviewing earlier results, however, it was found that in 
many subjects a sample taken 10 minutes after cessation of LBNP showed a 
slight increase in plasma AVP compared to control levels which, if 
extrapolated backwards (taking a biological decay time for AVP of 6-7 
minutes), would suggest that most subjects could have had elevated levels 
of plasma AVP either at, or shortly following, the development of 
presyncopal symptoms. To test this hypothesis, additional blood samples 
were taken shortly after cessation of suction from two subjects during 
their second LBNP run, and both showed substantial increases in plasma 
AVP. To confirm this finding, a second study was undertaken in which 
blood samples were taken from all subjects 2 minutes following the 
development of presyncope. The possible differences in biochemical 
response between subjects having either high or low tolerance to LBNP, has 
also been investigated.
Experimental Procedure
For the first experiment, eight subjects (four male and four female) 
each undertook three runs, two at -90 mmHg and the third a control at 
0 mmHg, Included were two of the subjects from the propranolol experiment
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(Chapter 2) who had produced anomalous results. The experimental 
conditions were as described below, but with the omission of the 2 minute 
post-suction blood sample for six of the eight subjects. For the 
remaining two subjects blood samples were collected during their second - 
90 mmHg run at 5 minutes, as well as 10 minutes post termination.
In the second experiment, six new (male) subjects participated. Each 
underwent four runs, two at -90 mmHg and two controls at 0 mmHg. A period 
of at least one week was allowed between runs which were randomised using 
a Latin square. All subjects underwent prior familiarisation runs in the 
LBNP box to reduce novelty aspects. Subjects were asked to relax as much 
as possible.
The subject entered the LBNP box, a green Venflon catheter, internal 
diameter 1,0 mm, was inserted into an ante-cubital vein and kept patent 
with sodium heparin (5000 i.u./ml). The subject was then left to recover 
for 15 minutes, during which time mercury in silastic strain gauges were 
fitted round each calf at a standard circumference of 13.5 inches, the 
calf circumference was continuously recorded on a pen recorder and the 
percentage volume increases estimated. EGG electrodes were attached to 
the chest. Ten ml blood samples were collected at the start of each run 
and then at 2 minute intervals until symptoms of presyncope occurred, when 
a further sample was taken. Two post-run samples were collected at 2 and 
10 minutes after cessation of suction. For the control run, samples were 
collected at 2 minute intervals, with the vacuum pump running until 6 
minutes had passed, when the pump was turned off. A further two samples 
were collected at 8 and 16 minutes from the start of the experiment. The 
blood samples were analysed for AVP, noradrenaline, adrenaline, dopamine 
and cortisol.
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Blood pressure was monitored using a Dynomap Vital signs indicator,
EGG and heart rate were recorded through a Gould Biotech 8000 and VIOOO 
recorder. Traces were displayed for medical monitoring on a Gould VIOOO 
monitor.
The subject had overall control of the vacuum pump to the LBNP chamber 
using an enabling switch.
The protocol BD/SP/Ia/87 was approved by the Ethics Gommittee and the 
subjects were fully briefed before giving their voluntary consent.
Statistical Analysis
Because of variation in the tolerance time of the subjects, only the 
results from time zero (0), termination, and termination +2 and +10 
minutes were used for statistical analysis.
Analysis of variance was used to investigate any significant factors. 
Also analysis of covariance was used to investigate any effect due to run 
order, or length of time of a run. Three factors were identified: 
subject, time, and the pressure level. Subjects were treated as a random 
effect, while pressure and time were treated as fixed effects. The 
assumption of analysis of variance for all variables was investigated 
using the methods of Box and Gox (1964) and Anscomb (1960), and the 
following transformations of the raw data were then carried out.
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Table 4.1.
Plasma AVP (pmols/1) high tolerance subjects to LBNP,
Time (minutes)0 2 4 6 8
Subject
1 0.8
2.3
0.8
2.7
2.7
5.2
22.3
24.7 44.0
2 4.2
1.6
4.8
2.1 3.2 7.2 11.7
3 1.4
3.6
1.3
2.8
1.9
6.1
8.0
8.5
13.5
9.3
4 11.8
2.4
12.3
11.3
46.2
105.9
5 1.8
2.9 8.7 23.2
PS +2 +10
77.179.2
79.5
61.9
22.2
27.4
28.2
20.7
208.7
17.2
46.2
5.9
160.8 
24. Od
85.5 
■ 17.1
41.1
13.0
167.8
268.4 312.5
74.8
138.5
72.4
209.3
61.7
252.2
27.0
28.3
* run terminated due to abdominal pain.
Subject 4 was from the first group. Subject 5 was included on the basis of 
his second run.
PS - Presyncope
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Transforms
Noradrenaline SQRT (X)
Adrenaline SQRT (X)
Dopamine Log (X)AVP SQRT (X+10)
Cortisol No transform
Systolic BP No transform
Diastolic BP Log (X)
Heart rate Log (X)
SQRT: Square root, (X): Va*lue.
Results
For the first experiment, there was a significant increase in plasma 
AVP (p< 0.001) at both termination and +10 minutes when compared with 
either the control runs or with starting values. The levels of plasma AVP 
for the first of the -90 mmHg runs tended to be higher than those for the 
second: there was, however, a considerable difference in the timing and 
magnitude of the responses, even in individuals.
For the analysis of the second series of experiments, the subjects 
were divided into two groups. Those who tolerated LBNP for 3 minutes or 
less were classed as having low tolerance, while high tolerance subjects 
were defined as those who went for over 3 minutes before developing 
symptoms of presyncope. Subjects conveniently split into equal numbers 
for each group. The longer subjects could tolerate LBNP, the more 
likely they were to produce small steady increases in plasma AVP during 
the run, usually reaching a peak response at presyncope. Table 4.1. Some 
low tolerance subjects did not produce any significant increase in plasma 
AVP until presyncope or at the time of the two minute post-termination 
blood sample. It must be emphasised, however, that in some low tolerance 
subjects, only one or two samples could be collected before the subject 
started to faint.
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Both low and high tolerance subjects, however, had a significant increase 
in AVP (p< 0.001) at presyncope and in the termination +2 minute and +10
minute samples when compared to the control level (Fig 4:1). There was
also a significant reduction in the plasma AVP level at +10 minutes
compared to the termination and +2 minute samples (p< 0.01).
For both series of experiments there was considerable variability in 
plasma AVP secretion and in tolerance to LBNP, even for the same 
individual (Table 4:1), In almost every case the subject's tolerance in 
the second run was longer than for his first. Subject three's second run 
was stopped at 14 minutes because of abdominal pain, although his heart |
rate and blood pressure suggested he could have gone on for several more I
I
minutes.
!
Twenty seven subjects have been investigated in this and the previous j
I
studies to LBNP and approximately 20% have failed to show a marked 
increase in plasma AVP either before or immediately upon presyncope.
Thus, a range of AVP secretion patterns has been observed.
Because of the strategy adopted for the statistical analysis, the 
interpretation of results for the plasma catecholamines was somewhat 
simpler than for the previous two series of experiments (Chapters 2&3).
For both parts of this investigation there was a significant increase in 
plasma noradrenaline at termination (p< 0.001) when compared to time zero 
(0) and termination +10 minute plasma samples (Fig 4:2). In addition for 
the second group of experiments, the termination +2 minutes samples were 
significantly higher than the 0 mmHg and termination +10 minutes 
(p< 0.01). The plasma noradrenaline at -90 mmHg were also significantly 
higher than the equivalent control (0 mmHg) runs (p< 0.001). There were no 
differences between the low and high tolerance subjects.
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Fig 4:1 Comparison of high tolerance subjects mean plasma AVP (N=3) at 
~90 mmHg to low tolerance subjects mean plasma AVP (N=3) at
-go mmHg O O. The control (0 mmHg) is the mean of all the subjects
(N=6) A  A. There was a significant increase of plasma AVP attermination for high (*** p< 0.001) and low tolerance subjects 
(v«v p< 0.01) and at +2 minutes (p< 0.001) for both low (*** p< 0.001) 
and high tolerance subjects (*** p< 0.001), compared to control (0 mmHg) 
and time zero values.
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Time
Zero
Termination +2 Minutes + 10 Minutes
Fig 4:2 Mean plasma noradrenaline (N=28, +2 minute sample N=12) at
-90 mmHg A  A ,  and 0 mmHg A  A. There was a significant increase innoradrenaline at termination (*** p< 0.001) and +2 minutes (** p< 0.01), 
compared to time zero and the 0 mmHg runs.
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Fig 4:3 Segmented trace of (1) LBNP, negative pressure 0 to -90 mmHg
(2) Heart rate (running average of 10
beats).
(3) EGG.
(4) Chart speed 5 mm/S
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The response o£ plasma adrenaline was inconsistent; in the first series 
of experiments plasma adrenaline increased significantly in both -90 mmHg 
runs (p< 0.01) and remained elevated in the 10 minute post LBNP sample.
For the second series there was, however, no significant increase in 
plasma adrenaline.
No differences could be detected in plasma dopamine levels between 
control and -90 mmHg experiments, nor within runs, in either of the two 
investigations.
The plasma cortisol responses were similar in both series of 
investigations. There was a slight, but significant increase in plasma 
cortisol (p< 0.05) in the -90 mmHg runs 10 minute post termination samples. 
There were no differences between low and high tolerance subjects.
The blood pressure response to the application of suction for both 
investigations was an immediate fall in systolic pressure, which tended to 
level off and be maintained, until, as symptoms of presyncope developed, 
there was a sudden and precipitous fall (p< 0.001). The fall of systolic 
pressure was less in the second series of -90 mmHg runs (p< 0.05). 
Diastolic pressures showed no significant change until they fell at 
presyncope (p< 0.001).
Heart rate showed a steadily developing tachycardia (p< 0.05), then an 
imperceptible slowing which was more easily detected by the averaging 
display of the Biotech, (Fig.4:3), followed again by a precipitous fall 
depending precisely upon when suction i/as terminated. The ensuing 
bradycardia was sustained for several minutes and in many subjects lasted 
until the end of the period of observation.
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One subject was not included in the data analysis. He was 
aerobically very fit, but had little cardiac response to suction. After 
one minute he fainted without prior warning, exhibiting a 14 second 
asystole: his plasma AVP levels increased in a few seconds from 5 to over 
800 pmols/1. No adverse effects were observed on recovery.
There has been a wide range of tolerance to -90 mmHg LBNP from the 
experimental data collected so far, from 54 seconds to over 14 minutes. 
The mean time (n=28) was 4 minutes-28 seconds S.D. + 3 minutes-2 seconds.
No differences in the various analyses could be attributed to the sex 
of the volunteer.
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DISCUSSION
As well as LBNP, head up tilt and prolonged standing following a 
period of supination have been used to investigate the effect of AVP on 
postural control, hydration and syncope. Shvartz et al (1981) 
investigated the differences between fainters and non-fainters during heat 
acclimatisation and showed that fainters had greater increases in plasma 
AVP upon tilting than non-fainters, but also showed lower increases in 
plasma renin activity (PRA). A similar study in hydrated and dehydrated 
subjects (Baylis and Heath 1977) again showed significant increases in 
plasma AVP in fainters. Davies et al (1976) carried out a systematic 
investigation of plasma AVP secretion in head up tilt and demonstrated a 
large increase in plasma AVP within four minutes of the development of 
vaso-vagal symptoms. In subjects who did not exhibit immediate vaso-vagal 
symptoms, there was a biphasic response of plasma AVP. An initial small 
rise of plasma AVP at 3 minutes was followed at 30-45 minutes by a
striking rise which was associated with a fall of 17% in plasma volume.
In those subjects who developed symptoms of presyncope after 3 minutes, 
but during the 30 minute test period, blood samples taken within 2-4 
minutes while a bradycardia was still present showed an eight fold 
increase in plasma AVP levels which was significantly greater than the
elevated levels found at 30 minutes in non-fainters.
The biphasic response described by Davies et al (1976) may be due to a 
similar vascular response to that seen in this series of experiments with 
LBNP. By using strain gauges, it is possible to demonstrate an immediate 
increase in calf circumference on application of suction, followed by a 
slower increase over a longer period. The interpretation is that the 
application of LBNP causes an elevation in lower body vascular transmural
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pressure, the magnitude of which is directly related to the level of 
reduced pressure applied. This elevation in vascular transmural pressure 
leads to sequestering of blood in capacity vessels in the lower body 
(predominantly veins) and, to a lesser extent, the translocation of plasma 
filtrate to the extravascular space according to Starling's law. This loss 
of circulating blood is probably similar in head-up tilt, but over a much 
longer time span than with LBNP.
In recumbent man more than 50% of the total blood volume is contained 
in the systemic veins and about 30% in the intrathoracic vessel 
compartment, therefore blood volume shifts are almost entirely confined to 
the low pressure system. On standing, intravascular pressures decrease 
above the point where the intravascular pressures stay constant (the 
hydrostatic indifferent point, HIP) and rise in the dependent parts of the 
body. Large displacements of blood volume then take place. There is a 
drop in arterial pressure to the head of 20-30 mmHg, and the most 
extensive pressure increase takes place in the leg veins with a measured 
intravenous pressure at the ankle of 88-95 mmHg. The mean distending 
pressure in the leg veins has been estimated to rise to 36 mmHg from a 
recumbancy pressure of 11 mmHg (Gauer and Thron, 1966). The initial 
increase in blood volume in the legs is almost 500 ml, although this is 
dependent on body temperature.
With prolonged passive standing, the high filtration pressure leads, 
after an initial fast increase, to an additional slow rise of leg volume 
which may proceed for many hours and is mainly due to extravasation of 
plasma filtrate (Gauer and Thron, 1966)
It has been estimated that about 78% of the blood displaced to the 
dependent parts of the body is derived from the intrathoracic vascular
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compartments, which act as a blood reservoir, with a reduction of 25% in 
the heart and pulmonary circuit. There appears to be little change in the 
blood volume of the abdomen on passive standing: this is likely due to a 
linear pressure gradient in the region between the pelvic floor and the 
diaphragm which balances the intravascular pressure gradient found there. 
The zero level of the intra-abdominal pressure is almost identical with 
the HIP of the vascular column at approximately the height of the liver. 
Therefore, changes of distending pressure are small (Gauer and Thron, 
1966). This is different from LBNP where pooling of up to 500 ml of blood 
in the abdomen has been estimated by Glaister and Crossley (1974). Also, 
the blood loss of the combined leg and abdomen have a synergistic effect 
on reducing LBNP tolerance compared to leg or abdomen alone, which may be 
one of the reasons for the shorter tolerance to LBNP than passive 
standing.
Passive standing exacerbates blood pooling in the legs due to the 
lack of muscle activity. An exercising muscle reduces its volume and 
thereby constricts blood vessels in its vicinity, particularly deep veins, 
and so effectively act as a pump. Blood reflux is prevented by the venous 
valves and blood from the superficial veins is sucked into the interfacial 
deep veins (Henry and Gauer, 1950). Contraction of leg muscles 
particularly would aid venous return during standing.
An elevation in circulating AVP is known to cause a reduction in 
forearm blood flow (Simpson et al 1986; Edbert et al 1986; Epstein et al 
1968), and there was, therefore, the possibility that sampling from an arm 
vein might produce different values for peripheral plasma AVP at syncope 
compared to the levels found in the central circulation. However, samples 
taken from the superior vena cava (Heath et al, 1979) showed a general
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increase of 5-20 pmol/1 AVP during mild hypotension, but with the onset of 
severe hypotension, plasma levels of 1250 pmol/1 were recorded, a similar 
range of values to our results.
The inference from some of the literature is that plasma AVP levels 
are more elevated in people who are prone to fainting than in non- 
fainters. Our results suggest that this is not so, probably the majority 
of people produce elevated levels of plasma AVP at the time of syncope.
It seems likely, therefore, that other factors may be more relevant to a 
person's susceptibility to fainting. A more significant factor as to 
whether a person faints or not may be the initial response in AVP 
secretion to the particular stress. The level of LBNP chosen for this 
study, -90 mmHg, usually induces syncope within 6 minutes, but subjects 
had a wide range of tolerance to LBNP.
Some factors have been noted during this research which appear to 
affect subject tolerance. There was a considerable reduction in subject 
tolerance between familiarlisation runs and the actual experiment. This 
was particularly noticable with subjects who had a short tolerance in the 
experimental conditions, where previously they had tolerated step 
increases of reduced pressure up to -90 mmHg for 5 minutes, followed by 
several excursions directly to -90 mmHg with no problems. The only 
differences in the experimental condition was the insertion of a catheter 
and fixing of strain gauges: EGG electrodes were fitted on all occasions. 
Stevens (1966) investigated the problem of invasive techniques and found a 
considerable reduction in tolerance to LBNP, and it is therefore likely 
that the insertion of the catheter is one of the causes of a reduced 
tolerance to LBNP. There is no explanation for this phenomenon, as the 
chemistry which we investigated appears normal in the context that few 
changes appear to take place during the control runs. No increases in
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plasma AVP, which has been associated with fainters, were noted following 
venepuncture. Apprehension may also be a factor, plasma adrenaline was 
raised in the first experiment (Chapter 2) before the start of the first 
experimental run in 50% of subjects. This plasma sample was not collected 
in later experiments. In approximately half of all the subjects used to 
date, there has been a marked increase in tolerance in their second - 
90 mmHg runs and this was even more noticable in three subjects who have 
undertaken more runs at -90 mmHg, where the tolerance to LBNP has doubled.
For some considerable time it was thought that the the pressor 
activity of AVP was of purely pharmacological interest. This view has 
largely changed, since it has been shown that AVP in physiological 
concentration can have a considerable influence on the cardiovascular 
system (Cowley and Liard, 1987). Small increases in circulating AVP have 
a pressor action, particularly in peripheral vessels which are more 
sensitive to the action of AVP, thus helping to maintain BP in a 
developing hypotensive state. Simpson et al (1986) infused small amounts 
of AVP (1.9 pg/ml mean plasma level) which produced a change in forearm 
blood flow and cardiac output on tilting, suggesting a role for AVP in 
the postural control of BP. Although small increases of circulating AVP 
can have a profound effect on the vasculature, high circulating levels of 
plasma AVP do not appear to cause an elevation in blood pressure above 
normal, even when the stress is removed.
The overall results raise the question as to what the actual role of 
AVP is at syncope, and what is the actual trigger for the rapid release of 
the large amounts of plasma AVP observed under these experimental 
conditions? Epstein (1968) concluded that the major factors for the 
hypotension of vasovagal syncope are bradycardia and loss of peripheral
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resistance due to inhibition of the adrenergic sympathetic system, 
combined possibly with stimulation of the sympathetic cholinergic system 
which would reduce peripheral resistance (Hyatt et al, 1969). It is 
possible, therefore, that the large amounts of plasma AVP observed at 
syncope are an attempt to reconstrict the vascular system to maintain 
blood pressure. The reduction in circulating blood volume is relevant, as 
Davies et al (1976) estimated a loss of 17% to be critical. This loss 
would have been mainly be to the legs, whereas the results from our 
experiment which included the abdomen as well as the legs, gave an 
estimate of 18-24%, taking a value of 5-5.5 litres for the normal 
circulating blood volume.
The various receptors which have been cited as influencing AVP 
secretion, by baroreflex, are the carotid sinuses and afferent nerve 
fibres (Share & Levy, 1962), as well as intrathoracic receptors (Segar & 
Moore, 1968; Rogge & Ward, 1968). One factor, however, which may have a 
significant effect on AVP secretion is cerebral oxygen level. Although 
hypoxia alone has little effect on AVP secretion in experienced altitude 
subjects (Forsling & Milledge, 1977), cerebral blood haemoglobin and 
oxyhaemoglobin levels fall dramatically in man exposed to +G^ acceleration 
and LBNP (Glaister and Jübsis-VanderVliet, 1987). This fall occurs during 
an increasing tachycardia and several seconds before the terminal pre­
syncope bradycardia. It is possible that this cerebral oxygen
insufficiency may be the stimulation for AVP secretion when high plasma
levels are associated with syncope.
It could also be argued that AVP is part of the fainting mechanism
itself, since as well as its pressor action in hypovolaemia, AVP at normal
blood concentrations can significantly decrease heart rate and cardiac 
output. Although arterial pressure remains unchanged, indicating that
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total peripheral resistance has increased, the decrease in cardiac output 
is in part a direct result of the bradycardia, rather than depressed 
cardiac performance or other possible alteration in systemic vascular 
resistance (Wolthuis et al, 1974). Bradycardia following infusion of AVP 
has been demonstrated by several groups of workers (Kelby et al, 1980; 
Siriveh and Mumford, 1975; Azor, 1977 and Eden et al, 1983). It is 
possible, therefore, that a sudden increase in circulating blood AVP may 
help induce a bradycardia and so precipitate syncope. A particular 
feature of LBNP exposure, and also noted in this series of experiments, is 
a sustained bradycardia, often still present 10 minutes after termination 
of the suction period.
The role of AVP at syncope is still very unclear. The elevated levels 
of plasma AVP at presyncope were approximately the same order of magnitude 
for all subjects, although in low tolerance subjects there may be delay in 
production, in some cases until after symptoms of presyncope have 
occurred. The overall function of AVP under these experimental conditions 
appears to be the maintenance of blood pressure and as an aid to recovery, 
although it also seems to have an earlier protective physiological role in 
some subjects.
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CHAPTER 5
THE EFFECT ON TOLERANCE TO LBNP OF INTRAVENOUSLY INJECTED AVP
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Introduction
The accumulation of evidence from the previous investigations has 
suggested that AVP may have a role in protecting some subjects against 
fainting during the experimental procedures used. There was a wide range 
of tolerance to LBNP. In subjects with a high tolerance to suction there 
was usually an initial small increase in AVP secretion which increased 
steadily as the run progressed. Large increases in plasma AVP were found 
in all subjects at or within two minutes of the development of signs of 
presyncope. In an attempt to clarify the situation, a series of experi­
ments has been carried out in which a bolus injection of AVP has been 
given prior to the application of LBNP, to ascertain whether pre-elevated 
levels of plasma AVP are of benefit in preventing syncope and in 
increasing tolerance to LBNP. The amount of AVP injected was chosen to 
produce a circulating blood level equivalent to the mid-range plasma 
levels noted in previous experiments as occurring at the time of 
presyncope.
Our interest had also been aroused in the response of another vaso­
active peptide to LBNP, atrial natriuretic peptide (ANP). ANP has 
antagonistic actions in man to AVP, ie. it has a diuretic effect, reduces 
blood pressure, increases heart rate and causes vasodilation (Bussien et 
al 1986, and Biollaz et al, 1986).
Atrial Natriuretic Peptide
Atrial natriuretic peptide (ANP, formally Atrial Natriuretic Factor, 
or ANF) is found in mammalian atria. ANP is a relatively new compound to 
be identified (de Bold et al, 1981) and investigations into its role in 
man have only recently started. Earlier research had used other species 
of mammal, or in vitro tissue studies.
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Several forms of atrial natriuretic peptide have been identified which 
depend largely on the number of amino acid residues present. This 
variation in structure has some effect on their actions and potency (Maack 
and Kleiner, 1986 and Yamaji et al, 1985). In man, the active form 
appears to be aANP which has 28 amino acid residues, and a circulating 
half life in the blood of about 3 minutes (Weidmann et al, 1988).
Injected in man, ANP induces vasodilation and a reduction in blood 
pressure', but with an increased heart rate and skin blood flow. There is 
also a decrease in renal and hepatic blood flow, a natriuresis and 
transient diuretic effect (Bussien et al, 1986; Biollaz et al, 1986; 
Rodeheffer et al, 1986 and Weidmann et al,' 1988). Physiologically, ANP is 
secreted from the atria during atrial distension secondary to an increase 
in central blood volume and/6r, right or left atrial pressures.
ANP has an antagonistic action to vasoconstrictors, although Maack and 
Kleiner (1986) considered that the action was not at the receptor level, 
but was probably caused by alterations in the intracellular calcium 
homeostasis with c-GMP acting as a putative second messenger. ANP is 
particularly powerful at suppressing the action of angiotensin II, whereas 
high levels of noradrenaline will overcome any suppressive action by ANP 
(Maack and Kleiner, 1986). Although Biollaz et al (1986) found no effect 
by ANP on AVP secretion, there is some confusion as other workers have 
found suppressive effects (Weidmann et al, 1988). The variation may be 
due to the amount of ANP given, as small quantities of ANP have produced a 
reduction in plasma renin activity (PRA), but high aANP infusion rates 
either produce no change or an increase in PRA.
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Experimental procedure
Eight male subjects age 19-44 years undertook two experiments. In one 
experiment a bolus injection of Pitressin (Parke-Davis) was given 
intravenously and in the other a placebo bolus of dextrose-saline was 
given. A preliminary study suggested that to obtain a circulating AVP 
blood concentration of 50 pmol/1 (the mid-range plasma AVP value at 
presyncope obtained from previous experimentation see Chapters 2-4), 
double that amount would need to be injected per litre circulating blood 
volume. Therefore, the dose of Pitressin given was equivalent to lOOpg 
AVP/ml circulating blood volume,in 10 ml dextrose/saline. Blood volume 
was calculated on the weight and age of a subject (Geigi normogram). The 
initial injection was flushed through the catheter with a further 5 ml of 
dextrose/saline. For the placebo injection, 10 ml of dextrose/saline was 
given followed by a further 5 ml.
The subject entered the LBNP chamber, a green venflon catheter (1 mm 
internal diameter) was inserted into an antecubital vein of the left arm. 
When the subject had settled down, a 10 ml blood sample was taken. A 
butterfly catheter was inserted into a right forearm vein and the 10 ml 
bolus + 5 ml flush was injected. After 1 minute, a 10 ml blood sample was 
taken from the left arm and a suction of -90 mmHg applied. Ten ml blood 
samples were then taken at 2 minute intervals until symptoms of presyncope 
occured at which time the run was stopped and a 10 ml blood sample taken. 
Further 10 ml samples were taken at 2 and 10 minutes post suction.
The blood samples were analysed for AVP, ANP, noradrenaline, 
adrenaline, dopamine and cortisol. Blood samples for AVP and ANP were 
collected into tubes containing peptidase and EDTA, while for catechola­
mine analysis, collection was into tubes containing heparin.
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Blood pressure was monitored continuously using an Ohmeda Finapres and 
recorded on a Gould 1000 recorder. Mean heart rate was measured with a 
Gould Biotach and recorder, and displayed on a Gould VlOOO monitor.
All subjects were fully briefed and gave their written informed 
consent to the procedure which had received ethical approval.
(BD/SP/lb/88, with modifications to procedure '89).
Statistical Analysis
Analysis of variance was carried out on the data derived from the pre, 
start of suction, first 2 minutes of suction, presyncope, and the 
presyncope +2 minute and +10 minute values. Three factors were 
identified: time, the type of dosage given, and the subject. The ANOVA 
was tested by the methods of Box and Cox (1964) and Anscomb (1960). Where 
it was not upheld, the following transformations were carried out:-
Transformations
AVP Log (X)
ANP Log (X-1)
Cortisol Log (X-6)
Noradrenaline Log (X+60)
Adrenaline Log (X+50)
Dopamine No transform
Heart rate No transform
Blood pressure No transform
Results
Although a calculated dose of AVP for each subject had been injected, 
a wide range of actual plasma AVP levels was obtained (28.8-105.7 pmol/1). 
There was a significant increase in plasma AVP (p< 0.001) as the individual 
runs progressed for both control and dosed runs (Table 1). Plasma AVP was
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Table 1.
AVP results in pmol/L for control (C) and dosed (D)experiments
Subject Pre 0 2 4 6 8 PS + 2 +10
1. C. 
1. D. 3.8 _ 3.8
2.8
61.9
3.5 2.6 8.9 31.4
79.8
25.5
112.7
7.1
28.1
2. C. 
2. D.
1.2
1.2
1.7
29.1
1.2
32.6
13.6
94.5
4.0
16.5
3. C. 
3. D.
0.4
0.4 1.372.1 41.1
7.8
32.6 31.947.3 6.76.5
4. C.
4. D.
1.8
1.9
1.7
84.6
6.4
79.1
108.4
263.7
269.1
213.6
72.9
84.7
5. C.
5. D.
2.2
1.7
1.8
27.5
1.7
31.5
2.6 2.5 
24.0 24.6
2.8
18.4
6.5
11.7
5.3
8.5 3.95.2
6. C.
6. D. 2.73.0
3.4
23.0
15.5
127.8
67.8
89.7
17.3
19.5
7. C.
7. D___
7.6
6.1
8.4
113.1
59.2
95.2
42.0
61.9
12.7
21.7
8. C. 
8. D.
0.2
0.2
0.5
36.8 0.940.6 1.4 6.0 62.3121.1
66.1 20.4
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also significantly higher in the dosed subjects when compared to their 
control levels (p< 0.001).
There was no significant difference in tolerance to LBNP between 
placebo and AVP injected subjects, but in two cases the effect of injected 
AVP appeared detrimental (Table 1). Thus, the length of tolerance time 
was substantially reduced, 6 minutes for one and 4 minutes for the other 
subject. Interestingly, both subjects had a high tolerance to LBNP and 
+Gg on the human centrifuge and had experienced levels of +9Gz, wearing 
anti-G garments, with no apparent problems.
Plasma noradrenaline and adrenaline increased steadily in response to 
LBNP during placebo and AVP injected experiments, with a maximum response 
at presyncope (p< 0.01) for both catecholamines. There was no significant 
effect on plasma dopamine for any of the conditions, and there were no 
differences in any of the plasma catecholamines responses to AVP injection 
when compared to placebo values.
There appeared to be a rapid rise in plasma ANP following injection of 
AVP (Fig 5:1), but it was not statistically significant when compared to 
the surrounding control values. Indeed, there did not appear to be any 
significant response of plasma ANP to AVP injection or to suction.
Plasma cortisol increased significantly following the infusion of AVP 
(p< 0.001). There was a further increase following presyncope, also 
present in the control group (Fig 5:2). The increase in plasma cortisol 
was greatest in the +10 minute samples (p< 0.001) for both placebo and AVP 
injected groups.
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Fig 5:1 Mean plasma ANP values following injection of 100 pg AVP/ml
blood# #  and placebo O — —O. There was no significant
differences between the two conditions. (S-presycope).
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Fig 5:2 Mean (N=8) plasma cortisol values following injection of
100 pg AVP/ml blood # --- #and placebo O O* There was a significant
increase in plasma cortisol (***p< 0.001) following infusion of AVP 
compared to placebo and pre LBNP values (###p< 0.001). There was 
also a significant increase in plasma cortisol in both placebo and 
AVP injected subjects (***p< 0.001) in the +10 minute post LBNP 
sample. (S-presyncope).
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Heart rate increased rapidly following the application of suction (p< 
0.01). At presyncope, there was a sudden and rapid fall in heart rate 
and at this point suction was stopped. There were no differences between 
placebo and AVP injected subjects (Fig 5:3). A sustained bradycardia was 
observed in all subjects until the end of the experiment.
No differences could be detected in blood pressure between the AVP 
injected subjects and their control values (Fig 5:4). With suction, 
systolic blood pressure initially dropped rapidly (p< 0.01), then levelled 
and finally fell precipitously at presyncope (p< 0.01), as compared to the 
pre-run levels. No significant changes were noted in diastolic blood 
pressure until a fall was seen at presyncope. There was a rapid recovery 
of blood pressure to pre-run levels within 0.5-1 minutes, without over­
shoot.
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Fig 5:3 Mean heart rate (N=8) in beats per minute (BPM) following 
injection of 100 pg AVP/ml blood #  #and placebo 0 — 0* There was 
no significant difference between placebo and AVP injected subjects. 
(S-presyncope).
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Fig 5:4 Mean systolic blood pressure, following injection of 100 pg 
AVP/ml blood# #and placebo 0 —— Q. There was no significant difference 
between placebo and AVP injected subjects.
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Discussion
The bolus injection of AVP was intended to mimic the plasma AVP 
response that has been associated with the high levels of LBNP used during 
previous experimentation. It had appeared that rapidly increasing amounts 
of AVP were part of a mechanism involved in maintaining blood pressure and 
consciousness during LBNP exposure. It was, therefore, argued that pre­
elevated levels of AVP should increase a subject's tolerance time to LBNP. 
This does not, however, appear to be the case. Thus, the present results 
have not shown any advantage during LBNP from pre-elevated levels of 
plasma AVP. The subjects still produced endogenous AVP even though they 
usually had considerably elevated plasma AVP levels. Blood pressure was 
maintained no better in the AVP than the placebo injected subjects. In 
two cases there was a reduction in tolerance, as measured by time to 
presyncope, although the group was small and further work is required to 
validate this observation. It appears that AVP-induced vaso-constriction 
has limited value in maintaining consciousness under these physiologically 
severe experimental conditions. The variation in levels of plasma AVP 
attained suggest, either that the method used to calculate blood volume 
was inaccurate, or that there is possibly a wide range of receptor 
densities between individuals, so making a considerable differance in the 
amount of AVP rapidly removed from the circulation. Thus, the time scale 
appears too short for significant enzymatic degradation to have taken 
place, the half life for AVP being about 7 minutes.
It is possible that had the AVP been infused more slowly over a longer 
period, so as to produce a steady plasma level of AVP, it would have had 
a different effect on subject tolerance time. Ebert et al (1986) infused 
a low dose of AVP (0.15 or 0.40 ng/Kg min) over a period of 55 minutes, to 
obtain a steady state plasma AVP level. The result was a small, but
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significant increase in systolic and diastolic blood pressure during the 
higher level of AVP infusion. LBNP was applied for 3 minutes at the 
begining and end of the infusion, with three 10 second breath holds. LBNP 
provoked reflex increases of total peripheral resistance. These increases 
were enhanced 60% during AVP infusion compared with pre-AVP control 
increases. It was thought that the effect was mainly in the splanchic 
circulation as no AVP enhancement of forearm vascular resistance was 
observed. The level of suction was low compared to our study, being only 
10 mmHg, and was applied for a comparitively short time. A significant 
reduction in plasma noradrenaline was also observed, whereas our study 
consistently showed an increase as the period of suction progressed. The 
more severe conditions imposed on our subjects suggest that the 
sympathetic response to LBNP may override the suppression of noradrenaline 
secretion by AVP and the blood pressure increase observed by Ebert et al 
(1986), who concluded that AVP maintains arterial pressure during 
orthostasis both by direct vasoconstriction and by augmenting reflex 
vasoconstriction mediated by cardiopulmonary receptors. AVP may therefore 
only be an aid to recovery. There is also the possibility that an 
elevated plasma AVP level may actualy trigger a faint by inducing a 
bradycardia.
The possibility that the injected AVP was immunologically active for 
assay purposes, but biologically inactive was considered. The cortisol 
response, however, appears to negate this argument. Arginine vasopressin 
is believed to stimulate ACTH secretion, through two centres (Gash and 
Boer, 1987) which in turn would affect cortisol secretion. Arginine 
vasopressin can act directly on the pituitary to stimulate ACTH secretion 
which seems the likely path for exogenous AVP because of the crossover of 
the blood brain barrier which can take place in the pituitary. Arginine
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vasopressin can also indirectly affect ACTH release by stimulation of 
corticotropin release factor (CRF) secretion from the hypothalamus, which 
in turn stimulates ACTH release from the pituitary. However, in the dog, 
AVP infusion reduced ACTH production (Brooks & Blakemore, 1989), though 
glucocorticoids were increased by what appeared to be direct action of AVP 
on the adrenals, providing that some plasma ACTH was still present. This 
effect may be species dependent.
Decreases in plasma ANP secretion have been observed following 
exposure to LBNP (Schmedtje et al, 1987). Our results, however, do not 
support this finding, although there was considerable variation in 
individual responses. Experiments in the dog using hypotensive 
haemorrhage (Edwards et al, 1988) produced a significant fall in plasma 
ANP due to reduced atrial stretch and it might be expected that LBNP, 
which produces a similar reduction in central circulating blood volume to 
haemorrhage (the blood pooling in the lower limbs) would also produce a 
fall in plasma ANP. Under our experimental conditions, however, no 
significant reduction in plasma ANP levels were observed. The observation 
of a transient rise in plasma ANP following injection of AVP suggest that 
vasoconstriction had taken place and tends to support the biological 
activity of the injected AVP. Although AVP is antagonistic in its action 
to ANP, increases in ANP are known to occur following increases in right 
atrial pressure produced by many procedures, including AVP induced 
vasoconstriction (Needleman, 1988, and Manning et al, 1985). There is 
also the’possibility that our methodology was not sensitive enough to 
detect small changes in already low basal levels of plasma ANP. However, 
significant small falls in plasma ANP have been detected by us during very 
mild dehydration experiments (Green et al, 1989). One response of man to 
LBNP is a developing tachycardia with time, and it may be this stimulation 
of the atrium which counters the response to any reduction in atrial
124
stretch* Pathological tachycardias have been shown to produce increases 
in plasma ANP (personal communication), and Yamaji et al (1985) showed an 
increase in plasma ANP following paroxysmal atrial tachycardia.
Although ANP and AVP have antagonistic actions, the results from this 
series of experiments suggest that they generally act independently of one 
another, and that it is the prevailing conditions which dictate the actual 
response.
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Final Discussion and Conclusions
The overall findings of this work have been somewhat disappointing: no 
relationship could be established between any of the circulating levels of 
plasma catecholamines and plasma AVP, although in many subjects there was a 
fall in plasma dopamine as symptoms of syncope developed. It is possible 
that some of the anomalies noted in the literature for the response to AVP 
following infusion of dopamine, may be due to the normal body posture of 
the specific animal used. Man, being upright, has different orthostatic 
problems to those of the dog, cat and rat, and evolutionary selection may, 
therefore, have led to differing control systems.
The original hypothesis had been that dopamine was controlling AVP by 
suppressing its secretion from the pituitary. However, from the 
literature review, it seems likely that the control of AVP secretion 
by dopamine in the pituitary, if it occurs at all, is under the control of 
the CNS. Therefore, it is unlikely that biochemical events taking 
place in the pituitary would be reflected in peripheral blood and it was 
probably optimistic to expect to see changes in circulating plasma 
dopamine levels, particularly a reduction in concentration.
Although there is an interchange between the pituitary and the general 
circulation, changes in dopamine levels that occur in the pituitary are 
likely to be swamped by the quantity of dopamine already present in the 
general circulation. Nevertheless, in subjects who developed symptoms of 
presyncope, a significant reduction in plasma dopamine was observed. It 
is plausible that, because of interchange between the pituitary and the 
general circulation, a significant reduction in plasma dopamine could have 
an influence on pituitary D2 receptors and hence on AVP secretion, in much 
the same way as circulating blood noradrenaline has an influence on the
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chemistry of the synaptic cleft, as demonstrated by active uptake. Also, 
as has been demonstrated for several compounds analysed in this thesis, 
(specifically noradrenaline, AVP and cortisol), the timing of blood sample 
collection is absolutely critical. Thus, the lack of any correlation 
between plasma dopamine levels and AVP secretion may be due, at least in 
part, to an inadequate frequency of blood sampling for the experimental 
conditions under study.
There was a consistent increase in plasma noradrenaline in response 
to the higher levels of LBNP, though the effect on adrenaline was less 
clear, with significant increases on some occasions and little effect on 
others. This variation may be due to subject variability and the small 
number of subjects used for each group of experiments. In some subjects 
at pre-syncope there was a fall in plasma levels for all the 
catecholamines which may indicate a collapse of the entire central system. 
A recent review paper on the control of AVP release by Bisset and 
Chowdrey, (1988) concluded, with some reservations, that noradrenaline, 
stimulates the release of AVP by an action on receptors, and inhibits 
AVP release by action on &2 and h receptors. There was, however, no clear 
role defined for dopamine.
The response of noradrenaline to the cardiovascular stress of LBNP was 
of considerable interest, in relation to the rapid changes in plasma 
levels demonstrated. The increase in plasma noradrenaline was immediate 
and its rapid disappearance indicated a half life of 15 seconds or less. 
Several possible explanations have been considered in the previous 
chapters, and it seems likely that several control mechanisms must be 
involved. The initial increase in plasma noradrenaline coincided with a 
fall in systolic blood pressure, which, had a tendency to level off and 
then be maintained for a time at a new lower level. This suggests that a
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closed loop control system was in operation, but because of the large and 
rapid changes in plasma noradrenaline, this would not appear to be 
biologically efficient. Pulsatile^secretion was considered to be a more 
likely explanation. Thus, because of the rapid removal of noradrenaline, 
by 0-methylatfon, large quantities would be required to produce a 
significant response and there would be the possibility of a refractory 
state developing in the receptors or effector organs if a high secretion 
rate were continuous. Pulsatile secretion would produce high 
instantaneous plasma levels and tend to reinforce the response to the 
stress without risk of a refractory state developing. A high degree of 
nerve stimulation might be expected during LBNP, and this would also 
contribute to the rapidly changing levels of plasma noradrenaline because 
of changes in the synaptic cleft.
Lower body negative pressure has been used to model the cardiovascular 
stress of +0^. From Mills' (1983) work and in recent experiments using 
the human centrifuge, not directly related to this thesis, a range of 
plasma AVP values (5-60 pmol/1) has been observed in young pilots taken to 
greyout, ie. to loss of peripheral vision. These values are similar to 
those obtained during LBNP exposures, although because our subjects were 
supine, peripheral vision was maintained.
Evolution has produced many example of complimentary systems of 
control, and this appears to be the case in the maintenance of blood 
pressure. AVP in a pressor role appears to aid the fine control of blood 
pressure, supplementing the sympathetic and baroreceptor reflex actions 
which are the body's immediate response to a fall in blood pressure. As 
AVP has a selective action on blood vessels, other portions of the 
vascular system are not affected and could be acted on by other pressor
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agents. There thus appears to be a tiered system of control for the 
maintenance of blood pressure. There is the immediate reflex response, 
followed by the pressor action of AVP with a half life of approximately 
six minutes, followed by the angiotensin-renin pressor action which can 
take ten to fifteen minutes to develop fully. Thereby, a complete 
control system to cover and maintain immediate, intermediate and long term 
control of blood pressure can be brought into operation.
Release of AVP is controlled by changes in blood volume, or pressure, 
and by plasma osmolality. Blood volume and pressure control changes are 
mediated reflexly by peripheral receptors in the cardiovascular system. 
Stimuli for blood volume and pressure changes are haemorrhage, hypotension 
and carotid occlusion, all of which produce increases in AVP secretion. 
Generally, activation of baro- and stretch receptors results in inhibition 
of AVP secretion, whereas activation of chemoreceptors results in 
stimulation of AVP release.
The indication from the series of experiments described in this thesis 
was that the majority, of normal subjects, if not all, secreted AVP in 
large quantities as, or immediately after symptoms of presyncope 
developed. The AVP response to presyncope is dependent on the 
individual’s tolerance to LBNP, so that in those subjects where the 
exposure time was low, the AVP response appears to take time to develop 
and increased AVP secretion may take place after, symptoms of presyncope 
have occurred. The secretion of AVP also appears to be related to the 
severity of the cardiovascular stress, as was demonstrated by the 800 
pmol/1 AVP analysed in the subject who had a 14 second period of asystole 
following syncope, although further observations would be needed to
justify this claim.
These very large increases in plasma AVP at presyncope raise the
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question, what are their function? It seems likely that modest increases 
in plasma AVP would produce almost total vasoconstriction in blood vessels 
possessing AVP receptors, a conclusion based on the profound effects that 
small quantities of infused AVP have on forearm blood flow. It would seem 
that, during the effective hypovolaemia caused by LBNP, there is no 
negative feedback on AVP secretion once it has been triggered. Thus, when 
high blood levels of AVP were obtained by infusing a bolus of AVP, 
endogenous AVP was still secreted in response to LBNP.
A feasible though somewhat teleological explanation is that if there 
is a loss of peripheral resistance at syncope, due to inhibition of the 
adrenergic sympathetic system combined with stimulation of the 
sympathetic cholinergic system, the large quantities of AVP rapidly 
produced might be a desperate attempt to reconstrict the vascular system 
and, to maintain blood pressure.
The possibility that AVP may actually cause syncope by inducing a 
bradycardia has also been considered, but if this does occur it would 
probably only involve a modest increase in plasma AVP. A sustained 
bradycardia was a particular feature of these experiments where levels of 
between 20-100 pmol/1 of AVP usually occur, so this does not offer an 
explanation for the very high plasma levels of AVP often observed. Total 
AVP receptor saturation may have occured and large quantities of AVP may 
be required to ensure that the vasoconstrictive effect of AVP is 
maintained as receptor sites become available.
AVP, which appears to be a factor in maintaining blood pressure and 
increasing tolerance to LBNP, was of no pharmacological value to the 
subject when injected. Although LBNP produces an effect comparable to 
+Gg acceleration, as the subject is supine the gravitational effect is in
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the +G^ axis, rather than +G^, reducing the hydrostatic problems which 
occur in upright man. Nevertheless, it seems unlikely that any real 
advantage could be gained from the use of other pharmacological agents in 
protecting against G^ acceleration as the hydrostatic problems and 
physiological stress appear too great for any simple vasoconstrictor to 
overcome. The theoretical requirement for pharmacological intervention 
has also been reduced, as recent developments in anti-G protective 
equipment have already produced an appropriate increase in the pilot's 
tolerance to high +Gg acceleration. However, what effect high onset rates 
of acceleration will have on the pilots' physiology and cardiovascular 
responses, is a question that can only be answered once suitable test 
equipment becomes available (ie, a new high performance centrifuge), and 
the action of vasoactive peptides and similar compounds may be part of 
that answer.
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Analysis of Catecholamines
There are several methods available for the analysis of catecholamines 
in biological samples. Earlier methods which used trihydroxindole 
fluorescence, Lund (1949), for plasma and Crout (1960) for urine, have now 
been largely abandoned, although the techniques and instrumentation have 
been improved, the analysis does not have the accuracy and sensitivity of 
more recently developed techniques.
Methods in common use for measuring plasma catecholamines are double
and single isotope radioenzymatic derivative essays. Engleman et al
(1970) and Siggers et al (1970) used the methyl derivitisation of
adrenaline and noradrenaline using C14 labelled S-adenosyl-L-methionine-
C14 (SAM) and catechol-O-methyl transferase (COMT) with an added tracer 
3 .quantity of 7- H adrenaline. Both methods required initial preparation 
and fairly large quantities of blood and where twin isotopes are used 
reagent costs are expensive.
A more recent development is the use of High Performance Liquid 
Chromatography(HPLC) with Electrochemical Detection (ECD), although Yui et 
al, (1980) used fluorimetric assay after HPLC separation. The electro­
chemical methods require preliminary sample preparation, usually an 
alumina column (Mefford et al, 1981) or an ion exchange column (Bertoni- 
Dziedzic et al 1981). For the HPLC stage a reverse phase silica gel 
column with an acid eluant, eg. acid phosphate, or an ion exchange column, 
are usually used.
Some doubt has been cast as to the specificity and sensitivity of 
electrochemical methods. Bouloux et al (1985) have shown considerable 
improvement in analytical levels and reproducibility by studying the
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precise methodology involved and identifying the critical stages. The 
essential feature appears to be the use of a short HPLC column with 3 urn 
particle packing material. They also considered that for maximum 
sensitivity it is more important to work at optimal signal-to-noise ratio 
than at maximum peak height. This reduced problems of tryptophan 
interfering with the internal standards. Coulochem have recently 
produced an ECD detector in which the reactants flow through the
electrode, rather than over it, and claim a 100% reactivity compared with
10% for the older type, which should greatly increase sensitivity.
The single isotope method of Peuler and Johnson (1977) was initially 
selected for use in this laboratory. No expensive equipment is required, 
although the reagent costs are comparatively high. The method does not 
require prior extraction and isolation before derivitisation, and an 
analysis can be carried out on 50 ul of plasma. In reality, however, as
quadruplet samples and internal standards are used, to reduce error,
500 ul of plasma is a more realistic volume. Unlike the general detection 
of ECD, the UV detection of the aromatic ring structure of methylated 
catecholamines provides a more specific method of detection. The 
catecholamines are methylated using tritiated SAM and COMT. The deriva­
tives are isolated by extraction into toluene/iso amyl alcohol and back 
extracted into acetic acid. The final separation of catecholamines, 
including dopamine, was by silica gel Thin Layer Chromatography (TLC) 
using UV detection. The method requires the addition of unlabelled methyl 
derivatives of the catecholamines, after the derivitisation step, this 
helps reduce losses and enables identification under UV.
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Development of a method for analysing catecholamines in plasma.
A particular problem with the Peuler and Johnson method was the 
separation by TLC, which for several reasons was not entirely satis­
factory. Variation was found between different batches of TLC plates in
solvent running time, this in turn affected the quality of the individual
catecholamine and band widths. Another potential source of error was the 
quantitive removal of the silica gel bands containing the catecholamine 
from the TLC plates, before extraction with ammonia. There are also 
health hazards associated with the TLC, the solvents which include benzene 
are potentially toxic and protective glasses must be worn against UV.
It was, therefore, decided to replace the TLC separation with HPLC and 
collect the on-line UV identified catecholamine fractions, in an effort to 
overcome the problems associated with TLC.
A second problem was the analysis of plasma dopamine which had
produced inconsistent results and generally failed to work satisfactorily.
A Pye LC3 HPLC pump with an LC UV detector was already available and a 
250 X 4.6 mm Partisil IQ-ODS reverse phase column was obtained to complete 
the assembly. Several mobile phases were tried, sodium dihydrogen 
phosphate with and without hydrochloric acid, and 0.2% perchloric acid in 
distilled water. An absorbance curve was plotted for the methyl 
derivatives of adrenaline, noradrenaline and dopamine in 0.2% perchloric 
acid and sodium dihydrogen phosphate/hydrochloric acid, using a Pye SP6 
550 spectrophotometer with deuterium lamp. The results were plotted (Fig 
7:1) this shows the maximum absorbance around 280 mu, probably due to the 
delocalised electrons of the aromatic rings. No differences were noted
139
1
N
MN
MO
VIN
1 m m / 1 minute
Fig 7:2 Serial HPLC chromatograms of NMN Normetanephrine, MN 
Metanephrine and MD 3-Methoxytyramine. Eluant 0.2% perchloric 
acid delivered at 1.5 ml/minute. Recorder 1 mm/minute with an 
attenuation of 0.32A.
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between the two solvents. There was little to choose between the various 
mobile phases tried but the 0.2% perchloric acid was adopted as this gave 
slightly shorter elution times for the chromatogram than the other 
solvents. The eluant pumping rate varied between 1 to 1.5 cm per minute 
depending on individual columns. Total run times of the three catechola­
mines on different columns have varied from 12 to 17, presumably due to 
packing density.
In an attempt to reduce the relatively long retention time of the 
catecholamines, particularly dopamine, methanol was introduced into the 
mobile phase, 4% V/V (methanol/0.2% perchloric acid) appeared to produce 
the best results and gave a run time of 7 minutes, Endert (1979) using 
acid phosphate/methanol produced similar results. Although the initial 
results using perchloric/methanol were excellent an unacceptably high 
number of runs had latterly to be abandoned because of spuriously high 
radioactive counts, particularly with the noradrenaline fraction. This 
was probably due to excess tritiated SAM being eluted with the noradren­
aline, there being normally only a short distance between the elution of 
the two peaks (Endert, 1979). This has latterly been confirmed by us, 
using an on-line "Ramona" liquid scintillation counter, discussed more 
fully below. It was decided, therefore, to revert to the original 0.2% 
perchloric acid which gave excellent separation Fig. 7:2. The peaks were 
recorded on a Lloyd CR 550 recorder, fractions were collected directly 
into glass scintillation phials. Initially, peak height of unknowns 
compared to standards was used to calculate recovery, but it is now 
considered some form of integration is essential for quantitative 
measurment of catecholamines, as there can be considerable differences in 
the quality of peak characteristics between columns.
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The primary extract was injected in total, there did not appear any 
advantage in evaporating to dryness and redissolving in perchloric acid. 
The acetic acid present in the extract did not affect the chromatography 
and generally the recoveries were better. Column life was not affected by 
direct injection of the extract, which was usually in excess of 1500 
injections, Endert (1979) estimated a column life to be about 1000 
injections. The use of a guard column has been tried in an effort to 
increase column life, but was abandoned as it not only greatly increased 
run time, but there was also a considerable increase in band width and 
therefore fraction volume.
It may not be possible to prolong column life Molnar et al (1984) 
states that pumping pulses can produce breakdown of materials which are 
lost and dissolution of silica gel can cause losses of column packing 
material of between 4 to 5 mm after several months of use.
Although satisfactory results had been obtained with the Peuler and 
Johnson method for adrenaline and noradrenaline, it had been 
unsatisfactory for dopamine. This was due to two factors, there was 
considerably greater variation in background counts in the dopamine 
fraction after TLC, due possibly to the dopamine running nearest to the 
solvent front and therefore being more prone to underlying contamination 
from the ^H-SAM or labelled debris. Also the final solvent extraction was 
found unwieldly, because of the large volumes used and the recovery of 
standards added to plasma was variable and poor, being less than 50% at 
that stage.
It was decided to derivatise dopamine in an attempt to overcome these 
problems and improve recovery. The method chosen was the acylation of
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the amine group of dopamine with acetic anhydride. For versatility, the 
process was designed for use with TLC as well. The primary extraction 
from TLC was into ammonia and for HPLC the eluate was made alkaline with 
ammonia. The optimum time for reaction with acetic anhydride appeared to 
be about 15 minutes, the reaction was stopped using sodium carbonate, the 
solution was re-acidified with acetic acid before extraction with toluene 
scintillator. Peuler and Johnson used Toluene/Diatol scintillator a 
relatively complex cocktail. Toluene with 5% Butyl PHD a good primary 
scintillator for tritium has been used by us with good results in the 
past. A comparison of the two scintillations showed no difference in the 
quality of results, although the Toluene/Butyl PBD had slightly higher 
overall counts, the differential counts were effectively the same, and no 
differences in counting efficiency were noted. The simpler scintillator 
was adopted for use.
Recoveries and Errors
Attempts to use 14C labelled adrenaline for recovery purposes and as a 
potential internal standard were not successful. Although large amounts 
of tritiated metanephrine were recovered, no increase in counts could 
be detected, over background, in the isolated metanephrine fraction. The 
loss may have been due to it being carried on the side chain of the 
adrenaline molecule and therefore possibly lost during the extraction. 
Although the actual position could not be established from Amersham who 
supplied the isotope. The loss did not appear to be due to the final 
derivatisation stage.
Total recovery experiments have not been carried out, although 
internal standards were run in parallel with the samples which gave good 
reproducibility of radioactive counts for given amounts of standard.
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Feuler and Johnson (1977), quoting other workers, claim a recovery of 3- 
methoxytyramine (7-^H) in the assay was 65% and of normetanephrine (7-^H) 
85% when allowing for a theoretical loss of 50% of during periodate 
oxidation. Initial work in this laboratory would suggest that dopamine 
recovery of the original method (Feuler and Johnson, 1977) was extremely 
variable, particularly in the final stage.
Hjemdahl (1984) doubted the true value of recovery experiments, he 
considered that validation of radioenzymatic and HPLC assays have often 
been based on experiments demonstrating good reproducibility and accurate 
recoveries of known amounts of added catecholamines from samples, as well 
as comparisons of levels obtained with the new assay with the levels 
reported in the literature. These criteria Hjemdahl considers are, 
however, not sufficient, since it is quite possible to reproduce errors, 
since recovery experiments do not test the adequacy of the level measured 
by assay. Use of HFLC gave a general improvement over TLC in reducing the 
variability of multiple determinations.
A correction factor can be employed (Table 7.1) using the integrated 
areas of the emergent peaks detected by UV during the HPLC phase. When 
compared against standards, this effectively gives a recovery of the 
unlabelled methylated catecholamines added in the stopping solution and 
has been found to be between 48-72%. It has been found essential that the 
stopping solution be added using a syringe, the variability being 
considerably greater when using disposable tip pipettes.
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TABLE 7.1 Four Plasma Adrenaline Assays
CPM_______ Corrected
414 583
450 659
443 592
151________ m .
Mean 465 610
SD 59.74 33.97
To calculate the mean coefficients of variation for the catecholamine 
assay, eight analyses were carried out on a pooled plasma sample for each
batch, and this was repeated on four separate days. The results were the
same for all three catecholamines.
Within batch CV% 10.8
Between batch CV% 12.9
Quality control plasmas are normally included in each batch. It is
felt, however, that an interlaboratory system would improve measurement 
of absolute levels. As applies to most methods, complete standardisation 
is essential throughout the whole procedure, errors may occur through lack 
of maintenance or incorrect use of autodispenser/dilutors and disposable 
tip pipettes. A method of this type is very dependent on the dedication 
of the operator.
During the course of this investigation some problems have been 
experienced with day-to-day reproducibility of the catecholamine assay, 
although within batch reproducibility has generally been good. Particular 
problems were encountered during the experiments into the effect of beta- 
blockade (Chapter 3) and with some of the later clinical investigations 
where the overall measurements appeared too high. One of the main causes
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for this problem had been a variable and at times high method blank. 
Initial investigation suggested the possible deterioration of some of the 
reagents particularly the gluthione and buffer, although these had been 
aliquoted and stored at -70°C. Remaking these reagents on a regular 
basis, ie. monthly, appeared initial to solve the problem. Another factor 
appeared to be environmental, assays being worse in cold damp weather.
It is now felt that all the problems were probably due to water 
quality. An investigation not related to this thesis, for the analysis 
of salivary melatonin revealed a connection between water quality and poor 
analysis. Although deionized single distilled water had been used, it was 
found that storage of distilled water in plastic aspirators for several 
days before deionising appeared to have had a detrimental affect on the 
assay. The problem for both assays appears solved. Since adopting a 
procedure of only using freshly prepared distilled water before deionising 
and running at least 1 litre of water through the deioniser before 
collecting. The catecholamine assay has greatly improved, not only have 
the blank CPM's been reduced to a low level, but there has been a three 
fold increase in unknown plasma and differential counts of internal 
standards, with the considerable improvement in consistency, the method is 
more sensitive and reliable.
The HPLC method appears to offer advantages over the TLC method, 
although, as previously stated, individual sample total recoveries cannot 
be carried out, which necessitate, for accurate work the use of duplicates 
plus duplicates with added standards, but this is half the number of 
replicates it is felt advisable to use for the TLC method. However, for 
serial samples or pathological samples single determinations could be 
used. Much variability has been removed by the ability to add a
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correction factor for the recovery of the metanephrines and 3-tnethoxy- 
tyramine. The use of HPLC has some limitations as to the number of 
samples than can be processed in one day compared with TLC. An assay of 
six plasmas can normally be completed in one working day.
Hjemdahl (1984) carried out a survey, in which 34 laboratories took 
part, with the various methods for assaying catecholamines and found less 
variability with the Peuler & Johnson method providing a few obviously 
erroneous results were excluded. Although the least variability was found 
with microparticulate cation exchange HPLC. It is felt the modified 
method described does offer a useful, specific and reasonably accurate 
method for the determination of catecholamines in plasma, where a few 
analyses are required, without the necessity to invest in expensive 
dedicated equipment.
The purchase of an on-line HPLC liquid scintillation "Ramona" system 
has led to an attempt to improve the methodology, with partial success, by 
removing the necessity for derivatisation at the final stage, considerably 
reducing the number of manipulations.
The outlet from the HPLC UV monitor is taken to a mixing pump where a 
2.8:1 mix of Monofluor scintillator (National Diagnostics of New Jersey 
USA) : perchloric eluant takes place. The resultant solution is pumped 
through a short mixing tube to a Raytest Ramona Scintillation counter.
The resulting digital output is transfered to a Walters IBM compatible XT 
computer, with Raytest software, which records, displays and integrates 
the peak areas of the Ramona outputs and through an A to D converter the 
10 mv output of the UV detector.
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Although good results can be obtained (Fig 7:3), there is a limit to 
the sensitivity that is available at the present time, about 25 pg 
catecholamine/ml plasma, due to a comparatively low level of detectable 
radioactivity spread over a time eluted volume. This is not a problem 
with the basic HPLC system described earlier, as all the sample Is 
available for counting. The method does, however, offer a useful 
alternative method of analysis, where elevated levels of catecholamines 
may be expected.
Catecholamine Method
Reagents
TRIS buffer l.OM of approximate pH8.4.
This consists of 12.14g TRIS, 6.099g MgC12 6 H20 and 3.8035g EGTA made 
up to 100ml. Stored frozen at -20°C in suitable aliquots.
A solution of reduced glutathione 60 mg and EGTA 95 mg per ml is 
prepared and adjusted to between pH 6-7.
Internal Standard
Prepare a stock solution containing 1 mg/100 ml of noradrenaline, 
adrenaline and dopamine. This is kept in frozen aliquots at -70°C. For 
daily use the stock standard is diluted to give a final concentration of 
all the catecholamines of 100 pg in 10 ul the equivalent of the reduced 
glutathione/EGTA 2 ml/100 ml plasma was added to the final dilution.
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Basic Reaction Mixture
This consists of one part each of TRIS buffer, water, COMT and 
tritiated SAM. Fresh basic reaction mixture must be prepared daily. 
S-adenosyl-L-[methyl-^H] methione was supplied by Amersham International; 
Code TRK 236, 1,0m li/ml (37M Bq/ml) and diluted with an equal volume of 
water before use. The unused isotope was stored at ~70°C.
.Stopping Solution
This consists of SOOmM boric acid 9.8928g
80mM EDTA Nag 5.9558g4mM metanephrine 0,187g
4mM normetanephrine 0.176g 
4mM methoxytyramine 0,163g
Dissolve the solids in distilled water, adjust to pHll with 
approximately 20 ml 10 M NaOH and make up to 200 ml. After thorough 
mixing divide into 500 ul aliquots and store deep frozen. The solution 
usually requires warming to ensure that all the compounds redissolve as 
precipitation tends to occur on freezing. Scintillation reagents were 
supplied by Koch-Light (now supplied by BDH). All reagents were Analar 
Grade unless otherwise stated. BCL Positive displacement pipettes or 
syringes were used for standard and stopping solutions. The other 
reagents were added with an Oxford P-7000 or adjustable sample range of 
pipettes. For standard reagents, eg. acetic acid and acetic anhydride, 
seripettors reagent dispensers were used.
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Catecholamine Assay
Into 15 ml conical glass centrifuge tubes is pipetted;- 
Unknowns, 50 ul plasma plus 10 ul dilute glutathione
Standards, 50 ul plasma plus 10 ul working standard solution Blanks,
60 ul dilute glutathione/EGTA (20 ul->l ml)
Unknown and standards are normally carried through in duplicate.
To all tubes is added 40 ul of basic reaction mixture, the tubes are 
capped and the contents mixed and placed in a shaking water bath at 37°C 
for one hour. The reaction is halted by adding 50 ul of stopping solution 
and 2 ml of tolueneliso amyl alcohol 3:2 using a Hamilton dispenser to add 
the solvent. The tubes are placed in a Multivortex and shaken for 5 
minutes at sufficient speed to insure total intermixing of the two layers. 
The phases are separated by centrifuging at room temperature for 5 minutes 
at 1000 rpm. The aqueous phase is frozen by immersing the tube, to a
depth just to the top of the aqueous phase, for 15 seconds in an
ethanol/dry ice bath, the organic layer being decanted off into a second 
tube containing 100 ul of O.IM acetic acid. The aqueous phase is 
discarded. The tubes containing the toluene acetic acid are shaken 
vigorously in the Multivortex for 10 minutes to back extract the 
methylated catecholamines. The phases are again separated by centrifuging 
for 5 minutes. The aqueous phase is frozen in the ethanol/dry ice bath 
and the organic layer aspirated off using a pasteur pipette and suction. 
Care must be exercised to avoid touching the frozen aqueous phase with the 
pipette tip as localised thawing can take place. Add 1 ml of toluene/iso 
amyl alcohol 3:2, vortex mix quickly and centrifuge to separate phases. 
Again, freeze the aqueous phase and aspirate the toluene wash. The 
aqueous phase can be kept frozen until required for HPLC.
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0.2% perchloric acid in water is pumped through a 250 x 4.6 mm 
Partisil lO-ODS reverse phase column for half an hour before use to 
equilibriate the system. The total sample, usually between 80 and 90 ul 
is injected using a SGE. HPLC syringe with flat end needle into a 
Rheodyne 7125 injector with 100 ul injection loop. The catecholamines 
are detected using a PYE LC-UV detector set at 280 mu with a range setting 
of 0.32A, the peaks are displayed on a Lloyds 550 Potentiometric recorder. 
As a peak starts to emerge the fraction is collected into a standard glass 
scintillation vial, the dead space being kept to a minimum.
The catecholamines are eluted in the order noradrenaline, adrenaline 
and finally dopamine, the next sample can be injected when the dopamine 
peak has passed maximum. On completion of the days work, the HPLC column 
should be throughly washed with water.
To all the fractions is added 100 ul 6M ammonia. For the noradrena­
line and adrenaline fraction is added:-
50 ul 4% sodium periodate, freshly prepared.
The samples are reacted for 5 minutes with shaking. Then 50 ul 10% 
glycerol is added plus 200 ul glacial acetic acid. The samples are mixed 
after the addition of each reagent. Finally, 10 ml of 0.5% butyl PBD in 
scintillation grade toluene is added and the samples thoroughly mixed.
To the dopamine fractions is added 300 ul acetic anhydride, and 
reacted for 15 minutes with shaking. At the end of this period 
approximately O.IM sodium carbonate is added, from a calibrated scoop, 
and left to effervesce for 5 minutes after which time 500 ul glacial 
acetic acid is added plus 10 ml toluene scintillator. All the samples are
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placed in an Intertechnique SL30 scintillation spectrometer with 
refrigeration, now superseded by a Kontron Betamatic I, left for at least 
one hour to reduce chemo-luminescence problems and allow equilibrium 
between the solvent phases to occur, before counting the tritium present. 
The counts per minute(CPM) being used to calculate the concentration of 
the unknown.
Calculation:
Mean CPM unknown - mean CPM blank________ x 100x1
Mean CPM(int.std+ unknown)-mean CPM unknown 0.05 
= unknown pg/ml AVP
Validation of Method
In order to test the efficacy of the method, the analysis of 
catecholamines was undertaken to complement Clinical Studies which were 
being carried out by the University of Surrey, Clinical Biochemistry 
Department. Angiography was carried out on a patient with a suspected 
phaeochromocytoma. This showed high levels of adrenaline (Table 7.2) in 
the blood sample taken from the left adrenal vein compared to the right 
adrenal vein, a 30 fold increase. Noradrenaline and dopamine were also 
raised, but not to the same degree. The levels of adrenaline in the IVC 
Suprarenal compared to the IVC Infrarenal did not appear to be much 
elevated. Either there being considerable dilution in passage from the 
left adrenal to the IVC suprarenal or the removal of the blood sample from 
the left adrenal vein may have stimulated the tumour to release 
adrenaline.
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Table 7.2
Plasma Catecholamine Assay Results from a Suspected 
Phaeochromocytoma
pg/ml plasma
Sample Noradrenaline Adrenaline Dopamine
Random 15.2.84 375 653 213
Left innominate 253 547 97
Superior V.C. 571 563 69
Right atrium 773 1213 600
Hepatic vein 146 307 316
Right renal 800 588 213
Right adrenal 653 506 186
Left renal 751 1063 986
Left adrenal 1412 15,223 1653
IVC Suprarenal 455 520 490
IVC Infrarenal 560 293 207
Left common iliac 1146 327 615
Right common iliac 906 153 193
Right adrenal 1213 146 383
(further sample)
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Fig 7:4 The plasma catecholamine responses of four patients to 
insulin stress tests. The vertical units are the same for 
adrenaline #  #and noradrenaline
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In some conditions, such as hypoglycaemia, adrenaline is secreted 
preferentially (Marks and Rose, 1981) often too many orders of magnitude, 
whilst noradrenaline may or may not increase and then only by a relatively 
small amount. This has been interpreted as being due to the sympathetic 
nervous system not responding as a whole to hypoglycaemia, but 
selectively. The reason for this is not entirely clear possibly being 
entirely due to the sympathetic neurones innervating the adrenal medulla or 
to the post-synaptic sympathetic neurones innervating the liver and 
possibly the pancreas. The result being an increase in noradrenaline 
which is not noticed because of the dilution within the whole amount of 
noradrenaline that is normally circulating. Cases where hypoglycaemia 
might be expected, have been investigated.
Several patients suffering from complex symptoms, such as unidentified 
causes of sweating or giddiness attacks, were subjected to insulin stress 
tests. The plasma adrenaline and noradrenaline responses of four patients 
are shown in Fig. 7.4 for clarity the plasma dopamine results have not 
been included as no distinct response pattern was obvious. In some dozen 
subjects investigated, the plasma adrenaline response was usually in 
excess of a tenfold increase at or around the nadir for blood glucose but 
was usually at +30 minutes, although the data for blood glucose levels was 
not always available. Some patients exhibited their highest plasma 
adrenaline levels at the +45 minutes which suggests there may often be a 
distinct lag before the plasma adrenaline response to hypoglycaemia.
Plasma noradrenaline generally mimicked the plasma adrenaline response, 
but usually the level was lower with between 2 to 5 fold increases, except 
for a patient suffering from insulin dependent diabetes, where the plasma 
noradrenaline increased more than the adrenaline. These results are 
similar to those of other workers (Hilstead et al, 1984) although
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generally the adrenaline had not returned to normal levels after 2 hours. 
This may have been due to the clinical conditions as Hilstead's results 
were based on normal subjects. Elevated plasma adrenaline levels at basal 
conditions may be due to apprehension, this has been observed in normal 
subjects participating in their first experiment, and tended to disappear 
in subsequent experiments. The initially elevated levels of plasma 
adrenaline, when a catheter had been inserted in an experimental situation 
as opposed to a single venipuncture, generally fell when the experiment 
proper started and there was a lot of activity to distract the subject. 
This may explain the fall of adrenaline in some of the demonstrated cases, 
Fig. "7.4, or the initial fall in adrenaline could be due to the onsetting 
hypoglycaemia.
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CHAPTER 8 
AVP ASSAY 
CORTISOL ASSAY 
ANP ASSAY
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AVP (Arginine Vasopressin)
The method of plasma AVP analysis is based on that of Thomas and Lee 
(1981), For the first two experiments, Chapters 2 and 3, an AVP R2 anti­
body kindly donated by the Department of Biochemistry Leeds was used. For 
the latter experiments an antibody supplied by Amersham International was 
used which appeared to have the characteristics of an R2 antibody and 
produced similar plasma levels. An attempt was made to raise an antibody 
here with partial success. Initially, AVP was iodonated in this 
laboratory, but it was found difficult to produce consistant results and 
as now Amersham produce a reliable product, this is now used exclusively. 
AVP was originally extracted from plasma by adsorption onto Florisil, 
eluted with HCl and acetone, the subsequent elution being dried down under 
a steam of air. The extract was reconstituted with buffer and assayed by 
radioimmunoassay. This extraction method has now been replaced by a Sep- 
Pak column extraction, the procedure is described under analysis of ANP.
200 ul of reconstituted eluent was used for each AVP assay.
Plasma Collection
10 ml blood is collected into heparinised tubes and kept on ice until 
centrifugation at 4°C within one hour of collection. The plasma is stored 
at -70“C.
N.B. 1, Freeze and thaw specimens before extraction otherwise fibrin 
clots interfere with absorption and elution.
2. Proteolytic enzymes present in plasma destroy AVP, therefore
after thawing, never let specimens warm up above 4*C.
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Extraction procedure for Plasma
Pipette 5 ml heparinised plasma (or less if the level is known to be 
high) into an extraction tube. Centrifuge plasma specimens at 4"C before 
use). Add 100 mg (one scoopful) of Florisil. With each batch of plasma 
specimens, set up high and low controls and a recovery specimen consisting 
of 5 ml inactivated horse serum plus 12.8 pg AVP (25 ul of 1024 pg 
standard). The high and low controls are made from spiked, inactivated 
horse serum, aliquotted and stored in the deep freeze. For plasma
extractions acid-wash tubes before use with 10% nitric acid. Because of
the low levels of AVP in plasma, the assay is sensitive to the presence of 
interfering substances such as traces of detergent.
Extract the AVP onto Florisil for 30 minutes on a rotary mixer.
Discard the plasma by suction. Wash the Florisil twice with 10 ml 
distilled water and discarding the washings. Wash the Florisil with 5 ml 
Acetone mixing gently by inversion several times. Discard the washings. 
Acidify Florisil with 0.4 ml of 0.2 M HCl mix on whirlmix, add 2 ml 90% 
aqueous acetone and mix on whirlmix for 5-10 seconds. Transfer eluate to 
a siliconised 4 ml glass tube. Repeat this procedure a second time and 
pool eluates.
Centrifuge plasma extraction tubes at 100 revs/min for 5 minutes 
before removing eluates. This eliminates turbidity and improves 
precision. Dry down eluates under a stream of air at 40*C on the sample 
concentrator (Takes about 3 hours).
This extraction procedure gives a recovery of 70-80% for plasma.
Store the dried down extracts in the deep freeze at -70*C.
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Siliconisation process for glass tubes
Immerse 4 ml glass tubes in Repelcote and stand overnight in sealed 
dessicator. Pour off Repelcote and leave tubes to dry at room 
temperature. Wash with distilled water and dry in oven. Repeat this 
process once more. The water wash is very important as this is the actual 
siliconisation process. When the tubes have been siliconised twice, wash 
in mild Decon solution, rinse well with tape water and finally with 
distilled water. Dry in oven.
Perform all operations involving Repelcote in a fume cupboard.
Reagents for Extraction
Florisil Washed and activated. Each new batch of Florisil is washed with 
distilled water until the supernatant is clear, then dried at 200°C for 48 
hours. Check each new batch before use against present batch by using 
labelled AVP recovery.
HCl 0.2M prepared from concentrated Analar HCl.
Acetone
Ultrar Grade (Hopkins and Williams)
90% aqueous Acetone. Add 10 ml distilled water to each 90 ml acetone. 
Radioimmunoassay
Dried extracts are reconstituted with 1,0 ml HSA barbitone buffer, 
and allowed to reconstitute for 2 hours, mixing several times on vortex 
mixer. Centrifuge before use. The reconstituted extract is quite stable 
when stored at -70*C and can be assayed again if necessary. Set up the 
assay in numbered LP3 tubes in the following manner:
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Tubes Code Std/Unks(ul) Buffer(ul) Antibody(ul) Label
1&2 Blank - 620 - —
3&4 Totals - - - 20
5&6 128pg STD 200 375 25 20
7&8 64pg STD 200 375 25 20
9&10 32pg STD 200 375 25 20
11&12 16pg STD 200 375 25 20
13&14 8pg STD 200 375 25 20
15&16 4pg STD 200 375 25 20
17&18 2pg STD 200 375 25 20
19&20 Zero - 575 25 20
21&22 Unknowns 400 175 25 20
23&24
- recoveries 200 375 25 20
On day one all the reagents and samples except the labelled AVP are added 
to the tubes, the tubes capped and the contents mixed and incubated at 4° C 
for 48 hours. The label is then added and the tubes mixed and incubated for 
a further 48 hours.
Reagents for Assay
1. Barbitone Buffer Stored at 4°C pH 8.6 
12.76 g sodium barbitone
1.66 g barbitone
Make to 1 litre with distilled water
2. Human Serum Albumin Obtained from Blood Products Laboratory.
Each vial 2.5 ml 10% aqueous protein. Stored at 4°C.
3. HSA - barbitone Buffer Add 1 vial of human serum
Albumin to 200 ml barbitone buffer and store in deep freeze when not 
in use.
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Antibody to AVP
This is stored in the -70"C deep freeze as 1 ml aliquot of 1:500 
dilution of antibody in HSA buffer. This is diluted with buffer to a 
dilution which will give approximately 50% zero binding. Each new batch of 
1:500 dilutions prepared from stock R2 AVP antibody is checked before use 
by setting up an anitibody dilution curve to determine the dilution needed 
for assay.
Labelled AVP
Obtained from Amersham International. Dissolve lyophilised solid in 
2 ml of assay buffer. Further dilute to 6.26 ml with assay buffer. Store in 
suitable aliquots at -70* C 
AVP Standards
The stock standard contains 25.6 ng in 0.4 HSA buffer.
Preparations of Working Standard from Stock Standard
The following stock solutions, prepared from synthetic AVP 
(A.B. Ferring, Malmo, Sweden) are stored at -20 *C.
1. 1000 ug/cm^
■52. 4 ug/cm
3. 2 ug/cm^
34 . 64 ng/cm
To prepare working standard, dilute these solutions as below
Dilution Take______ Volume Dilute to
1000 ug/cm^ = 40 ug in 40 ul ----- > 10 cm^
4 ug/cm^ = 2 ug in 500 ul------ > 1 cm^
2 ug/cm^ = 400 ng in 200 ul > 6.25 cm^
64 ng/cm^ = 25.6 ng in 400 ul----- > 10 cm ^
2560 pg/cm^ = 512 pg in 200 ul
= 1024 pg in 400 ul (stock working standard)
9.6 cm^ HSA buffer is added to dilution 4, total volume
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3 • • .10 cm , and this solution is aliquotted in 400 ul quantities
and stored at -20“C. This working standard is diluted 1:4
before use to give a working concentration of 127 pg/0.2
3 • ‘ 3cm . This is equivalent to 128 pg/cm in the assay of
plasma.
SEPARATION
Weigh out the required amount of charcoal and wash in Tris-HCl 
buffer. Centrifuge and remove supernatant and suspend washed charcoal in 
required volume of Tris-HCl buffer. Add 15 ml horse serum per 100 ml of 
charcoal mixture and mix at 4*C for 30 minuted. Chill centrifuge buckets 
in deep freeze for about 15 minutes before use. Remove assay tubes from 
fridge and stand on ice. Divide assay into batches of 30-40 tubes. Add 1 
ml charcoal mixture to each tube from first batch. Mix on vortex mixer and 
centrifuge in refrigerated centrifuge at 3000 r.p.m for 5 minutes. The 
process of adding charcoal, mixing and transferring to the centrifuge must 
be completed within 5 minutes. Decant supernatent into another labelled 
LP3 tube as quickly as possible, always keeping tubes at 4®C. Repeat this 
procedure with the other batches. Count the supernatent (bound) tubes for 
10 minutes per tube in a Gamma Counter.
Reagents 
Tris-HCl Buffer
pH 7.5 stored at 4°C 12.1 g Tris
Adjust pH to 7.5 with O.IM HCl (Approximately 810 ml) and make up to 2 
litres with distilled water.
Charcoal Norit Grade
1 g charcoal is used for every 100 ml of Tris-CHl buffer. Less or 
more is weighed out according to the number of samples to be analysed.
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Inactivated Horse Serum Obtained from Wellcome Laboratories.
Calculation
Work out the percent bound label for each assay tube,
i.e. Count obtained for supernatent tube x 100
total count
Quality Control
All the above parameters - i.e. zero binding, % damaged label and 50% 
of zero % bound in pg/t are plotted on the quality control charts. All 
other control and recovery results are likewise plotted, on quality control 
charts.
Assay control - run with every assay.
Plasma controls - horse serum (inactivated) is AVP standard to give 
controls with values of 2-3 pg/ml and 7-8 pg/ml.
Plasma recovery AVP standard is added to inactivated horse serum which 
is virtually free of AVP.
The recoveries of added AVP to pooled human plasma produced similar 
results for both methods. A range of recoveries 2.5-26.0 pmol AVP/I gave 
for the extraction method an average recovery (N = 10) of 77.7% ± 7.8 and 
for the Sep-Pak column method (N = 10) an average recovery of 84% ± 8.
It should be emphasised that the Sep-Pak column method only requires 
2 ml of plasma as opposed to 5 ml for the extraction method.
The results were similar for both methods except at the low end of 
normal where lower results, often less than 1 pmol/1 of AVP, were observed 
with the Sep-Pak method, whereas with the extraction method most were above 
1 pmol/1. Whether this is due to greater losses at low concentration of 
AVP using the Sep-Pak method or whether there are interfering substances
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which elevate the low concentration of AVP with the extraction method, is 
difficult to decide.
Reference T H Thomas and M R Lee. (1976) The specificity of antisera for 
the radioimmunoassay of argine vasopressin in human plasma and urine during 
water loading and dehydration. Clinical Science and Molecular Medicine,
51, 525-536.
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Co r t i s Q1 Rad i.o immuno a s s ay
Cortisol was measured using Araerlex cortisol kits supplied by Amersham 
International.
The antiserum is immobilised on to the surface of polymer particles of 
uniform diameter ( Amerlex antibody suspension) so that separation of bound 
and unbound label is easily effected by centrifugation. In this solid phase 
separation system the amount of label bound by antibody is inversely 
proportional to the concentration of unlabelled cortisol present in the 
plasma.
An important feature of this assay is that cortisol is released from 
transcortin by a chemical blocking agent (which is not specified, 
commercial in confidence) contained in the ^^^I labelled cortisol 
derivative solution. The total cortisol in the sample is then free to 
compete with the label for binding sites on the antibody-coated particles. 
This, therefore, means that no heat dénaturation or extraction process is 
required prior to assay.
The performance characteristics specified for the Cortisol RIA kit
are: -
The mean recovery from serum of added cortisol over the range of 5-60 
ul/lOO ml serum were 96-102%.
Reproducibility Within assay a mean of 10 replicates
2.0 ug cortisol/100 ml CV 5.7%
32.3 ug cortisol/100 ml CV 3.4%
Between assay mean of duplicates for 20 separate
assays
2.2 ug cortisol/100 ml CV 8.9%
34.3 ug cortisol/100 ml CV 6.7%
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Sensitivity The sensitivity of the standard curve was approximately 
0 .lug/100 when using duplicate determinations.
Specificity The cross reactivity with other steroids and metabolites 
in normal subjects is very low, with the highest cross reactivity 
being cortisone 1.6% and 17a~hydroxyprogesterone 1.7%.
Assay Protocol
Cortisol standards (ul/lOOml) Unknowns
0 1 4 10 28 60 1 2 etc
Tube numbers 1,2 3,4 5,6 7,8 9,10 11,12 13,14 15,16
Standard serum 50 50 50 50 50 50 -
Unknown samples - - - 50 50
IZ^i-iabelled
cortisol
derivative 200 200 200 200 200 200 200 200
Amerlex cortisol
antibody
suspension 200 200 200 200 200 200 200 200
Vortex mix. 
at 37°C ± 2 
Centrifuge 
Decant and
Cover
*C
count
tubes and incubate for 1 hour
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aANP Radioimmunoassay
The assay is based on the competition between unlabelled human aANP
and a fixed quantity of labelled human aANP for a limited number of
binding sites on an aANP-specific antibody. In order to achieve greater
sensitivity, a disequilibrium technique is used. Unlabelled human aANP is
125pre-incubated with the antibody for 24 hours before addition of the I- 
tracer. This technique reduces the number of binding sites available to the 
tracer, being dependant on the quantity of unlabelled human aANP present.
This situation of 'disequilibrium' leads to a more sensitive dose response 
curve.
Sample Collection
All operations should be carried out at 4*C.
The blood is collected into plastic tubes containing EDTA, equivalent 
to 1 mg EDTA/ml of blood,
5 uM peptatin is used as a protease inhibitor.
Sample Purification.
A Sep-Pak C^g is prewashed with 10 ml of methanol and 10 ml of 0.9% 
saline. 2 ml of plasma is added to the column and the column washed with 5 ml 
of 0.9% saline. The column is eluted with 4 ml 60% acetonitrile + 0.1% 
trifluoroacetic acid.
The eluent is reduced in volume using an inert gas and the final 
traces of aqueous liquid removed by freeze drying. For use the dried 
extract is reconstituted in 1ml of assay buffer.
Radioimmunoassay Procedure
Reagents.
Assay buffer 0.025M phosphate pH 7.8 containing sodium 
azide.
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Antiserum (supplied by Amersham International) add 11.0 ml assay 
buffer and carefully mix.
Tracer ( 3 - [ ]iodotyrosyl^®)aANP, (Supplied by Amersham 
International), carefully add 11.0 ml assay buffer and gently mix.
Preparation of working standards.
Label 6 polypropylene tubes 1,2,4,8,16, and 32. Pipette 500 ul of 
assay buffer into all tubes.
Into tube 32 pipette 500 ul of assay standard (640 fmol/1) and vortex. 
Transfer 500 ul to tube 16 and so on to give serial dilutions which give 6 
standards of aANP with a range of 1-32 fmol.
Assay Procedure.
Day 1.
Equilibrate all reagents to room temperature and prepare fresh working 
standards. Prepare tubes in duplicate total counts (TC), zero standard 
(Bo), standards and samples.
Pipette 100 ul assay buffer into the (Bo) tubes and starting with the 
most dilute, pipette 100 ul of standard into the appropriate tubes and 
lOOPOul of unknown (diluted with assay buffer) into their respective tubes,
Pipette 100 ul antiserum into all tubes except TC.
Vortex mix, cover and incubate at 4°C for 16-24 hours.
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Day 2
Remove tubes from 4 °C and pipette 100 ul of [^^^]aANP into all tubes. The 
TC tubes are set aside for counting. Vortex all tubes and incubate at 4“C 
for 24 hours. |
Day 3 |
Add 250 ul Amerlex-M second antibody and incubate at room temperature for I
10 minutes. Separate the bound fraction by magnetic separation or by 
centrifugation. Count in an appropriate Gamma counter.
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APPENDIX B
Raw data tables
Chapter 2 - Raw data tables
Plasma noradrenaline fpg/ml> response to different levels of LBNP
0, -30, -60 and -OOmmHg 
Subject Time (minutes)
0.00 2.00 2.30 3.00 3.30 4.00 4.30 5.00 5.30 6.00 6.30 7.00 T+10
TH 0 218 551 343 383 673 336 604 766 393 193 268 332 278
TH30 320 240 90 142 341 226 184 140 263 97 64 424 133
TH60 324 453 484 680 251 634 276 432 1075 764 575 750 280
TH90 325 656 182 575 227 142 745 857 685 1186 * 522
PCO 169 64 - 277 187 255 410 176 134 80 66 76 136
PC30 403 739 620 1054 470 658 409 231 507 204 300 174 270
PC60 120 458 403 614 227 897 767 636 546 577 786 350 342
PC90 124 335 362 708 374 417 473 1004 917 528 487 968 554
PRO 167 70 366 220 64 210 402 - 521 505 283 294 214
PR30 427 153 735 880 612 993 245 160 421 426 369 167 233
PR60 95 307 249 798 556 1025 1706 620 740 1025 1249 1380 1062
PR90 410 364 906 278 600 242 879 1248 862 1142 I 1657 772MSO 169 64 97 120 277 187 255 310 176 134 80 26 136
MS30 551 668 945 632 830 572 681 545 554 616 610 251 252
MS60 135 447 1162 463 321 1127 644 897 1588 1356 1306 987 895
MS90 448 723 781 809 474 157 * 106
DKO 390 335 145 215 232 321 295 226 250 292 360 345 109
DK30 110 605 1012 630 540 290 730 716 540 214 710 268 364
DK60 716 506 205 1146 594 666 264 358 1014 453 389 758 207
DK90 88 63 933 261 569 486 426 1591 1077 593 1185 1845 865
DGO 167 201 563 510 579 880 711 560 805 714 538 953 593
DG30 516 220 189 283 608 520 697 861 668 596 644 375 338
DG60 221 783 900 1932 1405 2105 794 858 558 1532 723 527 483
DG90 469 388 567 950 289 274 485 * 935
GMO 418 184 202 477 844 325 635 584 178 331 187 346 81
GM30 273 333 241 751 485 464 373 310 243 250 490 385 600
GM60 677 924 236 1066 500 174 622 288 352 621 439 774 437
GM90 125 660 309 93 71 840 860 1326 789 * 935
I 6.30 combined with 7 
* presyncope
Plasma adrenaline fpg/ml> response to different levels of LBNPat 0.-30.-60 and -90mmHa
Subject Time (minutes/seconds)
0.00 2.00 2.30 3.00 3.30 4.00 4.30 5.00 5.30 6.00 6.30 7.00 T+10
THO 134 98 152 55 161 57 186 125 38 25 216 204 114
TH30 79 90 29 314 440 152 175 85 106 65 271 347 65
TH60 18 201 104 350 263 380 205 324 449 104 40 302 138
TH90 232 185 219 530 214 147 286 513 190 176 * 115
PCO 169 60 - 116 57 47 294 311 125 49 54 23 126
PC30 172 710 341 723 398 135 59 288 256 117 51 10 59
PC60 46 189 110 200 63 147 114 82 42 38 64 4 160
PC90 152 320 100 507 187 125 232 86 183 126 205 290 74
PRO 22 429 228 228 96 267 309 - 132 354 267 143 253
PR30 350 88 334 476 182 137 256 51 108 43 130 38 57
PR60 237 38 23 182 310 244 346 52 380 279 220 303 201
PR90 151 402 454 423 1130 837 344 209 295 436 1 690 233MSO 169 60 87 116 57 47 294 311 125 49 54 2 126
MS30 130 128 116 56 37 53 12 136 10 55 14 15 154
MS60 38 36 266 211 287 429 414 151 342 337 575 343 530
MS90 1255 758 568 566 476 23 * 224
DKO 419 310 378 258 47 310 409 193 121 174 131 211 92
DK30 10 460 183 265 258 239 111 215 51 671 843 224 456
DK60 483 540 243 122 725 446 88 261 625 488 363 373 251
DK90 259 265 1132 505 708 551 720 845 718 606 641 677 789
DGO 273 55 65 126 170 360 160 173 438 352 99 188 321
DG30 110 90 160 43 225 86 70 241 102 115 183 82 134
DG60 309 104 311 483 1254 718 650 367 87 828 255 76 66
DG90 198 85 51 450 159 92 41 * 616
GMO 783 337 796 682 708 450 555 151 417 416 187 181 146
GM30 92 192 223 228 413 246 177 282 418 225 286 554 264
GM60 18 250 137 416 687 405 671 392 315 301 435 467 116
GM90 48 170 487 216 210 485 1083 464 642 * 476
j 6.30 combined with 7 
* presyncope
Plasma dopamine fpg/mh response to different levels of LBNPat 0. -30. -60 and -90mmHa
Subject Time (minutes/seconds)
0.00 2.00 2.30 3.00 3.30 4.00 4.30 5.00 5.30 6.00 6.30 7.00 T+10
THO
TH30
TH60
227 107 11 11 100 38 230 435 10 10 248 96 18
TH90 188 936 262 542 1172 730 1557 100 243 65 * 761
PCO 9 27 - 68 31 410 421 337 133 200 60 70 87
PC30 87 1360 719 1571 920 357 320 349 319 474 309 526 500
PC60 10 146 121 20 19 74 43 165 103 17 246 149 208
PC90 45 115 90 702 486 161 151 202 243 86 136 274 126
PRO 14 330 112 216 154 848 724 - 220 511 285 50 36
PR30 949 45 166 447 134 125 275 121 469 173 46 45 137
PR60 60 124 77 783 685 308 267 42 193 349 334 102 225
PR90 324 741 1319 1643 784 286 408 357 228 88 1 516 636MSO 8 27 30 68 31 410 421 337 133 200 70 87 87
MS30 85 153 273 105 126 134 34 268 231 333 194 500 240
MS60
MS90
63
829
205
560
255
547
526
742
358
741
591
107
422* 135 444 493 322 455 34011
DKO 840 418 720 666 447 600 341 418 361 134 61 30 114
DK30 168 262 54 651 304 993 627 313 741 751 1922 1568 516
DK60 1463 634 217 69 454 217 145 368 749 387 330 528 109
DK90 104 116 881 373 579 468 217 490 168 285 230 971 445
DGO 375 248 106 46 761 535 95 137 292 299 351 592 554
DG30 188 173 150 52 125 303 406 627 129 252 294 128 245
DG60
DG90
240
201
337
410
308
170
474
844
746 1211 
101 31
945
39
388* 441 326 610 154 382197
GM 0 672 739 236 569 559 112 616 221 390 103 629 617 800
GM30 23 664 324 1050 609 273 235 1181 759 1376 500 1203 1148
GM60 204 500 191 39 
GM90 48 170 487 216
1 sample 6.30 combined with 7
57
210
20
485
194
1083
157
464
66
642
103* 413 232 355476
presyncope
Plasma AVP (po/mn response to LBNP at 0. -30. -60 and -90mmHq
Subject Time
Pre-LBNP Post-LBNP Post +
THO 4.8 0.1 1.0
TH30 0.1 0.1 0.1
TH60 0.1 0.1 0.1
TH90 1.5 3.9 54.4
PCO 2.8 5.4 1.4
PC30 0.5 0.2 0.2
PC60 4.5 108.6 26.3
PC90 1.1 1.2 1.3
PRO 1.2 3.1 2.5
PR30 3.2 1.5 2.1
PR60 3.4 43.1 10.2
PR90 2.6 100.4 5.4
MSO 2.2 0.9 2.3
MS30 1.0 1.0 1.2
MS60 1.2 1.2 1.2
MS90 0.9 5.8 7.3
DKO 1.2 1.0 1.3
DK30 1.2 1.1 1.1
DK60 1.1 1.1 1.2
DK90 2.2 46.3 205.4
DGO 2.5 1.0 4.1
DG30 1.0 1.0 2.1
DG60 11.0 61.5 5.0
DG90 1.2 41.4 12.0
GMO 2.3 1.4 2.2
GM30 3.5 32.3 18.1
GM60 1.2 34.6 1.0
GM90 1.2 181.0 33.1
Heart rate <BPMI response to different levels of LBNP at
0, -30, -60 and -SOmmHg
Subject Time (minutes/seconds)
0.00 0.30 1.00 1.30 2(S) 2.30 3.00 3.30 4.00 4.30 5.00 5.30 6.00 6.30 7(T) 7.30 8.00 T+10
THO 56 59 54 48 60 53 54 57 48 54 50 54 54 54 54 53 54 56
TH30 57 53 54 56 60 60 63 69 66 63 69 66 72 72 60 54 54 60
TH60 43 43 45 46 51 60 62 74 66 77 66 72 78 81 75 53 44 44
TH90 57 63 60 60 72 96 108 108 108 120 144 132 120 114* 66 54 48 53
PCO 69 60 65 65 60 69 63 66 60 60 66 60 66 69 66 72 63 66
PC30 50 48 48 48 66 48 48 51 54 60 63 57 54 53 56 48 48 44
PC60 60 63 54 54 63 66 72 72 72 72 78 81 78 78 72 48 42 48
PC90 50 45 48 48 60 75 84 90 90 93 99 108 102 102 84 48 42 39
PRO 66 66 60 60 66 63 60 60 60 63 60 60 63 63 66 54 60 59
PR30 63 60 60 60 66 60 63 66 66 60 66 66 60 66 60 66 62 60
PR60 66 69 65 66 84 105 108 117 126 126 126 126 126 123 99 65 63 66
PR90 66 69 66 66 72 105 117 121 132 138 138 144 150 150 138* 63 45 66
MSO 57 59 63 56 63 57 57 57 54 54 69 57 56 54 54 54 54 54
MS30 63 66 66 60 63 62 60 66 66 60 66 66 66 72 69 71 - 71
MS60 63 69 63 66 75 99 102 108 108 105 108 108 114 114 108 72 60 54
MS90 69 66 66 66 78 120 132 129 117* 90 78 56 54 57 57 54 56 60
DKO 89 96 93 96 105 78 78 78 78 78 78 75 72 72 72 75 72 69
DK30 84 96 96 102 102 81 84 84 81 84 84 78 81 78 78 78 66 66
DK60 78 96 90 78 90 102 108 108 99 108 99 102 96 92 84 87 66 69
DK90 90 93 95 93 114 144 150 150 153 162 162 156 132 126 90 66 59 65
DGO 60 63 57 63 66 60 66 63 63 63 60 60 63 60 63 63 57 60
DG30 63 60 60 60 60 60 66 66 66 72 72 66 66 69 69 63 57 57
DG60 60 60 60 60 60 63 66 72 78 78 78 81 84 72 60 66 53 63
DG90 57 69 63 60 72 75 81 81 60 48* 57 48 48 48 48 48 48 48
GMO 72 66 66 60 63 66 60 66 66 66 66 66 60 63 63 63 63 60
GM30 78 84 72 72 78 87 75 72 69 72 69 78 72 72 72 75 66 60
GM60 90 81 78 81 87 108 105 96 108 120 138 129 132 129 105 90 93 63
GM90 66 69 63 60 66 93 108 114 117 123 114 96* 66 50 48 48 48 54
(8) application of LBNP 
(T) end of LBNP 
* symptoms of presyncope
Blood pressure fS) systolic fP^  diastolic response to LBNP at 
0, -30, -60 and -OOmmHg
Subject Time (minutes/seconds)
0 0.3 1 1.3 2 2.3 3 3.3 4 4.3 5 5.3 6 6.3 7 7.3 8 T+10
TH OS 122 122 122 122 116 120 124 124 118 122 114 120 122 122 122 118 120 120
THOD 60 60 60 60 58 60 56 60 60 60 60 60 60 60 60 60 60 60
TH30S 110 110 110 110 120 110 110 110 110 110 110 110 110 110 110 110 110 110
TH30D 60 60 60 60 60 50 60 60 60 60 60 60 60 60 60 60 60 60
TH60S 110 110 110 120 110 100 90 100 100 100 100 100 100 100 100 110 110 110
TH60D 60 60 70 70 70 60 60 50 50 50 50 50 50 60 60 70 70 70
TH90S 110 110 120 120 120 90 90 90 90 90 100 100 130 130 120 120 110
TH90D 60 60 60 55 55 60 60 60 60 60 50 50 90 85 60 70 60
PC OS 110 110 114 112 112 116 112 112 114 110 110 108 112 110 112 118 118 110
PC OD 70 70 72 68 70 70 70 70 74 76 74 70 70 68 74 74 78 70
PC30S 110 110 110 110 100 100 100 100 100 100 100 100 100 100 100 110 100 100
PC30D 60 60 65 65 50 60 60 60 60 60 60 60 60 60 60 65 60 60
PC60S 120 100 100 100 90 100 90 90 90 90 90 90 90 80 80 100 110 110
PC60D 60 60 60 60 30 60 60 60 60 60 60 60 50 60 50 60 70 70
PC90S 118 130 124 130 130 124 126 118 118 112 116 116 120 120 118 136 130 126
PC90D 80 85 76 80 80 80 88 86 90 86 90 86 84 86 90 80 84 82
PR OS 120 116 120 116 116 114 116 118 116 116 115 115 118 116 116 115 118 115
PR OD 70 70 70 70 68 68 70 70 70 70 68 70 70 70 68 72 68 70
PR30S 125 120 118 120 120 106 106. 110 110 112 110 110 110 112 110 114 116 120
PR30D 70 72 70 70 65 80 76 76 78 76 76 76 76 76 76 66 68 76
PR60S 110 110 110 110 110 100 100 100 100 110 105 105 105 100 100 120 120 110
PR60D 70 50 60 60 60 60 60 70 70 60 50 60 70 70 70 50 60 70
PR90S 110 115 115 120 115 110 115 112 108 110 110 110 108 107 104 125 130 125
PR90D 80 75 70 70 70 90 88 90 90 85 90 90 90 86 86 75 80 85
MS os 126 120 120 122 122 124 \ 2 a 120 120 120 120 118 118 118 118 116 120 118
MSOD 70 70 72 70 70 70 70 68 68 70 70 66 70 70 70 68 70 68
MS30S 126 130 128 124 128 126 126 123 120 110 114 114 112 110 114 125 122 122
MS30D 70 74 74 74 74 75 75 75 70 70 70 70 75 72 75 72 70 73
MS60S 130 132 128 130 126 116 118 116 114 116 110 100 102 108 108 126 130 122
MS60D 72 72 70 70 68 80 80 76 80 76 74 68 70 70 70 66 70 70
MS90S 130 136 128 124 130 106 102 104 90 126 128 126 124 124 122 124 118
MS90D 75 74 78 80 78 80 80 80 50 80 82 80 82 74 78 80 76
DKOS 148 154 152 156 160 142 140 140 140 140 140 138 138 136 138 130 134 130
DKOD 70 80 80 84 90 74 70 70 70 68 70 70 70 70 70 70 68 76
DK30S 145 140 145 150 150 135 120 120 118 112 110 112 114 112 116 116 130 130
DK30D 90 76 90 90 80 80 80 80 80 80 85 80 85 78 90 76 80 80
DK60S 140 142 145 142 145 130 142 134 140 134 126 126 118 124 126 130 132 122
DK60D 75 82 90 88 110 90 100 95 96 100 98 90 98 94 94 84 90 90
DK90S 138 150 148 140 150 135 140 130 130 115 116 110 106 98 76 150 140 124
DK90D 76 80 80 76 85 94 94 96 88 90 96 90 80 75 64 96 100 80
DGOS 130 130 130 130 120 130 130 120 130 130 130 130 130 140 130 130 130 130
DG OD 90 90 90 90 80 90 90 90 90 85 90 90 90 95 90 90 90 85
DG30S 130 130 130 130 130 130 120 120 120 120 110 120 120 120 120 130 130 130
DG30D 80 80 90 90 80 90 90 100 90 90 90 90 90 90 90 100 100 90
DG60S 135 135 130 130 130 120 120 120 125 130 120 125 120 100 100 120 140 135
DG60D
DG90S
DG90D
100
140
110
100
145
100
95
140
110
90
140
100
90
134
90
80
130
100
85
130
105
80
130
100
90 90
•Ms
'kk
90
110
80
90
116
100
85
130
104
60
132
104
60
140
110
80 100 95
GMOS 120 116 115 120 120 118 120 120 120 118 120 120 114 118 114 116 114 116
GMOD 70 72 70 78 75 75 75 76 75 76 76 72 76 76 74 78 74 74
GM30S 126 130 128 130 124 130 132 128 130 126 124 122 124 122 118 118 122 126
GM30D 80 82 80 76 80 82 80 86 80 84 82 84 84 80 80 74 78 76
GM60S 134 130 130 126 124 130 125 122 122 122 135 124 124 120 115 126 126 120
GM60D 80 80 80 75 90 85 90 90 92 95 90 80 90 98 94 84 84 82
GM90S 120 122 122 122 120 120 118 110 98 94 86 60* 110 116 114 114 114 120
QM90D 80 80 78 82 74 95 95 92 72 70
*  p resyncope
* *  p resyn co p e  and  blood p ressu re  too low  to record
80 50* 80 82 82 80 82 80
% increase in calf circumference during LBNP at -30. -60 and 
-90mmHa. strain gauges placed at 13.5 Inch circumference
Subject mmHg Time(minutes.seconds)
2.00 2.30 3.00 3.30 4.00 4.30 5.00 5.30 6.00 6.30 7.00 7.30 8.00 8.30 9.00
TH-R 30 0.25 0.79 0.92 1.11 1.18 1.18 1.18 1.25 1.25 1.25 1.05 0.33 0.25 0.00
TH-L 30 0.00 0.87 0.94 1.17 1.31 1.31 1.31 1.31 1.31 1.36 0.66 0.22 0.11 0.00
TH-R 60 0.93 1.00 1.23 1.54 1.97 2.11 2.11 2.18 2.25 1.23 0.25 0.00 0.00 0.00
TH-L 60 0.33 0.49 1.00 1.31 1.41 1.55 1.55 1.55 1.55 1.23 0.00 0.00 0.00 0.00
TH-R 90 0.33 0.93 1.23 1.23 1.31 1.90 2.11 1.54 2.11* 0.33 0.00 0.00 0.00 0.00
TH-L 90 0.79 1.31 1.84 2.08 1.96 2.20 2.20 2.08 2.08* 0.52 0.00 0.00 0.00 0.00
PR-R 30 1.05 1.97 2.12 2.27 2.27 2.27 2.35 2.35 2.35 2.35 1.36 0.00 0.00 0.00
PR-L 30 0.37 0.84 0.94 0.94 1.12 1.12 1.12 1.12 1.12 1.22 0.56 0.00 0.00 0.00
PR-R 60 1.15 1.57 1.71 1.97 2.10 2.10 2.36 2.49 2.56 2.62 1.31 0.00 0.00 0.00
PR-L 60 0.44 1.31 1.72 1.97 2.13 2.30 2.30 2.62 2.62 2.79 1.80 0.00 0.00 0.00
PR-R 90 0.10 0.46 2.30 2.46 2.71 2.95 3.12 3.28 3.44 3.61 3.20 0.33 0.16 0.08
PR-L 90 1.09 1.58 1.97 2.06 2.06 2.16 2.36 2.42 2.52 2.71 2.32 0.33 0.00 0.00
PC-R 30 } not correctly calibrated
PC-L 30 } " " "
PC-R 60 0.00 0.56 0.37 0.56 0.84 0.98 1.15 1.15 1.31 1.31 0.56 0.09 0.00 0.00
PC-L 60 1.97 2.62 2.62 2.83 2.83 3.17 3.28 3.38 3.49 3.49 1.97 0.44 0.22 0.00
PC-R 90 0.98 1.85 2.18 2.40 2.62 2.84 3.06 3.28 3.28 3.50 2.19 0.34 0.00 0.00
PC-L 90 0.94 1.54 1.88 2.05 2.22 2.30 2.35 2.39 2.47 2.62 2.22 0.22 0.00 0.00
MS-R 30 0.28 0.84 0.94 0.94 0.94 1.12 1.12 1.12 1.21 1.21 0.66 0.00 0.00 0.00
MS-L 30 0.98 0.82 0.98 1.05 1.05 1.18 1.31 1.31 1.57 1.57 1.05 0.00 0.00 0.00
MS-R 60 0.33 0.49 0.57 0.66 0.82 0.98 1.06 1.06 1.16 1.16 1.02 0.08 0.00 0.00
MS-L 60 0.00 0.44 0.65 0.87 0.87 0.98 1.31 1.47 1.47 1.64 1.47 0.00 0.00 0.00
MS-R 90 0.73 1.24 1.38 1.60 1.75* 0.87 0.07 0.00 0.00 0.00
MS-L 90 1.58 1.58 1.77 2.36 2.76* 1.97 0.00 0.00 0.00 0.00
DK-R 30 0.24 0.24 0.24 0.30 0.36 0.36 0.42 0.48 0.54 0.54 0.36 0.00 0.00 0.00
DK-L 30 0.00 0.22 0.44 0.44 0.44 0.55 0.66 0.66 0.76 0.76 0.66 0.00 0.00 0.00
DK-R 60 0.84 1.05 1.40 1.40 1.48 1.57 1.57 1.75 1.75 1.75 1.05 0.19 0.00 0.00
DK-L 60 0.22 0.22 0.44 0.77 0.87 0.98 1.09 1.20 1.31 1.42 0.77 0.00 0.00 0.00
DK-R 90 1.57 2.43 3.08 3.41 3.54 3.54 3.61 3.28 3.28 2.89 1.57 0.79 0.46 0.26 0.09
DK-L 90 0.13 0.39 0.92 1.18 1.31 1.51 1.71 1.72 1.78 1.05 0.26 0.07 0.00 0.00 0.00
DG-R 30 0.58 0.73 0.80 1.02 1.11 1.18 1.18 1.18 1.18 1.18 0.44 0.15 0.00 0.00
DG-L 30 1,07 1.22 1.31 1.39 1,56 1.64 1.64 1.64 1.64 1.64 0.49 0.08 0.00 0.00
DG-R 60 1.08 2.27 2.35 2.42 2.55 2.77 3.06 3.21 3.43 3.50 1.81 0.08 0.00 0.00
DG-L 60 1.15 1.72 1.84 1.97 2.34 2.41 2.62 2.73 3.06 3.39 1.84 0.00 0.00 0.00
DG-R 90 3.08 4.70 4.93 5.09 5.24* 3.54 0.87 0.87 0.66 0.55 0.44 0.00 0.00 0.00
DG-L 90 2.75 3.14 3.41 3.80 4.19* 2.62 0.33 0.16 0.16 0.16 0.16 0.00 0.00 0.00
GM-R 30 0.00 0.51 0.44 0.58 0.58 0.58 0.66 0.73 0.73 0.36 0.00 0.00 0.00
GM-L 30 0.66 1.12 1.03 1.03 1.03 0.94 0.94 0.94 0.94 0.44 0.00 0.00 0.00
GM-R 60 0.44 1.48 1.64 1.64 1.64 1.64 1.64 1.64 1.80 1.89 1.12 0.11 0.00
GM-L 60 0.44 1.31 1.51 1.61 1.61 1.41 1.21 1.41 1.41 1.61 0.77 0.00 0.00
GM-R 90 1.09 2.24 2.24 2.15 2.24 1.49 2.06* 0.66 0.33 0.00 0.00
GM-L 90 0.25 1.31 1.56 1.72 1.74 1.72 1.88* 1.31 0.25 0.00 0.00
R right calf 
L left calf 
* presyncope occured following this point, LBNP stopped
Chapter 3 - Raw data tables
Plasma noradrenaline fpq/m» following beta blockade before
LBNP at -SOmmHa or OmmHa fP-olacebo or D-propranoloH
Subject Time (minutes)
0 2 4 60) T+10
GM 90P 894 983 191 657 342
GM 90D 1225 533 1050 360 1025
GM OP 630 90 200 673 323
GM CD 90 960 1160 1130 690
DG 90P 897 1217 571 251
DG 90D 950 150 570 384
DG OP 580 93 213 110 467
DG OD 1133 389 281 287 279
PR 90P 390 740 740 1090 920
PR 90D 610 1090 1100 940
PR OP 61 315 328 710 126
PR OD 477 706 509 365 460
MS 90P 89 361 793 970
MS 90D 1293 447 767 487
MS OP 40 360 930 500 350
MS OD 120 87 486 866 1393
TH 90P 1633 976 530 810 688
TH 90D lost 1667 1985 lost 2107
TH OP 184 580 88 400 147
TH OD 392 290 1280 1953 363
JMC90P 780 570 1000 340 1080
JMC90D 280 1070 1436 660
JMC OP 16 597 510 418 207
JMC OD 922 521 661 457 110
6(T) 6 minutes or termination of run
Plasma adrenaline results fpg/mR following beta-blockade before
LBNP at -SOmmHa or OmmHa fP-placebo or D-propranoloH
Subject Time (minutes)
0 2 4 6(T) T+10
GM 90P 803 85 651 991 753
GM 90D 747 632 1020 699 723
GM OP 248 527 190 697 606
GM OD 160 780 620 831 130
DG90P 945 973 800 678
DG 90D 1020 1172 869 801
DG OP 369 268 475 269 300
DG OD 619 721 370 682 677
PR 90P 1690 1559 520 1220 830
PR 90D 1820 1180 1270 760
PR OP 297 595 130 490 100
PR OD 693 1390 707 641 740
MS 90P 70 750 530 360
MS 90D 1040 190 1165 1155
MS OP 130 795 545 380 25
MS OD 930 395 940 860 1450
TH 90P 620 700 290 220 780
TH90D lost 1423 1389 lost 793
TH OP 255 714 36 495 515
TH OD 988 368 725 1044 1320
JMC90P 975 443 1075 480 1023
JMC90D 500 1100 1075 775
JMC OP 160 310 200 453 626
JMC OD 953 799 673 804 250
6(T) 6 minutes or termination of run
Plasma dopamine results (pg/ml) following
LBNP at -90mmHg or OmmHg (P-placebo,
beta-blockade before
D-propranolol)
Subject Tlme(minutes)
0 2 4 60) T+10
GM 90P 740 650 339 644 325
GM 90D 604 591 578 464 407
GM OP 444 520 160 192 136
GM OD 930 685 170 205 80
DG 90P 640 280 80 120
DG 90D 840 150 280 963
DG OP 661 606 576 489 646
DG OD 690 50 330 693 853
PR 90P 123 470 432 664 527
PR 90D 1220 530 390 210
PR OP 512 130 515 505 313
PR OD 353 368 332 339 358
MS 90P 147 120 127 827
MS 90D 710 45 175 250
MS OP 1405 850 780 1005 40
MS OD 565 405 95 2455 55
TH 90P 160 230 1140 970 90
TH 90D lost 460 42 lost 430
TH OP 571 500 195 830 138
TH OD 230 170 272 850 50
JMC90P 438 501 649 409 554
JMC90D 460 100 50 193
JMC OP 610 535 342 30 90
JMC OD 832 532 96 776 216
Plasma AVP results (pmol/l) following beta
LBNP at -90mmHg or OmmHg (P-placebo,
-blockade before
D-propranolol)
Subject Time(mlnutes)
0 2 4 6(T) T+10
GM 90P 3.6 4.5 10.9 92.4 22.8
GM 90D 4.3 17.6 9.4 106.3 56.8
GM OP 5.0 5.3 8.9 13.3 4.5
GM OD 6.2 5.6 5.4 6.3 5.4
DG 90P 3.6 2.2 1.8 27.9
DG 90D 9.1 2.3 60.9 50.5
DG OP 4.4 3.3 5.5 4.4 3.0
DG OD 3.3 2.7 3.0 4.4 6.1
PR 90P 1.9 6.8 21.5 222.3 44.2
PR 90D 2.0 1.4 12.0 101.8
PR OP 11,3 1.3 3.1 2.5 3.4
PR OD 3.6 3.7 3.1 2.6 0.9
MS 90P 5.2 6.5 54.2 12.1
MS 90D 4.7 6.1 9.3 4.8
MS OP 6.7 12.6 10.0 13.6 7.3
MS OD 6.3 5.9 10.5 8.3 10.5
TH 90P 18.6 8.5 10.7 20.7 22.8
TH90D 6.1 3.6 7.3 3.0 6.8
TH OP 11.4 14.6 11.2 6.2 5.6
TH OD 2.3 16.0 8.5 7.3 7.2
JMC90P 6.0 5.7 16.4 40.8 59.3
JMC90D 5.3 10.5 11.6 10.0
JMC OP 3.2 1.0 4.9 2.8 2.0
JMC OD 4.2 8.4 4.4 10.6 3.7
6(T) 6 minutes or prior termination of run
Plasma cortisol (ug/100ml) results following beta-blockade
before LBNP at -QOmmHg or OmmHg (P-placebo, D-propranolol)
Subject Time(minutes)
0 2 4 600 T+10GM 90P 59.7 47.3 44.0 27.1 95.5
GM 90D 24.5 22.4 Ins Ins ins
GM OP ins ins ins ins ins
GM OD 24.4 26.1 21.2 21.7 22.8
DG 90P 66.4 74.4 54.8 90.9
DG 90D 48.8 48.8 47.8 79.3
DG OP 77.8 88.7 86.4 77.6 78.3
DG OD 82.8 77.8 67.8 79.7 53.9
PR 90P 39.3 lost 42.3 38.8 65.3
PR 90D 19.3 21.5 28.1 88.8
PR OP 26.2 38.8 25.1 43.1 27.8
PR OD 24.5 25.6 21.0 28.2 23.0
MS 90P 7.1 17.4 ins 34.7
MS 90D 56.2 25.9 35.5 47.4
MS OP 22.1 25.1 33.7 23.6 26.1
MS OD 24.0 ins 24.1 43.0 26.4
TH 90P 27.5 24.6 25.1 30.9 30.0
TH 90D ins 20.7 ins ins 24.4
TH OP 38.7 26.7 62.1 31.5 43.2
TH OD 31.7 33.2 27.7 35.4 25.6
JMC90P 48.9 39.9 55.2 50.6 74.0
JMC90D 83.9 85.8 80.3 79.5 Ins
JMC OP 53.1 78.3 39.6 24.8 41.6
JMC OD Ins ins ins ins ins
ins-insufficient plasma
6(T) 6 minutes or termination of run
Blood pressure (s-systolic, d-diastollc) following beta-blockade
before LBNP at -QOmmHg or OmmHg (P-placebo, D-propranolol)
Subject Time(minutes)
0 2 4 600 T+10
GM 90Ps 133 121 120 tl 116
GM 90Pd 80 91 80 tl 73
GM 90Ds 108 120 115 69 98
GM 90Dd 65 74 75 44 58
GM OPs 113 107 111 114 112
GM OPd 66 68 66 62 58
GM ODs 104 110 101 106 109
GM ODd 61 61 61 59 59
DG 90PS 124 84 tl 131
DG 90Pd 86 62 tl 83
DG 90Ds 123 81 68 132
DG 90Dd 89 64 42 80
DG OPs 141 137 132 128 138
DG OPd 89 82 82 83 79
DG ODs 127 135 130 136 127
DG ODd 90 85 83 84 77
PR 90Ps 119 123 108 107 108
PR 90Pd 55 78 82 68 52
PR 90Ds 112 102 93 105
PR 90Dd 63 64 65 50
PR OPs 119 113 113 107 109
PR OPd 53 49 52 44 46
PR ODs 115 116 114 112 109
PR ODd 48 49 51 43 45
MS 90Ps 131 157 tl 118
MS 90Pd 84 78 tl 60
MS 90Ds 122 106 tl 113
MS 90Dd 59 66 tl 57
MS OPs 120 119 118 124 113
MS OPd 59 54 55 49 57
MS ODs 121 118 123 126 117
MS ODd 62 58 54 51 57
TH 90Ps 116 101 92 tl 100
TH 90Pd 47 51 40 tl 48
TH 90Ds 106 97 62 tl 92
TH 90Dd 51 61 29 tl 70
TH OPS 120 115 118 122 118
TH OPd 60 55 52 60 54
TH ODs 109 116 109 102 111
TH ODd 54 51 49 53 53
JMC90PS 123 mm 86 tl 117
JMC90Pd 57 mm 29 tl 53
JMC90DS 118 126 119 tl 124
JMC90Dd 73 73 76 tl 70
JMC OPs 128 115 113 112 109
JMC OPd 59 66 72 70 59
JMC ODs 111 107 111 110 104
JMC ODd 53 49 54 44 48
tl-blood pressure too low to register on the "Dynamap" 
mm-blood pressure machine malfunction
Heart rate (BPM) following beta-blockade before LBNP 
-90mmHg or OmmHg (P-placebo, D-propranolol) 
Subject Time(minutes)
at
0 2 4 600 T+10
GM90P 93 125 144 113 51
GM 90D 44 55 68 69 41
GM OP 53 52 52 50 52
GM OD 43 42 41 42 42
DG 90P 73 69 54 60
DG 90D 59 38 15 55
DG OP 70 68 65 70 68
DG OD 54 55 55 56 54
PR 90P 62 144 156 153 69
PR 90D 55 75 38 49
PR OP 64 61 60 59 64
PR OD 57 60 60 55 58
MS 90P 141 144 110 tl 62
MS 90D 60 91 tl 50
MS OP 60 59 60 59 56
MS OD 58 57 60 60 55
TH 90P 55 90 107 84 46
TH 90D 40 56 53 42 42
TH OP 64 53 55 60 48
TH OD 51 46 50 54 48
JMC90P 49 76 88 84 46
JMC90D 44 44 43 47
JMC OP 53 53 48 52 48
JMC OD 46 45 45 44 44
tl-too low to register on machine
Chapter 4 - Raw data tables
Plasma noradrenaline fpg/ml) results following LBNP at -SOmmHa and OmmHg
Subject Time (minutes)
0 2 4 P
AA 90A 43 637 790
AA 908 82 1493 1418 1698
AA 0 885 824 114 1128
JB 90A 548 1740
JB 90B 149 1649
JB 0 137 355 1347 452
AD 90A 263 409 1074
AD 90B 467 753
AD 0 652 1000 140 113
JMC 90A 617 798 863
JMC 90B 492 1535 1543 793
JW 90A 888 1072 1680
JW 90B 776 1536 1696
JW 0 144 840 528 416
MS 90A 522 635 1409
MS 90B 264 792 1064 776
SP 90A 619 750 700 1153
SP 90B 368 400 592 624
SP 0 678 147 * 418
MAR 90A 576 1392
MAR 90B 1608 968
MAR 0 440 504 * 2760
* difficulty with bleeding 
P- presyncope
Subjects JMC and MS control runs in previous experiment
P+5
1047
2069
832
P=10
293
935
127
260
1085
763
620
150
279 
197 
1344 
440 
168 
521 
824 
831
280 
227 
784 
448 
432
Plasma noradrenallne results at -SOmmHa LBNP and OmmHg
Subject Time (minutes)
0 2 4 6 P P+2 P+10
MF 90A 543 1370 860 972
MF 90B 491 552 974 1061 454 322
MF OA 273 132 203 534 579 314
MF OB 293 455 131 481 339 394
ST90A 540 1163 488 361
ST90B 114 280 185 151
ST OA 131 69 93 179 226 146
ST OB 362 340 148 332 498 375
PR 90A 422 821 1080 1915 1068 485 605
PR 90B 176 214 184 1122
961(8) 1165 569 354
PR OA 271 214 496 392 148 574
PR OB 389 174 137 264 467 240
MR90A 245 230 206 655
625(8) 1209 594 309
MR90B 508 222 634 1157
1426(8) 859(10) 1362(12) 580 658 531
MR OA 79 114 221 78 135 261
MR OB 541 459 505 244 313 421
NP 90A 516 505 269 189
NP 90B 639 743 1595 1173 667
NP OA 320 92 280 200 160 481
NP OB 466 435 218 351 579 373
DD 90A 106 254 480 264 227
DD90B 652 834 534 702
796(8) 1027 842 352
DD OA 376 107 192 278 68 17
DD OB 145 290 455 108 101 256
P- presyncopy or run finish
Numbers in brackets time in minutes
Plasma adrenaline fpo/mh results after LBNP at -SOmmHa and OmmHg
Subject Time (minutes)
0 2 4 P
AA 90A 387 566 1113
AA 90B 87 478 227 813
AA 0 317 363 467 825
JB 90A 247 1553
JB 90B 271 1127
JB 0 50 357 807 166
AD 90A 94 264 907
AD 90B 105 810
AD 0 373 127 100 320
JMC 90A 29 592 657
JMC 90B 394 691 989 1149
JW 90A 269 663 1040
JW 90B 343 1189 817
JW 0 394 600 109 497
MS 90A 670 346 1473
MS 90B 303 926 1017 2046
SP 90A 215 1187 1147 1708
SP 90B 154 457 651 788
SP 0 375 169 * 48
MAR 90A 177 520
MAR 90B 240 1331
MAR 0 434 480 * 206
P+5 P+10
901
571
186
280
1225 1220
606 
420 
700 
210 
238 
34 
1206 
383 
360 
78 
1771 
722
920 914
217 
931 
2206 
286
* difficulty with bleeding 
P- presyncope
Subjects MS and JMC control runs from previous experiment used
Plasma adrenaline results after LBNP at -SOmmHo and OmmHa
Subject Time (minutes)
0 2 4 6 P P+2 P+10
MF 90A 9 644 175 271
MF 908 162 113 219 833 230 149
MF OA 189 53 130 279 402 46
MF OB 154 84 374 82 149 289
ST90A 219 128 454 592
ST 90S 108 234 69 90
ST OA 47 17 8 189 39 148
ST OB 212 90 142 257 229 288
PR90A 44 101 207 413 362 160 178
PR 90B 41 101 69 81
448(8) 314 30 153
PR OA 137 54 131 40 44 142
PR OB 187 155 83 97 201 148
MR 90A 51 296 52 272
337(8) 638 146 16
MR 90B 131 226 438 649
741(8) 384(10) 383(12) 193 147 96
MR OA 175 228 205 111 123 165
MR OB 105 185 403 209 270 345
NP 90A 906 574 481 273
NP 90B 223 347 190 105 226
NP OA 196 100 176 224 44 268
NP OB 87 256 26 258 132 239
DD 90A 46 10 15 77 31
DD 90B 187 259 151 233
455(8) 246 217 196
DD OA 153 158 175 219 249 25
DD OB 220 167 331 117 143 39
P-presyncope or run finish
Figures in brackets time in minutes
Plasma dopamine (pa/ml> results following LBNP at -SOmmHa and OmmHa
Subject Time (minutes)
P+5 P+10
447 
769 
312 
140
1867 81
600 
300 
760 
515 
972 
120 
1093 
564 
340 
1751 
200 
116
1107 1207
212 
562 
486 
660
P- presyncope
Subjects JMC and MS control used from previous experiment
0 2 4 P
AA 90A 422 317 918
AA 90S 140 735 1515 436
AA 0 152 400 1399 537
JB 90A 55 482
JB 90B 31 879
JB 0 1116 1034 654 933
AD 90A 279 392 401
AD 90B 703 424
AD 0 197 376 802 607
JMC 90A 411 302 804
JMC 90B 2160 333 327 153
JW 90A 833 880 167
JW 90B 350 1798 919
JW 0 273 1393 1367 340
MS 90A 625 224 1627
MS 90B 80 727 413 673
SP 90A 160 787 1256 553
SP 90B 180 113 13 87
SP 0 517 279 * 333
MAR 90A 125 2110
MAR 90B 353 107
MAR 0 253 580 * 1047
* Difficulty with bleeding
Plasma dopamine results after LBNP at -SOmmHa and OmmHa
Subject Time (minutes)
0 2 4 6 P P+2 P+10
MF 90A 86 75 87 214
MF 908 405 170 28 114 69 97
MF OA 72 103 96 123 162 68
MF OB 270 35 212 541 69 256
ST90A 48 15 28 35
ST 908 163 55 36 106
ST OA 72 5 34 68 84 148
ST 08 188 180 96 208 316 396
PR 90A 187 114 106 187 49 98 81
PR 90B 58 17 24 73
96(8) 151 42 47
PR OA 48 123 85 128 11 228
PR OB 113 57 119 63 166 31
MR90A 37 159 6 84
146(8) 213 96 175
MR 90B 118 42 358 178
157(8) 50(10) 32(12) 53 203 130
MR OA 183 105 211 84 53 97
MR OB 177 38 31 126 160 64
NP90A 53 36 47 168
NP 90B 96 4 36 168 114
NP OA 216 276 52 456 376 472
NP OB 59 82 111 100 218 283
DD 90A 76 39 66 98 87
DD 90B 186 344 167 73
174(8) 142 261 177
DD OA 191 13 54 121 153 46
DD OB 93 47 153 77 119 3
P- presyncope or end of run
Figures in brackets time in minutes
Plasma AVP (pa/mH after LBNP at -90mmHa and OmmHa
Subject time (minutes)
0 2 4 P
AA 90A 8.3 7.1 211.0
AA 908 9.4 14.3 22.0 475.0
AA 0 5.2 30.6 14.7 20.0
JB 90A 7.3 416.0
JB 90B 7.7 26.8
JB 0 7.0 7.3 5.0 5.5
AD 90A 4.6 14.0 83.8
AD 90B 7.9 30.5
AD 0 4.8 15.6 8.0 6.7
JMC 90A 5.4 5.8 45.1
JMC 90B 9.0 5.3 7.2 18.9
JW 90A 2.1 6.4 28.2
JW 90B 4.6 17.7 218.8
JW 0 6.3 lost 3.1 3.3
MS 90A 4.0 7.2 64.2
MS 90B 4.4 2.7 26.4 27.3
SP 90A 11.4 12.3 46.2 117.7
SP 90B 2.4 11.3 105.8 268.3
SP 0 4.4 4.5 7.5 7.9
MAR 90A 5.9 299.0
MAR 90S 6.4 32.9
MAR 0 9.6 5.9 * 3.9
* difficulty with bleeding
P+5
101.8
317.0
P+10
40.3
93.0 20.6202.0
40.3
4.3
43.0
15.8
6.0
42.5
17.7
51.3
34.9
3.1
30.5
52.9
74.8 
138.4
6.1 
267.086.8 
3.6
P-presyncope
JMC and MC control runs used from previous experiment
Plasma AVP fomol/h levels during LBNP at -SOmmHa and OmmHa
Subject Time (minutes)
0 2 4 6 P P+2 P+10
MF 90A 1,8 72.4 61.7 27.0
MF 908 2.9 8.7 23.2 209.3 252.2 28.3
MF OA 1.2 0.8 0.4 0.6 0.7 1.9
MF OB 1.7 2.5 4.2 2.3 2.5 2.0
ST90A 0.6 60.5 66.8 47.6
ST90B 1.8 8.9 110.5 46.9
ST OA 1.4 1.0 1.4 0.7 lost 1.1
ST OB 3.0 3.5 3.6 3.4 3.1 4.2
PR 90A 0.8 0.8 2.7 22.3 77.1 79.5 22.2
PR 90B 6.3 2.7 5.2 24.7
44.0(8) 79.2 61.9 27.4
PR OA 1.8 2.0 1.5 1.1 lost 1.6
PR OB 5.2 3.0 3.5 2.9 2.8 3,2
MR 90A 2.4 1.3 1.9 8.0
13.3(8) 160.8 85.5 41.1
MR 90B 3.6 2.8 8.5 6.1
9.3(8) 19.6(10) 17.4(12) 24.0* 17.1 13.0
MR OA 2.7 0.8 2.0 2.4 1.1 1.1
MR OB 5.8 3.6 2.6 2.5 2.8 3.4
NP 90A 2.1 2.1 90.5 lost 55.9
NP 90B 1.1 2.9 27.5 73.7 22.8
NP OA 4.0 0,6 2.1 5.6 4.8 7.5
NP OB 1.4 2.3 2.2 3.7 2.3 2.7
DD 90A 4.2 4.8 28.1 208.7 46.2
DD 90B 1.6 2.1 3.2 7.2
11.7(8) 20.1 17.2 5.9
DD OA 3.0 3.1 3.3 3.2 3.6 2.4
DD OB 1.3 lost 1.4 1.7 1.4 1.5
P-syncope or end of run
* run terminated as no sign of syncope occuring
Figures in brackets time in minutes
Plasma cortisol (ua/100mh during LBNP at -90mmHa and OmmHa
Subject Time (minutes)
0 2 4 P P+5 P+10
AA90A 32.6 37.5 44.3 47.2
AA90B 31.7 23.7 35.4 47.2 51.3
AA 0 44.1 35.6 39.6 41.5 35.5
JB 90A 10.9 8.7 29.5
JB 90B 6.8 8.3 13.2 28.7
JB 0 17.3 11.0 10.7 9.5 11.3
AD 90A 47.2 44.7 31.8 32.6
AD 90B 40.3 32.7 27.3
AD 0 54.9 52.4 50.1 35.2 49.2
JMC90A 18.6 29.6 16.8 27.0
JMC90B 24.2 29.2 25.8 23.9 26.0
JW 90A 38.0 47.3 37.1 41.9
JW90B 45.7 31.1 42.0 47.4
JW 0 32.1 43.4 36.5 33.8 37.6
MS 90A 19.3 12.9 22.1 64.7
MS 90B 31.1 25.7 36.1 20.1 28.7
SP 90A 44.2 24.1 44.3 41.1 43.0
SP 90B 42.3 40.8 47.6 49.4 51.6 48.1
SP 0 43.6 18.9 499.0 37.1 42.8
MAR90A 40.4 40.4 42.5
MAR90B 42.6 27.0 39.4
MARO 36.1 51.2 35.0 34.9
Plasma cortisol fug/lOOml) during LBNP at -SOmmHa and OmmHa
Subject Time (minutes)
0.0 2.0 4.0 6.0 P P+2 P+10
MF90A 15.4 20.8 22.4 23.3
MF 908 17.7 19.5 20.7 36.8 22.5 23.9
MF OA 12.1 10.2 10.5 10.8 11.4 10.7
MF 08 13.1 18.5 17.6 10.6 10.0 10.4
ST90A 19.8 19.0 19.0 21.4
ST 908 24.7 24.5 27.7 27.0
ST OA 23.2 23.1 23.7 25.3 24.3 20.9
ST OB 17.9 14.7 15.0 14.3 16.3 16.9
PR 90A 12.4 13.9 15.6 14.7 20.2 22.4 24.7
PR 90B 7.6 8.9 9.1 10.2
14.0(8) 15.3 19.4 22.9
PR OA 9.5 8.1 7.9 7.9 8.1 8.8
PR OB 10.8 10.0 10.3 9.4 8.8 8.9
MR 90A 14.2 15.7 16.4 16.4
16.8(8) 17.3 24.0 24.0
MR 90B 17.3 17.5 12.0 14.5
14.9(8) 18.2(10) 14.7(12) 17.1* 17.4 20.4
MR OA 10.2 10.5 11.1 13.1 13.5 14.4
MR OB 8.8 8.4 8.3 7.9 7.7 6.8
NP 90A 23.5 26.0 25.5 lost 25.1
NP 90B 22.5 22.0 22.7 24.3 26.6
NP OA 15.5 19.8 17.6 17.7 16.3 15.0
NP OB 16.2 16.4 14.7 16.6 15.6 16.5
DD 90A 13.5 10.7 10.1 10.7 19.1
DD 90B 20.7 16.6 17.2 17.5
17.8(8) 15.9 16.4 20.9
DD OA 18.4 13.6 14.6 15.6 15.1 20.0
DD OB 24.4 19.8 18.3 14.7 17.9 18.2
P-presyncope or end of run
* run abandoned no sign of syncope
Figure in bracket time In minutes
Blood pressure fmmHa) during LBNP at -SOmmHa and OmmHa
systolic fSL diastolic
Subject Time (minutes)
0 2 4 P P+2 P+10
AA90AS 122 93 92 127
AA90AD 73 65 37 59AA90BS 137 148 93 99 126AA90BD 67 107 59 55 61AA 0 S 132 114 117 113 126AA 0 D 60 71 58 63 67JB 90A S 136 44 129JB 90A D 72 20 77
JB 90B S 131 121 133 123
JB 90B D 60 77 70 64JB 0 S 134 127 130 128 120JB 0 D 70 66 64 68 59JMC90A S 115 109 47 114
JMC90A D 62 73 26 62
JMC90B 8 120 129 103 91 117
JMC90B D 71 55 65 54 62JW 90A S 132 88 118 127
JW 90A D 69 40 66 65JW 90B S 138 116 56 127
JW 90B D 65 70 41 71
JW 0 S 128 118 118 113 123JW 0 D 55 56 57 59 57MS 90A S 146 127 76 134
MS 90A D 70 80 36 67
MS 90B S 143 119 116 too low 141
MS 90B D 78 82 76 77
SP 90A S 127 118 70 70 121
SP 90A D 75 84 33 33 76
SP 90B S 143 135 116 96 133 122
SP 90B D 79 97 83 65 84 77
SP 0 S 132 121 127 128 130
SP 0 D 77 78 77 78 75
MAR90A S 131 49 118
MAR90A D 74 32 58
MAR90B S 126 64 122
MAR90B D 71 26 59
MARO S 130 118 112 119 124
MARO D 65 57 52 59 64
P-presyncope
Blood pressure results following LBNP at -SOmmHa and OmmHg
fS-svstolic. D-diastollc1
Subject Time (minutes)
0 2 4 6 P P+2 P+10
MF 90AS 135 121 85 120 96
MF 90AD 75 73 60 67 62
MF 90BS 143 128 109 102 135 107
MF 90BD 73 76 66 69 69 48
MF OAS 130 120 113 122 130 115
MF OAD 81 66 65 69 63 58
MF OBS 124 113 100 103 107 101
MF OBD 61 55 60 50 49 44
ST 90AS 127 97 113 106
ST 90AD 108 59 60 57
ST 90BS 101 90 124 102
ST 90BD 80 50 67 56
ST OAS 117 116 120 115 109 115
ST OAD 66 66 64 64 62 66
ST OBS 115 105 107 107 105 100
ST OBD 59 67 64 57 55 56
PR 90AS 127 136 135 113 114 120 112
PR 90AD 64 90 73 71 79 67 60
PR 90BS 119 120 110 104
105(8) - 109 102
PR 90BD 84 81 72 78
70(8) - 66 58
PR OAS 122 115 122 129 114 110
PR OAD 62 60 61 53 53 57
PR OBS 117 112 109 104 94 111
PR OBD 68 54 50 53 51 51
MR 90AS 140 123 127 123
132(8) - 148 129
MR 90AD 67 61 61 63
66(8) - 71 57
MR 90BS 152 149 140 144
135(8) 130(10) 132(12) 127 154 134
MR 90BD 80 81 74 73
84(8) 80(10) 87(12) 54 83 72
MR OAS 155 140 130 135 131 126
MR OAD 71 67 59 61 59 55
MR OBS 132 129 129 125 136 128
MR OBD 67 59 61 59 56 59
NP 90AS 147 114 99 142 130
NP 90AD 96 85 63 87 78
NP 90BS 147 97 88 150 124
NP 90BD 93 76 49 84 72
NP OAS 133 124 118 122 118 112
NP OAD 84 74 64 73 66 70
NP OBS 134 118 127 115 118 125
NP OBD 63 63 62 63 58 59
DD 90AS 140 120 55 125 116
DD 90AD 87 89 30 86 80
DD 90BS 133 133 135 132
121(8) 124 139 142
DD 90BD 85 95 89 91
87(8) 85 85 83
DD OAS 144 146 140 145 144 138
DD OAD 96 90 91 97 94 90
DD OBS 124 135 132 132 146 131
DD OBD 93 87 85 84 82 81
P-presyncope or end of run 
* Run terminated no sign of syncope developing 
- Blood pressure too low to record
Heart rate fBPM> during LBNP at -90mmHa and OmmHa
Subject Time (minutes)
0 2 4 P P+5 P+10
AA90A 102 168 120 87
AA90B 90 140 132 87 84AA 0 76 80 78 78 75
JB 90A 72 48 66
JB 90B 57 72 51 48
JB 0 68 63 61 66 60
AD 90A 84 147 132 73
AD 90B 84 156 85
AD 0 90 90 88 85 90JMC90A 75 90 108 54
JMC90B 60 88 105 120 48
JW 90A 78 138 54 57
JW 90B 72 160 84 48
JW 0 65 72 53 55 55
MS 90A 93 138 96 63
MS 90B 84 135 138 99
SP 90A 93 129 96 78 90
SP 90B 96 150 165 120 87 84SP 0 84 86 85 88 81
MAR90A 126 75 105
MAR90B 108 66 102
MARO 102 101 104 98
P-presyncope
Chapter 5 - Raw data tables
Plasma noradrenaline results (po/mh following injection
of lOOpg AVP/ml blood and Placebo
Subject Time (minutes)
Pre 0 2 4 6 P P+2 P+10
RM (A) 145 349 506 588 550
RM (B) 74 409 380 797 947 285 189 30
MAP(A) 260 62 149 348 244
MAP(B) 262 356 794 599 230
CPR(A) 202 304 526 446 254 341
CPR(B) 200 459 526 287 171
NP(A) 380 268 326 266 216 171
NP(B) 380 407 475 469 155 121
PR (A) 365 139 455 806 542
693(8) 954(10) 1567(12) 740(14) 1041 444 340
PR (B) 276 155 537 813 565
622(8) 914(10) 675(12) 144(14) 1721 798 404
RK(A) 282 292 534 311 273
RK (B) 311 267 482 527 151
NB(A) 166 211 525 187 101
NB (B) 167 222 233 180 179
JH(A) 128 140 171 524 248 48
JH (B) 252 367 329 1433 1784 3148 1033 266
P- Presyncope
Subject PR numbers in brackets sample time
Plasma adrenaline results fpg/ml> following Injection
of fA) 100pg AVP/ml blood and placebo
Subject Time (minutes)
Pre 0 2 4 6 P P+2 P+10
RM (A) 137 178 207 587 162
RM (B) 29 261 101 179 197 159 65 141
MAP(A) 90 60 140 102 136
MAP(B) 91 158 130 98 75
CPR(A) 59 111 126 193 134 84
CPR(B) 50 131 120 56 11
NP(A) 70 190 155 117 95 38
NP (B) 70 80 96 68 11 46
PR (A) 32 71 240 151 118
169(8) 201(10) 570(12) 179(14) 310 142 112
PR (B) 139 128 224 186 168
230(8) 142(10) 149(12) 60(14) 194 140 63
RK(A) 75 123 249 161 119
RK (B) 84 21 122 164 29
NB(A) 18 81 180 38 11
NB (B) 120 131 388 145 150
JH(A) 156 63 168 242 208 69
JH (B) 85 139 112 190 457 93 155 89
P- Presyncope
Subject PR numbers in brackets time of sampie
Plasma dopamine results fpg/mh following inîection
of fA) IOOpq AVP/ml blood and placebo
Subject Time (minutes)
PRE 0 2 4 6 P P+2 P+10
RM (A) 175 301 260 216 285
RM (B) 16 201 22 37 166 58 67 253
MAP(A) 30 13 31 12 7
MAP(B) 31 65 26 30 165
CPR(A) 148 71 60 74 102 60
CPR(B) 140 206 152 130 30
NP(A) 29 163 83 37 18 39
NP (B) 30 155 137 183 81 131
PR (A) 108 66 139 245 152
177(8) 162(10) 336(12) *27(14) 260 100 82
PR (B) 92 41 191 137 135
196(8) 115(10) 280(12) >24(14) 214 270 97
RK(A) 214 182 194 144 128
RK(B) 135 77 71 161 29
NB(A) 28 90 48 30 49
NB (B) 83 82 117 41 186
JH(A) 146 241 180 69 208 161
JH (B) 210 242 111 142 158 82 93 128
P- Presyncope
Subject PR numbers in. brackets time of sampie
Plasma cortisol results (ua/100m» following Injection
of IOOpq AVP/ml blood and placebo
Subject Time (minutes)
Pre 0 2 4 6 P P+2 P+10
RM (A) 10.0 16.0 12.2 13.1 23.1
RM (B) 10.1 9.7 10.4 10.8 9.8 9.0 18.4 10.2
MAP(A) 22.0 23.6 25.2 20.3 26.9
MAP(B) 22.2 22.6 23.4 25.4 24.7
CPR(A) 12.7 19.5 20.1 20.9 23.9 22.5
CPR(B) 12.0 18.0 18.5 14.8 21.5
NP(A) 25.0 35.0 31.2 28.5 37.0 34,2
NP(B) 24.0 21.4 30.1 36.5 40.1 418.0
PR (A) 11.9 14.2 17.1 18.1 16.5
24.2(8) 25(10) 26.8(12) 5.1(14) 27.4 31.4 39.0
PR (B) 9.9 10.0 9.9 7.6 9.6
10.1(8)10.8(10) 13.3(12) 1.3(14) 25.1 22.5 22.2
RK(A) 20.5 15.8 15.7 19.1 21.0
RK (B) 18.7 13.7 20.7 23.5 25.5
NB(A) 24.5 24.1 24.3 24.3 20.5
NB (B) 16.9 24.2 23.3 24.5 38.9
JH(A) 9.2 9.3 9.1 8.6 9.2 13.4
JH (B) 9.8 8.6 7.5 7.7 6.8 7.8 9.8 19.2
P- Presyncope
Subject PR numbers in brackets sampie time
Plasma AVP results fpmol/L) following injection
of (A) IOOpq AVP/ml blood and (B> Placebo
Subject Time (minutes)
Pre 0 2 4 6 P P+2 P+10
RM (A) 3.2 77.4 99.1 140.9 35.2
RM (B) 4.8 3.5 4.3 3.4 11.2 39.3 31.9 8.9
MAP(A) 1.5 36.4 40.8 118.1 20.7
MAP(B) 1.6 2 1.5 17 5
CPR(A) 0.1 90.2 51.5 40.8 59.2 8.2
CPR(B) 0.1 1.6 9.8 39.8 8.4
NP(A) 2.4 105.7 98.9 329.7 392.0 105.9
NP (B) 2.3 2.2 7.9 135.5 336.4 91.1
PR (A) 2.2 34.4 39.4 30.0 30.8
23(8) 19.2(10) 17.8(12) 3.7(14) 14.7 10.6 6.5
PR(B) 2.8 2.2 2.1 3.4 3.2
3.6(8) 6.2(10) 7.1(10) 1.1(14) 8.1 6.6 4.9
RK(A) 5.0 28.8 159.8 112.1 24.3
RK(B) 3.4 4.3 19.5 84.8 21.7
NB(A) 7.6 141.4 119.0 77.4 27.8
NB (B) 9.6 10.6 71.5 52.5 15.9
JH(A) 0.1 46.0 50.8 151.4 176.6 39.0
JH (B) 0.1 0.7 1.1 1.7 7.5 77.9 82.7 25.7
P- Presyncope
Subject PR numbers in brackets sample time
Plasma ANP results fpmol/ü following injection
of fA* IOOpq AVP/ml blood and (B) placebo
Subject Time (minutes)
Pre 0.0 2.0 4.0 6.0 P P+2 P+10
RM (A) 10.0 23.3 7.7 7.7 12.0
RM (B) 9.2 8.5 9.1 5.9 7.0 7.9 8.8 7.5
MAP(A) 10.1 9.3 9.9 9.5 9.3
MAP(B) 10.4 9.6 9.9 9.7 9.5
CPR(A) 10.4 11.0 11.6 11.9 11.1 10.8
CPR(B) 10.4 10.5 10.8 10.5 10.2
NP(A) 9.4 9.5 9.7 9.6 8.9 10.3
NP (B) 9.8 10.4 9.6 10.1 9.4 9.6
PR (A) 4.9 6.1 5.2 8.1 7.3
6.4(8) 6.4(10) 7.0(12) >.9(14) 7.1 7.2 6.7
PR (B) 7.7 8.8 8.0 8.2 6.5
7.5(8) 8.0(10) 9.0(12) *.2(14) 8.1 7.8 6.2
RK(A) 6.6 8.3 7.3 4.6 7.3
RK (B) 9.0 8.9 9.1 7.7 8.4
NB(A) 6.9 9.3 8.2 8.1 6.2
NB(B) 7.1 7.6 8.8 8.5 8.4
JH(A) 13.2 13.1 13.2 13.4 13.4 13.4
JH (B) 17.4 10.4 15.6 15.5 14.7 13.0 16.3 17.1
P- Presyncope
Subject PR numbers In brackets sample time
Heart rate results (beats per minuted following injection
Subject Time (minutes)
Pre 0 1 2 3
RM (A) 64 77 89
RM (B) 90 86 95 110 122
MAP(A) 60 45 107
MAP(B) 57 64 124 150
CPR(A) 72 65 137 143 155
CPR(B) 79 78 138
NP(A) 84 91 127 135
NP(B) 88 87 133 144
PR (A) 60 66 114 114 128
138(8) 132(10) 132(12) 32(14)
PR (B) 65 60 88 100 102
118(8) 124(10) 120(12) 25(14)
RK(A) 71 77 118
RK(B) 67 71 107
NB(A) 81 78 164
NB (B) 85 90 166
JH{A) 60 42 72 90
JH (B) 55 57 74 87 103
P- Presyncope
Subject PR numbers in brackets sample time
128
132
109
100
P P+1 P+2 P+3P+10
50 63 61 72 63
123 84 65 53 60 62
120 52 48 43 40
147 46 48 45 52
145 58 55 55 72
120 60 65 57 78
80 48 48 50 63
88 40 44 42 60
120
126 60 60 66 60
107
125 68 50 53 60
81 50 47 42 55
45 43 43 44 55
161 85 73 65 82
167 83 87 77 75
78 60 54 54 54
85 47 45 43 50
Blood pressure results fmmHa*. systolic and diastolic fP* following injection of (A) IOOpq AVP/ml blood 
and placebo
Subject Time (minutes)
Pre 0 1 2 3 4 5 6 P P+1 P+2 P+3P+10
RM A/S 150 150 90 50 126 129 138 122
RM A/D 83 90 53 38 80 78 77 70
RM B/S 157 155 146 123 115 125 121 115 52 138 142 150 143
RM B/D 85 82 85 68 68 70 70 69 40 80 81 79 82
MAP A/S 145 145 110 75 140 156 130 143
MAP A/D 90 92 75 60 92 93 78 80
MAP B/S 150 158 135 102 72 173 176 176 126
MAP B/D 80 86 80 70 62 90 100 89 68
CPRA/S 162 163 155 145 160 62 158 158 153 151
CPRA/D 105 110 112 103 112 48 95 96 94 100
NP A/S 157 178 131 102 57 139 142 129 131
NP A/D 82 98 86 73 52 89 89 70 75
NP B/S 168 166 152 113 75 139 140 136 131
NP B/D 80 82 80 72 43 83 83 75 76
PR A/S 142 142 139 137 136 125 121 122
PR A/D
124(8)
70
143(10)
73
145(12)
80
52(14)
78 78 73 69 69
128 126 133 128 113
PR B/S
72(8)
134
75(10)
142
82(12)
148
30(14)
146 146 136 130 122
68 70 75 72 67
PR B/D
121(8)
68
126(10)
74
131(12)
83
40(14)
88 84 78 75 73
118 140 132 148 128
RK A/S
70(8)
151
72(10)
138
77(12)
115
37(14) 70
58
74
138
72
125
87
124
74
113
RK A/D 64 65 62 35 76 64 58 52
RK B/S 144 117 107 56 135 140 153 136
RK B/D 72 58 60 39 76 77 85 70
NB A/S 156 155 116 72 151 150 149 140
NB A/D 77 79 70 43 83 82 74 69
NB B/S 161 166 122 79 162 163 160 150
NB B/D 83 89 72 56 76 82 80 76
JH A/S 118 132 116 105 70 120 132 131 126
JH A/D 68 72 72 64 43 72 72 73 69
JH B/S 140 138 142 142 126 123 120 100 77 142 150 150 141
JH B/D 76 79 90 89 80 76 76 63 50 86 88 79 78
P- Presyncope
Subject PR numbers in brackets sample time
